Functional respiratory imaging : opening the black box by Van Holsbeke, Cedric


Functionele respiratoire beeldvorming: een blik in de zwarte doos
Functional Respiratory Imaging: Opening the Black Box
Cedric Van Holsbeke
Promotoren: prof. dr. ir. P. Verdonck, prof. dr. W. De Backer
Proefschrift ingediend tot het behalen van de graad van 
Doctor in de Ingenieurswetenschappen: Biomedische Ingenieurstechnieken
Vakgroep Elektronica en Informatiesystemen
Voorzitter: prof. dr. ir. J. Van Campenhout
Faculteit Ingenieurswetenschappen en Architectuur
Academiejaar 2013 - 2014
ISBN 978-90-8578-641-2
NUR 954
Wettelijk depot: D/2013/10.500/74
Preface and acknowledgments
This thesis would not have been possible without the support of several people. First
and for all, I would like to thank my promoters, Prof. dr. ir. Pascal Verdonck and
Prof. dr. Wilfried De Backer. Pascal introduced me to the world of aerodynamics
and the possible applications in medicine. Without him I would never have started
a PhD in the first place. Wilfried has broadened my scientific vision and gave me
insights in the clinical problems that pulmonologists are dealing with every day.
Special thanks go to my colleagues dr. ir. Wim Vos and dr. ir. Jan De Backer
as they have made me a better engineer during these four years. Our numerous
pleasant face to face discussions, combined with a close follow up of the latest
technological advancements, resulted in a thesis that I am proud of!
I also want to express my gratitude to the members of my PhD committee as
their input helped me to give this work the final touch it deserves.
To my coworkers from FluidDA, Ghent University and Antwerp University
Hospital: Annemie, Benjamin, Caroline, Frédéric, Glenn, Heidi, Kirti, Kris, Lau-
rence, Lieve, Marijke, Mathias, Peter, Rita, Rodrigo, Samir, Sarika, Sneha, Stijn,
Tom, Vanita, Walter and many others. I want to thank you one more time because I
really enjoyed working with you!
Most importantly, I want to thank the people closest to me. My parents, Marc
and Anne-Marie, have given me all the opportunities in life, have always motivated
me to explore and exploit my full potential and are still giving me great advice!
Thanks to them, I became the person that I am now and I think they were doin’ it
right. I am also grateful to my godfather and godmother, Sabin and Marijke, as
they initiated my interest in computer technology, first leading to multiple short
circuits in motherboards, but finally leading to this thesis.
While family does not change, other relationships often do. That is why I am
so happy that this is the third thesis in which I can praise my girlfriend Lisa. There
is something about us that makes us a unique couple. The past seven years have
been amazing and I hope that a wonderful future lies ahead of us, including several
trips around the world!
The combination of a full-time job and a PhD is not straightforward. Especially
during the last few months, I spent most of the weekends behind my computer
screen. I hereby promise to all my friends that I will make up for the lost time,
harder, better, faster, stronger!
Ghent, August 2013
Cedric Van Holsbeke

Table of Contents
Preface and acknowledgments i
Nomenclature xiii
Nederlandstalige samenvatting xxi
Summary in English xxv
1 Introduction 1-1
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1-8
2 Functional respiratory imaging 2-1
2.1 Medical imaging . . . . . . . . . . . . . . . . . . . . . . . . . . 2-2
2.2 Image processing . . . . . . . . . . . . . . . . . . . . . . . . . . 2-5
2.3 Computational fluid dynamics . . . . . . . . . . . . . . . . . . . 2-5
2.4 Clinical relevance . . . . . . . . . . . . . . . . . . . . . . . . . . 2-9
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-10
I Obstructive sleep apnea syndrome
3 Anatomical and functional changes in the upper airways of sleep
apnea patients due to mandibular repositioning: A large scale study 3-1
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3-1
3.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 3-2
3.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3-2
3.4 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3-3
3.4.1 Patient data . . . . . . . . . . . . . . . . . . . . . . . . . 3-3
3.4.2 Computational domain and grid . . . . . . . . . . . . . . 3-4
3.4.3 Physical models and boundary conditions . . . . . . . . . 3-4
3.4.4 Outcome parameters . . . . . . . . . . . . . . . . . . . . 3-5
3.4.4.1 Upper airway morphology . . . . . . . . . . . . 3-5
3.4.4.2 Skull morphology . . . . . . . . . . . . . . . . 3-6
3.4.4.3 Functional parameters . . . . . . . . . . . . . . 3-7
3.4.5 Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . 3-7
iv
3.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3-7
3.5.1 Correlations between changes in functional and anatomical
parameters . . . . . . . . . . . . . . . . . . . . . . . . . 3-7
3.5.2 Correlations between changes in functional and baseline
parameters . . . . . . . . . . . . . . . . . . . . . . . . . 3-9
3.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3-9
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3-15
4 Functional respiratory imaging as a tool to assess upper airway pa-
tency in children with obstructive sleep apnea 4-1
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4-1
4.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 4-2
4.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4-2
4.4 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . 4-3
4.4.1 Study population . . . . . . . . . . . . . . . . . . . . . . 4-3
4.4.2 Questionnaire and physical examination . . . . . . . . . . 4-3
4.4.3 Polysomnography . . . . . . . . . . . . . . . . . . . . . 4-4
4.4.4 CT scan . . . . . . . . . . . . . . . . . . . . . . . . . . . 4-4
4.4.5 Upper airway morphology extraction from CT . . . . . . 4-4
4.4.6 Upper airway characteristics extraction from CFD . . . . 4-5
4.4.7 Statistical analysis . . . . . . . . . . . . . . . . . . . . . 4-6
4.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4-6
4.5.1 Patient characteristics . . . . . . . . . . . . . . . . . . . . 4-6
4.5.2 Correlation between imaging parameters and OSA . . . . 4-7
4.5.3 Correlation between clinical assessment of upper airway
patency and OSA . . . . . . . . . . . . . . . . . . . . . . 4-10
4.5.4 Correlation between imaging and clinical assessment of
upper airway patency . . . . . . . . . . . . . . . . . . . . 4-10
4.5.5 Correlation analyses for upper airway conductance and
minimal cross sectional area . . . . . . . . . . . . . . . . 4-10
4.5.6 Final model for oAHI . . . . . . . . . . . . . . . . . . . . 4-11
4.5.7 Post-treatment data . . . . . . . . . . . . . . . . . . . . . 4-11
4.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4-11
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4-14
II Simulation of inhalation medication
5 Lung deposition analysis of inhaled medication: Effect of upper air-
way morphology and comparison with in vivo data 5-1
5.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-1
5.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 5-2
5.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-2
5.4 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . 5-4
5.4.1 High resolution CT scans . . . . . . . . . . . . . . . . . . 5-4
v5.4.2 Three-dimensional airway models . . . . . . . . . . . . . 5-4
5.4.3 Flow simulations . . . . . . . . . . . . . . . . . . . . . . 5-5
5.4.4 Aerosol transport . . . . . . . . . . . . . . . . . . . . . . 5-6
5.4.5 Computational grid and boundary conditions . . . . . . . 5-7
5.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-7
5.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-12
5.7 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-13
5.8 Aknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . 5-14
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-15
6 Change in upper airway geometry between upright and supine posi-
tion during tidal nasal breathing 6-1
6.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6-1
6.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 6-2
6.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6-2
6.4 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . 6-3
6.4.1 Subject Data . . . . . . . . . . . . . . . . . . . . . . . . 6-3
6.4.2 CT and CBCT . . . . . . . . . . . . . . . . . . . . . . . 6-3
6.4.3 Airway segmentation . . . . . . . . . . . . . . . . . . . . 6-5
6.4.4 Computational fluid dynamics . . . . . . . . . . . . . . . 6-6
6.4.5 Outcome parameters . . . . . . . . . . . . . . . . . . . . 6-6
6.4.6 Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . 6-7
6.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6-7
6.5.1 Drop-outs . . . . . . . . . . . . . . . . . . . . . . . . . . 6-7
6.5.2 Differences between CBCT and CT . . . . . . . . . . . . 6-8
6.5.3 Indicators for the differences between CBCT and CT . . . 6-8
6.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6-10
6.7 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . 6-12
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6-13
7 Patient specific evaluation of regional antibiotic concentration levels
in a cohort of cystic fibrosis patients 7-1
7.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7-1
7.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 7-2
7.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7-2
7.4 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . 7-4
7.4.1 Study population . . . . . . . . . . . . . . . . . . . . . . 7-4
7.4.2 Chest Computed Tomography . . . . . . . . . . . . . . . 7-4
7.4.3 CT settings . . . . . . . . . . . . . . . . . . . . . . . . . 7-5
7.4.4 CT evaluation . . . . . . . . . . . . . . . . . . . . . . . . 7-5
7.4.5 Reconstruction of three-dimensional airway models . . . . 7-6
7.4.6 Meshing . . . . . . . . . . . . . . . . . . . . . . . . . . . 7-7
7.4.7 Reconstruction of three-dimensional lung lobes . . . . . . 7-7
7.4.8 Breathing profile . . . . . . . . . . . . . . . . . . . . . . 7-7
7.4.9 Aerosol characteristics . . . . . . . . . . . . . . . . . . . 7-7
vi
7.4.10 Flow simulation . . . . . . . . . . . . . . . . . . . . . . 7-9
7.4.11 Aerosol deposition analyses . . . . . . . . . . . . . . . . 7-9
7.4.12 Airway surface liquid . . . . . . . . . . . . . . . . . . . . 7-9
7.4.13 AZLI concentrations . . . . . . . . . . . . . . . . . . . . 7-11
7.4.14 Statistical analysis . . . . . . . . . . . . . . . . . . . . . 7-11
7.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7-11
7.5.1 Study population . . . . . . . . . . . . . . . . . . . . . . 7-11
7.5.2 Correlations . . . . . . . . . . . . . . . . . . . . . . . . . 7-12
7.5.3 Deposition analyses . . . . . . . . . . . . . . . . . . . . 7-12
7.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7-18
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7-21
III Effects of inhalation medication
8 The acute effect of budesonide/formoterol in COPD: a multi-slice
computed tomography and lung function study 8-1
8.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8-1
8.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 8-2
8.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8-2
8.4 Materials en Methods . . . . . . . . . . . . . . . . . . . . . . . . 8-3
8.4.1 Ethics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8-3
8.4.2 Patient population . . . . . . . . . . . . . . . . . . . . . 8-4
8.4.3 Study design . . . . . . . . . . . . . . . . . . . . . . . . 8-4
8.4.4 Image post-processing . . . . . . . . . . . . . . . . . . . 8-5
8.4.5 Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . 8-6
8.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8-6
8.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8-10
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8-15
9 Novel functional respiratory imaging of changes in small airways of
patients treated with extrafine beclomethasone/formoterol 9-1
9.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9-1
9.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 9-2
9.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9-2
9.4 Material and Methods . . . . . . . . . . . . . . . . . . . . . . . . 9-3
9.4.1 Patient Selection . . . . . . . . . . . . . . . . . . . . . . 9-3
9.4.2 Study Medication . . . . . . . . . . . . . . . . . . . . . . 9-4
9.4.3 Lung function tests and FRI . . . . . . . . . . . . . . . . 9-4
9.4.4 Statistical analysis . . . . . . . . . . . . . . . . . . . . . 9-6
9.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9-6
9.5.1 Total study population . . . . . . . . . . . . . . . . . . . 9-6
9.5.2 Steroid-naive patients . . . . . . . . . . . . . . . . . . . . 9-11
9.5.3 Partially controlled patients . . . . . . . . . . . . . . . . 9-11
9.5.4 Well-controlled patients . . . . . . . . . . . . . . . . . . 9-12
vii
9.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9-13
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9-15
IV Novel applications
10 Particle deposition in airways of chronic respiratory patients ex-
posed to an urban aerosol 10-1
10.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-1
10.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 10-2
10.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-2
10.4 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . 10-3
10.4.1 Air quality survey . . . . . . . . . . . . . . . . . . . . . . 10-3
10.4.2 Chemical analysis . . . . . . . . . . . . . . . . . . . . . 10-5
10.4.3 Airway models . . . . . . . . . . . . . . . . . . . . . . . 10-5
10.4.4 Particle deposition rates . . . . . . . . . . . . . . . . . . 10-6
10.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-7
10.5.1 Urban particulate pollution . . . . . . . . . . . . . . . . . 10-7
10.5.2 Particle deposition rates . . . . . . . . . . . . . . . . . . 10-8
10.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-11
10.7 Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . 10-15
10.8 Supporting Information Available . . . . . . . . . . . . . . . . . 10-15
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-16
11 Functional respiratory imaging as a tool to personalize respiratory
treatment in subjects with unilateral diaphragmatic paralysis 11-1
11.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11-1
11.2 Contributions of the author . . . . . . . . . . . . . . . . . . . . . 11-2
11.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11-2
11.4 Case report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11-2
11.4.1 Study subject 1 . . . . . . . . . . . . . . . . . . . . . . . 11-2
11.4.2 Study subject 2 . . . . . . . . . . . . . . . . . . . . . . . 11-5
11.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11-6
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11-8
12 Challenges in engineering 12-1
12.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12-1
12.2 Pre-processing and simulation . . . . . . . . . . . . . . . . . . . 12-1
12.3 Post-processing . . . . . . . . . . . . . . . . . . . . . . . . . . . 12-3
12.3.1 Surface area and volume . . . . . . . . . . . . . . . . . . 12-3
12.3.2 Cross-sectional area . . . . . . . . . . . . . . . . . . . . 12-5
12.4 Advanced algorithms . . . . . . . . . . . . . . . . . . . . . . . . 12-7
12.4.1 One-way coupled fluid structure interaction . . . . . . . . 12-7
12.4.2 Realistic device boundary conditions . . . . . . . . . . . 12-10
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12-13
viii
13 Conclusion 13-1
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13-7
Appendices 9
A Computational fluid dynamics A-1
A.1 The Generic Scalar Transport Equation . . . . . . . . . . . . . . . A-1
A.2 The Navier-Stokes Equations . . . . . . . . . . . . . . . . . . . . A-2
A.2.1 Continuity equation . . . . . . . . . . . . . . . . . . . . . A-2
A.2.2 Momentum equation . . . . . . . . . . . . . . . . . . . . A-3
A.2.3 Energy equation . . . . . . . . . . . . . . . . . . . . . . A-4
A.3 Discrete phase . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-4
A.4 Computational fluid dynamics . . . . . . . . . . . . . . . . . . . A-5
A.4.1 Laminar flow . . . . . . . . . . . . . . . . . . . . . . . . A-6
A.4.2 Turbulent flow . . . . . . . . . . . . . . . . . . . . . . . A-7
A.4.2.1 Reynolds Averaged Navier-Stokes equations . . A-7
A.4.2.2 Filtered Navier-Stokes equations . . . . . . . . A-9
A.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-10
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-11
List of Figures
1.1 The anatomy of the upper airway . . . . . . . . . . . . . . . . . . 1-2
1.2 The anatomy of the lower respiratory tract . . . . . . . . . . . . . 1-3
2.1 Images of the respiratory tract obtained from different imaging
modalities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-1
2.2 A patient inside a CT-scanner . . . . . . . . . . . . . . . . . . . . 2-2
2.3 Principles of computed tomography . . . . . . . . . . . . . . . . 2-3
2.4 Computed tomography with multiple detectors . . . . . . . . . . 2-4
2.5 Fissure lines in the lung . . . . . . . . . . . . . . . . . . . . . . . 2-6
2.6 Reconstructed models of the upper airway, lower airways, lung
lobes and pulmonary blood vessels . . . . . . . . . . . . . . . . . 2-6
2.7 A detail of a meshed airway, the Navier-Stokes equations and CFD
results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-6
2.8 Pressure values from an inspiratory flow simulation in an upper
airway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-8
2.9 Lobes at FRC and TLC and the resulting internal airflow lobar
distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-8
3.1 Registration bite . . . . . . . . . . . . . . . . . . . . . . . . . . . 3-4
3.2 Three-dimensional upper airway model . . . . . . . . . . . . . . 3-5
3.3 Angulus mandibulae . . . . . . . . . . . . . . . . . . . . . . . . 3-6
3.4 Correlations between changes in functional and anatomical parameters 3-8
3.5 Difference between the sexes in change in resistance . . . . . . . 3-10
3.6 Correlations between changes in functional and baseline parameters 3-11
4.1 Different regions of the upper airway . . . . . . . . . . . . . . . . 4-5
4.2 Correlations between the mean cross-sectional area of segment 3
with OAI and conductance with oAHI . . . . . . . . . . . . . . . 4-8
5.1 Patient specific airway model attached with inhaler . . . . . . . . 5-5
5.2 Modelled inhalation profile using three flow rates . . . . . . . . . 5-8
5.3 Upper airway region for the five asthmatic patients . . . . . . . . 5-9
5.4 Lung deposition obtained for five asthmatics . . . . . . . . . . . . 5-10
5.5 Comparison of lung deposition results from CFD with in vivo data 5-11
x6.1 Sagittal slice of a CT scan and a CBCT scan . . . . . . . . . . . . 6-5
6.2 The different airway zones and the definition of the cross-sectional
areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6-7
6.3 Cross-sectional area comparison between the CT scan and CBCT
scan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6-9
7.1 Breathing profiles . . . . . . . . . . . . . . . . . . . . . . . . . . 7-8
7.2 Coupled airway model . . . . . . . . . . . . . . . . . . . . . . . 7-10
7.3 Relative AZLI concentrations for mild CF patient . . . . . . . . . 7-16
7.4 Relative AZLI concentrations for severe CF patient . . . . . . . . 7-17
8.1 Airway models indicating distal airway branches . . . . . . . . . 8-6
8.2 distal airway volume changes after administration of placebo or
combination product . . . . . . . . . . . . . . . . . . . . . . . . 8-7
8.3 Individual changes in iVaw and iRaw after administration of com-
bination product and placebo . . . . . . . . . . . . . . . . . . . . 8-9
9.1 Three-dimensional reconstruction of an airway structure . . . . . 9-5
9.2 Changes in iVaw and iRaw . . . . . . . . . . . . . . . . . . . . . 9-9
9.3 Correlation between iVaw and ACT for all patients . . . . . . . . 9-11
9.4 Correlation between iVaw and ACT for well-controlled patients . 9-12
10.1 Schematic map indicating studied residential areas and consulted
network stations . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-4
10.2 Average mass and bulk composition of fine air suspended particles
at the heavy and moderate traffic sites . . . . . . . . . . . . . . . 10-8
10.3 Size-distribution of particle mass at the heavy and moderate traffic
site . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-9
10.4 Size distribution of the different particle classes on 15th of July at
the heavy and moderate traffic site . . . . . . . . . . . . . . . . . 10-10
11.1 The internal airflow lobar distribution . . . . . . . . . . . . . . . 11-4
11.2 A visualisation of drug deposition simulations of subject 1 . . . . 11-5
12.1 Solid angle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12-3
12.2 Area of a triangle . . . . . . . . . . . . . . . . . . . . . . . . . . 12-4
12.3 Volume under a triangle . . . . . . . . . . . . . . . . . . . . . . . 12-5
12.4 Closed polylines on an upper airway surface . . . . . . . . . . . . 12-6
12.5 Connecting the intersection points . . . . . . . . . . . . . . . . . 12-7
12.6 One-way coupled FSI simulation . . . . . . . . . . . . . . . . . . 12-9
12.7 Memory usage when constructing the affinity matrix . . . . . . . 12-10
12.8 Lobar resistance as a function of volume . . . . . . . . . . . . . . 12-11
12.9 Particles in an ethanol dilution . . . . . . . . . . . . . . . . . . . 12-12
13.1 Workflow example for a phase IIa study in pharmacological devel-
opment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13-3
List of Tables
3.1 Correlations between changes in functional and anatomical parameters 3-9
3.2 Correlations between changes in functional and baseline parameters 3-10
3.3 Relationship between sex and the change in resistance . . . . . . . 3-12
3.4 Risk factors for an MR induced obstruction . . . . . . . . . . . . 3-12
3.5 Description of the amount of patients . . . . . . . . . . . . . . . . 3-12
4.1 Patient and sleep characteristics of subjects with and without OSA 4-7
4.2 Imaging parameters in subjects with and without OSA . . . . . . 4-8
4.3 Correlation analyses between imaging parameters and OSA severity 4-9
4.4 Clinical assessment of upper airway patency in subjects with or
without OSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4-10
4.5 Correlation analyses between clinical parameters of upper airway
patency and OSA severity . . . . . . . . . . . . . . . . . . . . . . 4-10
5.1 Patient’s demographic details . . . . . . . . . . . . . . . . . . . . 5-4
5.2 Upper airway region resistance for five asthmatic patients . . . . . 5-10
6.1 Inclusion and exclusion criteria . . . . . . . . . . . . . . . . . . . 6-4
6.2 Differences between CT and CBCT . . . . . . . . . . . . . . . . 6-8
6.3 BMI versus difference between CBCT and CT . . . . . . . . . . . 6-9
6.4 Sex versus difference between CBCT and CT . . . . . . . . . . . 6-10
7.1 Baseline characteristics . . . . . . . . . . . . . . . . . . . . . . . 7-12
7.2 Comparison of CF-CT sub scores per lobe . . . . . . . . . . . . . 7-13
7.3 Differences between lobes in AZLI concentrations . . . . . . . . 7-13
7.4 Correlations between lobar AZLI concentration and CF-CT scores 7-14
7.5 Number of patients and lobes with AZLI <10xMIC90 . . . . . . . 7-15
7.6 Influence of inhalation technique on AZLI concentrations . . . . . 7-15
8.1 Comparison of lung function and imaging parameters before and
after the administration of budesonide/formoterol . . . . . . . . . 8-7
8.2 Average changes and standard deviations in iVaw and iRaw after
administration of budesonide/formoterol . . . . . . . . . . . . . . 8-8
8.3 Comparison of lung function and imaging parameters before and
after the administration of the placebo . . . . . . . . . . . . . . . 8-8
xii
8.4 Comparison between the changes in lung function and imaging
parameters induced by the combination product and placebo . . . 8-10
8.5 Predictive value of the change in FEV1 to determine the visit where
combination product was administered . . . . . . . . . . . . . . . 8-11
8.6 Predictive value of the change in iVaw to determine the visit where
combination product was administered . . . . . . . . . . . . . . . 8-11
8.7 Predictive value of the change in iRaw to determine the visit where
combination product was administered . . . . . . . . . . . . . . . 8-12
9.1 List of medications taken by enrolled patients before entering the
study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9-8
9.2 Changes in imaging and lung function parameters after 6 months
of treatment with extrafine beclomethasone/formoterol . . . . . . 9-10
10.1 Particle deposition rates in the airways of chronic respiratory pa-
tients by segment . . . . . . . . . . . . . . . . . . . . . . . . . . 10-10
10.2 Particle deposition rates in the lungs of chronic respiratory patients
by date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-13
10.3 Particle deposition rates in the lungs of chronic respiratory patients
by pathology and age . . . . . . . . . . . . . . . . . . . . . . . . 10-14
11.1 Pulmonary function tests subject 1 & 2 . . . . . . . . . . . . . . . 11-3
Nomenclature
Abbreviations
3D Three-dimensional
ACT Asthma control test
ASL Airway surface liquid
ATS American thoracic society
AZLI Aztreonam lysine
BC Black carbon
BDP/F Extrafine beclomethasone/formoterol
CBCT Cone beam computed tomography
CF Cystic fibrosis
CF-CT score Cystic fibrosis computed tomography score
CFC Chlorofluorocarbons
CFD Computational fluid dynamics
COPD Chronic obstructive pulmonary disease
CPD Coherent point drift algorithm
CRP Chronic respiratory patients
CT Computed tomography
DNS Direct numerical simulation
DPI Dry powder inhaler
ERS European respiratory society
F Female
FRC Functional residual capacity
xiv
FRI Functional respiratory imaging
FSI Fluid structure interaction
FVM Finite volume method
GINA Global Initiative for Asthma
GOLD Global Initiative for Chronic Obstructive Lung Disease
HFA Hydrofluoroalkane
HRCT High resolution computed tomography
HU Hounsfield unit
IALD Internal airflow lobar distribution
ICC Intraclass correlation coefficient
ICS Inhaled corticosteroids
LABA Long acting beta 2 agonist
LES Large eddy simulation
M Male
MCP Maximal comfortable protrusion
MDI Metered dose inhaler
MIC Minimal inhibitory concentration
MIC90 MIC to inhibit the growth of 90% of bacterial strains
MP Maximal protrusion
MR Mandibular repositioning
MRA Mandibular repositioning appliance
MRI Magnetic resonance imaging
OSA Obstructive sleep apnea-hypopnea syndrome
Pa Pseudomonas aeruginosa
PRO Patient reported outcome
RANS Reynolds averaged Navier-Stokes
RV Residual volume
xv
SABA Short acting beta 2 agonist
SD Standard deviation
SGRQ Saint George’s respiratory questionnaire
SPECT Single-Photon Emission Computed Tomography
SVC Slow vital capacities
TLC Total lung capacity
UA Upper airway
Greek symbols
α Density ratio ρ/ρp [−]
β Width of the Gaussian kernel [−]
∆ Change in parameter [−]
 Turbulent dissipation rate [m2/s3]
Γ Diffusion coefficient [−]
λ General parameter [−]
µ Dynamic viscosity [Pas]
∇ Del operator [−]
ν Kinematic viscosity [m2/s]
νT Kinematic turbulent viscosity [m2/s]
Ω Solid angle [−]
ω Specific dissipation rate [1/s]
φ A dummy physical quantity [−]
ρ Fluid density [kg/m3]
ρp Particle density [kg/m3]
τ Shear stress tensor [N/m2]
τp Particle response time [s]
θ Angle between two vectors [rad]
Variables
xvi
<SaO2> Mean oxygen saturation [%]
m˙ Mass flow rate through the upper airway [kg/s]
~N Normal vector [−]
~P Point [−]
a Acceleration vector [m/s2]
dh Hydraulic diameter [m]
E Total energy [J]
F External force vector [N]
f Drag factor [−]
FD Drag force [N]
Fx Additional acceleration forces [N]
G Affinity matrix [−]
g Gravitation vector [m/s2]
gi Gravity in a certain direction xi [m/s2]
H0 Null hypothesis [−]
k Turbulent kinetic energy [m2/s2]
kH Heat conduction coefficient [W/mK]
L Length of the upper airway [mm]
m Mass [kg]
n Number of data points [−]
np Amount of points [−]
p Pressure [Pa]
PosSmin The position of Smin, measured from hard palate [mm]
ptot Total Pressure [Pa]
R Upper airway resistance [Pas/kg or kPas/L]
rres Resistance based radius [m]
rs Spearman rank correlation coefficient [−]
xvii
Re Reynolds number [−]
Recrit Critical Reynolds number [−]
S Surface [−]
Savgbottom Savg between epiglottis and larynx [mm
2]
Savgcentral Savg between the end of uvula and epiglottis [mm
2]
Savgtop Savg between hard palate and the end of uvula [mm
2]
Savg Average cross-sectional area of the upper airway [mm2]
Si Source term [−]
Smin Minimal cross-sectional area of the upper airway [mm2]
Smin/Savg Concavity of the upper airway [−]
Ssurf Surface area [m2]
T Temperature [K]
t Time [s]
U Fluid velocity vector [m/s]
ui Fluid velocity in a certain direction xi [m/s]
Vair Volume of the upper airway [mm3]
vi Particle velocity in a certain direction xi [m/s]
Vtot Total volume [m3]
x Cartesian coordinate in x-direction [m]
y Cartesian coordinate in y-direction [m]
z Cartesian coordinate in z-direction [m]
AD Aerodynamic diameter [µm]
AHI Apnea-hypopnea index [−]
AM Angulus mandibulae [◦]
BMI Body mass index [kg/m2]
d1 Maximum Ferret’s diameter [µm]
d2 Minimum Ferret’s diameter [µm]
xviii
dp Average particle diameter [µm]
eNO Exhaled nitric oxide [ppb]
FEV1 Forced expiratory volume in one-second [L or %]
FEV1/FVC Tiffeneau index [%]
FVC Forced vital capacity [L]
iRaw Imaging airway resistance [kPas/L]
iVaw Imaging airway volume [cm3]
MMAD Mean mass aerodynamic diameter [µm]
MMD Mass median diameter [µm]
oAHI Obstructive Apnea-Hypopnea index [−]
OAI Obstructive apnea index [−]
ODI Oxygen desaturation index [−]
PEF Peak expiratory flow [L/s]
Raw Airway resistance [kPas/L]
RDI Respiratory disturbance index [−]
SaO2 nadir Lowest level of oxygen saturation [%]
sRaw Specific airway resistance [kPas]
VC Vital capacity [%]


Nederlandstalige samenvatting
–Summary in Dutch–
In de pneumologie bestaan er verschillende kwantitatieve meetinstrumenten om de
clinici te helpen met hun diagnose. Het probleem met deze traditionele technieken is
dat ze weinig gevoelig zijn in het detecteren van veranderingen en dat de variatie tus-
sen de verschillende metingen heel hoog is. Dit heeft als gevolg dat de ontwikkeling
van medicatie voor luchtwegziektes duurder is dan de geneesmiddelenontwikkeling
in andere takken van de geneeskunde. Er zijn namelijk grootschalige onderzoeken,
in meerdere centra, in een groot aantal patiënten, gedurende een lange periode nodig
om het effect van een nieuw product te kunnen aantonen. Deze kosten beperken de
innovatie, wat resulteert in een onvervulde behoefte aan gevoelige kwantificeerbare
parameters in farmacologische ontwikkeling en klinische praktijk.
De reden hiervoor is dat de traditionele technieken de patiënt aanschouwen als een
zwarte doos. In dit proefschrift wordt functionele respiratoire beeldvorming (FRI)
voorgesteld als een instrument om “een blik in de zwarte doos” te werpen. FRI is een
methode waarbij patiënt specifieke medische beelden worden gecombineerd met
numerieke stromingsberekeningen. Dit opent de mogelijkheid om lokale informatie
over de anatomie en functionaliteit van de luchtwegen te genereren. Op die manier
kunnen lokale waarden van luchtweg volume, diameter en weerstand worden
gemeten en vergeleken. De uitspraak “een blik in de zwarte doos” verwijst naar deze
lokale informatie, maar verwijst ook naar de mogelijkheden van FRI in verschillende
ziektebeelden en in verschillende wetenschappelijke domeinen binnen en buiten de
geneeskunde.
Het eerste deel van dit proefschrift handelt over de mogelijkheden van FRI bij
de evaluatie en behandeling van het obstructieve slaapapneusyndroom (OSA).
Er is aangetoond dat FRI de effecten van een behandeling op de morfologie en
functionaliteit van de bovenste luchtwegen kan kwantificeren en dat deze effecten
kunnen worden voorspeld. Bij pediatrische OSA patiënten is er geconstateerd dat
FRI parameters sterker gecorreleerd zijn met de ernst van OSA dan de klinische
scores die abnormaliteiten in de bovenste luchtweg quantificeren.
Het tweede deel behandelt de depositie van geïnhaleerde medicatie. FRI is in staat
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om het belang van de patiënt specifieke anatomie aan te tonen wanneer men de
effectieve medicatiedosis in de longen wilt simuleren. FRI analyses tonen ook
aan dat er een grote inter- en intra-individuele variabiliteit zit in de morfologie en
functionaliteit van bovenste luchtwegen. Deze bevindingen onderstrepen het belang
van het gebruik van zoveel mogelijk patiënt specifieke informatie wanneer men de
depositie van deeltjes wil simuleren. FRI is ook bruikbaar gebleken in het patiënt
specifiek optimaliseren van een behandeling met een geïnhaleerde antibioticum bij
patiënten met mucoviscidose.
In het derde deel wordt FRI gebruikt om de effecten van inhalatie medicatie bij
patiënten met astma en chronische obstructieve longziekte (COPD) te evalueren.
FRI blijkt erg gevoelig te zijn om wijzigingen in de lokale luchtweg morfologie en
functionaliteit op te merken. Zowel bij astma als bij COPD patiënten blijken FRI
gegenereerde parameters 3 à 6 maal gevoeliger te zijn in het opmerken van drugs
geïnduceerde veranderingen dan de traditionele testen. Verder is er een verhoogde
specificiteit waargenomen en zijn er, in tegenstelling tot de traditionele testen,
correlaties gevonden tussen veranderingen in FRI parameters en veranderingen in
het subjectieve gevoel van patiënten.
Het vierde deel is erop gericht om FRI te gebruiken buiten de klinische studies,
door het verkennen van nieuwe toepassingsgebieden. Er is aangetoond dat FRI
kan helpen om het gedrag van fijn stof in de longen te begrijpen door uitgebreide
fysisch-chemische analyses van vervuilde lucht te combineren met patiënt spe-
cifieke simulaties. Het potentieel van FRI in het personaliseren van respiratoire
behandelingen is ook bestudeerd. Twee patiënten met een idiopathische unilaterale
verlamming van het middenrif werden anders behandeld ondanks het feit dat beiden
soortgelijke anatomische en fysiologische afwijkingen vertoonden op radiologisch
onderzoek. FRI toonde aan dat er problemen waren met de ventilatie en genees-
middelafgifte bij een patiënt, terwijl dit niet het geval was bij de andere patiënt,
resulterend in respectievelijk een chirurgische en conservatieve benadering.
FRI bevindt zich nog in een vroege ontwikkelingsfase en is niet zo goed gevalideerd
in vergelijking met de traditionele testen. In dit proefschrift wordt echter aangetoond
dat FRI een meerwaarde kan betekenen in verschillende onderzoeksdomeinen
binnen de pneumologie en in de klinische praktijk.
De hoge sensitiviteit en specificiteit van FRI maken de techniek heel geschikt als een
instrument om een beter inzicht te krijgen in de fysiologische werkingsmechanismen
van een bepaald medisch apparaat of geneesmiddel. Dit kan helpen om beslissingen
te nemen vroeg in het ontwikkelingsproces van dit apparaat of geneesmiddel. Het
gebruik van FRI in kleinschalige klinische fase IIa studies maakt het mogelijk
om het risico te verschuiven van de zeer dure fase III studies naar de goedkopere
fase II studies. FRI is ook een interessante technologie voor nichemarkten met
onvervulde behoeften, zoals mensen die een ingrijpende operatie moeten ondergaan
of die lijden aan zeldzame ziekten. Het probleem met deze zeldzame ziekten is dat
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sommigen onder hen zo zeldzaam zijn dat het bijna onmogelijk is om grootschalige
studies uit te voeren. De kans is hier dan ook groot dat de traditionele technieken niet
gevoelig genoeg zijn om mogelijke effecten te detecteren. Dit opent de mogelijkheid
om FRI te gebruiken als een surrogaat eindpunt. Een andere uitdaging die kan
worden aangepakt met behulp van FRI is de kwestie van de bio-equivalentie. FRI
kan worden gebruikt om zowel de effectieve longdepositie als het effect van het
originele en generieke geneesmiddel beoordelen. Op die manier kan er bepaald
worden of de twee producten vergelijkbare effecten induceren. Gepersonaliseerde
geneeskunde is een ander domein waarin FRI een toegevoegde waarde kan hebben.
FRI maakt het mogelijk om patiënt specifieke inzichten te creëren waardoor de juiste
behandeling aan de juiste patiënt kan worden gegeven. FRI kan ook helpen om de
gezondheidseffecten van luchtverontreiniging te begrijpen in een multidisciplinaire
aanpak. De fysisch-chemische karakterisering van luchtvervuiling kan worden
gebruikt als randvoorwaarde voor FRI, dat op zijn beurt invoergegevens kan generen
voor algoritmes die de gezondheidseffecten modelleren. Wanneer dit gecombineerd
wordt met klinische studies kunnen er nieuwe inzichten verkregen worden in de
mechanismen en effecten van fijn stof.
Verder onderzoek is nodig om de mogelijkheden van FRI in de toekomst uit te
breiden. Een eerste nuttige onderzoekslijn is het zoeken naar correlaties tussen
depositie van medicatie en de effecten op de luchtwegen. Dit zou een verbinding
kunnen maken tussen het tweede en het derde deel van dit proefschrift. Het is
ook interessant om te zoeken naar drempelwaarden voor veranderingen in FRI
parameters die klinisch relevant zijn zodat FRI kan gebruikt worden om klinische
conclusies te trekken. Een laatste lijn van onderzoek voor de nabije toekomst is de
mogelijkheden van FRI te bekijken bij het fenotyperen van patiënten. Een nieuw
systeem van pathologieclassificatie zou kunnen leiden tot een betere behandeling
van de patiënt.
De lezers van dit proefschrift zullen opmerken dat dit onderzoek eerder vanuit
een klinisch oogpunt dan vanuit een technisch oogpunt is aangepakt. Terwijl veel
onderzoek in de biomedische ingenieurswereld gericht is naar de creatie van heel
ingewikkelde wiskundige modellen in geïdealiseerde geometrieën of kleine cross-
sectionele patiënten datasets, streeft de auteur van deze thesis ernaar om eenvoudige,
klinisch relevante en schaalbare modellen te ontwerpen die gemakkelijk te begrijpen
zijn en kunnen gebruikt worden in een normale klinische setting in grote longitudi-
nale studies. Hoewel beide benaderingen hun voor- en nadelen hebben, mag men
niet vergeten dat biomedische ingenieurs in dienst moeten staan van de patiënt. Als
een model in staat is om een patiënt te helpen, dan is het een zinvol model. Als
toevoegingen aan het model leiden tot een betere levenskwaliteit voor de patiënt,
dan is het een beter model. Dit proefschrift laat zien dat ingenieurswetenschappen
en geneeskunde niet hoeven te botsen. De schrijver gelooft dat multidisciplinaire
teams bestaande uit artsen, ingenieurs en (levens-) wetenschappers de toekomst
zijn van de geneeskunde en hoopt dat deze thesis een goede stap in die richting is.

Summary in English
In respiratory medicine, several quantitative measurement tools exist that assist
the clinicians in their diagnosis. The problem with these traditional techniques is
that they lack sensitivity to detect changes and that the variation between different
measurements is very high. The result is that the development of respiratory drugs
is the most expensive of all drug development because large multicenter studies in
a high number of patients over a long period of time are needed in order to asses
the effect of a new compound. This limits innovation, resulting in an unmet need
for sensitive quantifiable outcome parameters in pharmacological development and
clinical respiratory practice.
The main reason is that the traditional techniques are based on a black box
approach. In this thesis, functional respiratory imaging (FRI) is proposed as a tool
to “open the black box”. FRI is a workflow where patient specific medical images
are combined with computational fluid dynamics in order to give local information
of anatomy and functionality in the respiratory system. In this way, local measures
of airway volume, diameter and resistance can be assessed and compared. The
statement “opening the black box” refers to this local information, but also refers to
the possibilities in different pathologies and different fields of application.
The first part of this thesis deals with FRI in the evaluation and treatment of
the obstructive sleep apnea syndrome (OSA). It is shown that FRI is able to quantify
the effects on upper airway morphology and functionality due to a treatment and
that these effects can be predicted from baseline measurements. In pediatric OSA
patients it is found that baseline measured FRI parameters are better correlated with
OSA severity than clinical scores of upper airway patency.
The second part deals with deposition of inhaled medication. FRI is able to
capture the importance of patient specific features in having a significant impact
in the effective lung dose and therefore the treatment efficacy. Furthermore, FRI
analyses show that there is a large inter- and intra-subject variation in upper airway
morphology and functionality, stating the importance of using as much subject
specific information as possible when simulating particle deposition. FRI is also
shown to be useful in optimizing inhaled antibiotic treatment on a patient specific
base in cystic fibrosis patients.
In the third part, FRI is used to evaluate the effects of inhalation medication
in asthma and chronic obstructive pulmonary disease (COPD) patients. FRI is
found to be very sensitive in picking up changes in local airway morphology and
functionality. In both asthma and COPD patients, FRI parameters are three to six-
fold more sensitive in picking up drug-induced changes as compared to traditional
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tests. Furthermore, an increased specificity is observed and, unlike the traditional
tests, correlations were found between changes in FRI parameters and changes in
patient feeling.
The fourth part aims to bring FRI outside the clinical trials, exploring different
fields of application. It is shown that FRI can help to understand the behaviour of
airborne particles in the lungs by combining detailed physical-chemical analyses of
particulate pollution with patient specific particle simulations. The potential of FRI
in personalizing respiratory treatment was also revealed. In two patients with an
idiopathic unilateral diaphragmatic paralysis, a different treatment approach was
chosen despite both having similar anatomical and physiological abnormalities on
radiological examination. FRI showed impairments in ventilation and drug delivery
in one patient, while this was not the case in the other patient, resulting in a surgical
and conservative approach respectively.
While FRI is still in its early development phase and is not so well validated
when compared to the traditional tests, this thesis shows that FRI can have an added
value in multiple research domains within pulmonology and in everyday clinical
practice.
The high sensitivity and specificity of FRI make it very well suited as a tool
to assess the mode of action in order to reach go/no go decisions early in the
development process of a device or drug. Using FRI in small-scale clinical phase
IIa trials can significantly de-risk the very expensive phase III trials. FRI is also an
interesting technology for niche markets with high unmet needs, like people who
undergo major surgery or who suffer from orphan diseases. The problem with these
rare diseases is that some of them are so rare that it is almost impossible to perform
large-scale studies. Chances are real that traditional techniques are not sensitive
enough to detect possible effects in these studies, opening the possibility of FRI
as a surrogate endpoint. Another challenge that can be tackled using FRI is the
question of bioequivalence. FRI can be used to assess the effective lung deposition
and effect of both original and generic compound, making it possible to determine
if the two products induce similar effects. Personalized medicine is another domain
where FRI can have an added value. FRI can generate patient specific insights,
making it possible to deliver the right treatment to the right patient. FRI can also
help to understand the health effects of air pollution in a multidisciplinary approach.
Physical-chemical characterization of air pollution measurements can be used as
input data for FRI, which can on his turn generate input data for health-effect
modelling algorithms. Combining this approach with clinical trials can result in a
better understanding of the mechanics and clinical effects of air pollution.
Further research is needed in order to expand the possibilities of FRI in the
future. A first research line that comes to mind is to search for correlations between
drug deposition and effect size, making a link between the second and the third part
of this thesis. It would also be interesting to search for threshold values for changes
in FRI parameters that indicate clinical significance. In that way, FRI can be used
to draw clinical conclusions. A last line of research for the near future is the power
of FRI in phenotyping patients. A new system of pathology classification could
lead to better patient treatment.
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The readers of this thesis will notice that the research approach is more from a
clinical than from an engineering point of view. While a lot of research in biomedi-
cal engineering is targeted towards the creation of very complicated mathematical
models in idealised geometries or small cross-sectional patient datasets, the author
of this thesis strives to design simple, clinically relevant and scalable models that
are easy to understand and that can be used in a normal clinical setting in large
longitudinal studies. Although both top-down and bottom-up approaches have their
advantages and disadvantages, one should not forget that biomedical engineering
is not only about the algorithm but about the patient. If a model is able to help a
patient, then it is a useful model. If adding some complexity to the model leads
to a better quality of life for the patient, then it is a better model. This thesis
shows that engineering and medicine do not have to clash. The author believes that
multidisciplinary teams consisting of doctors, engineers and (life) scientists are the
future of medicine and hopes that this thesis is a good step forward in that direction.

1
Introduction
Breathing is one of the most elementary functions of the human body as it supplies
our cells with oxygen and removes excess carbon dioxide. Without this gas ex-
change, the various metabolic processes in our body would stop functioning and
our organs would shut down. Before this gas exchange occurs, the inhaled air flows
through several anatomical regions that are grouped under the term respiratory
system.
The upper airway is defined as the part of the respiratory system lying outside
of the thorax (extrathoracic region) [2]. Its main respiratory function is to clean,
heat and moisten the incoming air [16]. The anatomy of the upper respiratory tract
is shown in figure 1.1.
In order to perform its function in the most optimal way, the preferred entrance
of incoming air is the nose. The hairs in the nasal vestibule regions filter the large
airborne particles after which the various sinuses and conchae cleanse, humidify
and heat the air [2]. After passing the pharyngeal regions, the trachea leads the
air to the lower airways and lung. In between, the epiglottis prevents swallowed
objects from entering the downstream respiratory system [2]. Furthermore, the
cough reflexes of the upper airway protect the lungs from the inhalation of foreign
material and clear secretions from them [16].
The lower airways and lung are defined as the part of the respiratory system
lying inside of the thorax (intrathoracic region). The lower airways consist of the
trachea, different bronchi and bronchioles that lead the air to the lungs where the
gas exchange takes place in the alveoli. The anatomy of the lower respiratory tract
is shown in figure 1.2.
The lung consists of five lobes. The left lung is subdivided into upper and
lower lobes by the oblique fissure whereas the right lung is partitioned into upper,
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Figure 1.1: The anatomy of the upper airway [12]
middle and lower lobes by the oblique and horizontal fissures. All these lobes
contain a number of segments separated from one another by connective tissue
septa [12].
As the respiratory system is directly connected to the outside world, it is very
prone to infections and sensitive to pollution. These external factors can induce
respiratory diseases or worsen the symptoms of underlying pathologies.
In respiratory medicine, several quantitative measurement tools exist that assist
the clinicians in their diagnosis. Most of these techniques aim to quantify the state
of the airways, alveoli and lung tissue by measurements of flow, volume or pressure.
Small airway diseases are mostly assessed using pulmonary function tests
(PFT). One of the most important outcome parameters that can be obtained by
PFT is the forced expiratory volume in 1 second (FEV1). To obtain this value, the
subject has to blow out as hard as possible in a device that measures the exhaled
flow. The total volume of air that has been exhaled at the end of the first second is
defined as FEV1.
Sleep-related breathing disorders such as the obstructive sleep apnea syndrome
(OSA) are mostly evaluated by letting the patient sleep in a sleep lab environment.
During the sleep, a polysomnography study is performed, resulting in real-time
signals of respiratory airflow, respiratory effort and blood gasses. These signals
are then analyzed and scored by a clinician, resulting in outcome parameters such
as the apnea-hypopnea index (AHI). AHI is defined as the sum of all occurring
complete cessations (apnea) and partial obstructions (hypopnea) of breathing during
the night, expressed on an hourly basis.
The problem with these traditional techniques is that they measure the prop-
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Figure 1.2: The anatomy of the lower respiratory tract [15]
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erties of the whole (respiratory) system of the subject. At first sight, this can be
considered as a very strong asset but it also has some drawbacks. Using these
techniques, subjects are reduced to “black boxes”. When abnormalities are detected
in one of the parameters, the clinical cause cannot be localized. Also, the amount of
information that is included in these parameters is so large, that a lot of sensitivity
is lost. The human body is so powerful that it can keep its functionality intact
even when a disease is already in an advanced state. These internal compensating
mechanisms are also incorporated in the traditional techniques, making them not
sensitive to detect changes.
An even larger problem is the variability within the same test. As FEV1
measurements need an effort from the subject, this results in day-to-day variability.
The recent UPLIFT trial in 6000 chronic obstructive pulmonary disease (COPD)
patients showed that there is between-test variability of 0.141 ± 0.138 L and that
changes are only considered clinically important if they are higher than 0.323 L [10].
As a moderate COPD patient has an FEV1 in the order of 1.5 – 2 L, these variations
can be considered important. Night-to-night variations in the AHI value equal or
higher than 10 events per hour are observed in the majority of OSA patients while
the cut-off value for being diagnosed with OSA is set at 5 events per hour [4]. As
both tests are used to classify patients by disease severity, the possibility exist that
patients are wrongly categorized. This can result in the patient not receiving the
optimal therapy.
The development of respiratory drugs is the most expensive of all drug devel-
opment cycles with development costs of more than a billion dollars per product [1].
Due to the lack of sensitivity and the variability of the traditional tests, large multi-
center studies in a high number of patients over a long period of time are needed
in order to asses the effect of a new compound. Even in these studies, there is no
guarantee that the results will be satisfying. Very large trials such as ISOLDE [6],
TRISTAN [7] and TORCH [8] showed that it is very difficult to detect changes
using classic PFT and that only weak correlations exist between PFT values and
the patient’s condition.
This results in only a limited number of large companies who want to invest in
these therapies. Companies with more limited resources often invest in therapeutic
areas with a higher return on investment. This limits innovation from which the
patient will be the victim.
It can be concluded that there is an unmet need for sensitive quantifiable out-
come parameters in pharmacological development and clinical respiratory practice.
Medical imaging techniques have the capabilities to “open the black box” and
provide regional information of airway structure and function. More and more
researchers understand the usefulness of medical imaging in research and clinical
practice. Work by Martonen and Longest provided important insights into aerosol
deposition characteristics by combining medical imaging with advanced analysis
methods [3, 11, 13, 19]. Most of the research in that domain was however performed
in generalized or idealized airway geometries. Although these studies provided
useful information about general mechanisms, they lacked the possibility to give
information about the behavior in an individual subject. This is especially important
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when dealing with diseased subjects as most pathologies are so heterogeneous, that
a one size fits all model does not work. At that point, the step towards subject
specific models needs to be taken. This approach has already proven to be valuable
as the COPDgene cohort, based on patient specific computed tomography scans,
has yielded interesting results on the airway and blood vessel structure in relation
to smoking [17], exacerbations [18] and healthy lungs [20].
Despite increasing evidence of the added value of medical imaging in clinical
trails and clinical practice, the overall quantitative usage of imaging tools is low.
One of the reasons is that most of these techniques are not as quantitative as they
should be. In most cases, data have to be interpreted by a human, introducing
variation in the process. Another reason is that a lot of the outcome parameters are
so complex that it is difficult to relate them to the human physiology. However, the
main reason is that a lot of these techniques require a specialized infrastructure that
is not readily available in most clinical centers [9, 14]. In this thesis, functional
respiratory imaging (FRI) is proposed as a tool to counter the issues of the present
techniques. FRI is a workflow where patient specific medical images are combined
with computational algorithms in order to give local information of anatomy and
functionality in the respiratory system. This technique has the advantages that
minimal user interpretation is required, that the resulting outcome parameters
directly relate to human physiology and that the necessary equipment is present in
most clinical centers. A detailed description of FRI can be found in chapter 2.
FRI has already been the subject of research in the past. The PhD thesis of
Dr. Jan De Backer elaborated on the usefulness of medical imaging in the field
of respiratory medicine and gave first insights on how functionality is added to
these images by performing flow simulations using computational fluid dynamics.
It was shown that these techniques can be used to gain a better understanding of
biomechanical principles and that it opened the possibilities of evaluating treatment
effects. This work can be considered as the basis for FRI. In the PhD thesis of Dr.
Wim Vos it was shown that FRI outcome parameters can be obtained through a
repeatable, high quality workflow. Furthermore, it was shown that correlations exist
between traditional techniques and FRI and that FRI can have an added value for
both patient and clinician.
The goal of this thesis is to explore the real power of FRI in “opening the black
box”. At the end, it has to be clear where FRI can help to meet some of the needs
in pharmacological development and clinical respiratory practice. Furthermore, the
first steps towards personalized medicine will be set and it will be explored how
FRI can be used in non-medical domains. To achieve this, the following approach
will be taken:
• More advantage will be taken of the regional measurement possibilities of
FRI. The region of interest will be split into distinct anatomical regions and
local analyses will be performed
• Where previous FRI research focused on adult asthma, COPD and sleep
apnea patients, this thesis wants to explore the possibilities in more vulnerable
groups with higher unmet needs such as pediatric patients with cystic fibrosis
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• Previous work all happened in clinical trail settings. In this thesis, the
technology will be brought into environmental science and clinical practice.
The statement “opening the black box” refers thus not only to the regional
information, but also refers to the possibilities in different pathologies and different
fields of application. To accomplish this, this thesis is divided into four major parts.
The first part deals with FRI in the evaluation and treatment of OSA. OSA is
characterized by a repeated collapse of the upper airway during sleep. To overcome
this abnormal situation, the respiratory reflexes will activate the upper airway
muscles in order to restore the airflow to the lungs. These so-called arousals disturb
the patient’s sleep, causing comorbidities such as a constant feeling of tiredness,
depression and vascular diseases. Chapter 3 describes a large scale cross-sectional
retrospective study in adult OSA patients where the effects of mandibular protrusion
on upper airway geometry and functionality are investigated. It is also inspected
which baseline characteristics determine these effects and if they are in line with
clinical findings. The goal of chapter 4 is to search for correlations between FRI
parameters and OSA severity in pediatric OSA patients. Furthermore, it is examined
if FRI can predict the effect of treatment outcome.
The second part deals with deposition of inhaled medication. As the response
of a patient to a certain inhaled drug is driven both by the receptiveness of the body
to that drug as by the amount of the drug reaching the lung, it is important to have
insights in these mechanics on a patient specific base. Chapter 5 describes how
FRI can be used to assess the lung deposited fraction of a respiratory compound.
As upper airway morphology is considered important when assessing the effective
lung dose, it is investigated if FRI can capture the influence of these patient specific
features. A lot of drug deposition modeling is performed in vitro, using casts of
generalized upper airways. These casts are based on scans in a supine position
while inhaled medication is mostly administered in an upright position. Chapter 6
describes a prospective open cross-over study that tries to quantify the differences
in airway morphology and functionality between supine and upright position in
healthy volunteers. Cystic fibrosis is a genetic disorder that has an effect on the
composition of the mucus in the airways. The mucus becomes more viscous, leading
to decreased mucus clearance resulting in bacterial infections. Inhaled antibiotics
have become popular treatments to counter these infections. The problem with
antibiotics is that the delivered dose has to be high enough to kill the bacteria.
Too low local concentrations result in suboptimal eradication of the bacteria and
contribute to the development of antibiotic resistance. In chapter 7, FRI is used
to increase the understanding of deposition mechanisms in diseased airways of
pediatric cystic fibrosis patients.
In the third part, FRI is used to evaluate the effects of inhalation medication
in asthma and COPD patients. Asthma and COPD are both chronic inflammatory
diseases that involve the small airways and cause airflow limitation. The nature of
inflammation and the anatomical sites that are involved are different: while asthma
affects only the airways, COPD affects both the airways and lung parenchyma [5].
In chapter 8, the acute effects of administering a budesonide/formoterol combination
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in COPD patients are examined. This placebo controlled crossover study aims to
demonstrate the higher sensitivity of FRI compared to the classic lung function
parameters in detecting changes due to the medication. It is also assessed if FRI has
a higher specificity when it comes to distinguishing between product and placebo. In
chapter 9, it is examined how FRI can be used to evaluate the effects of transferring
asthma patients from the standard fine particle treatment to an extra fine particle
treatment. The goal is to show that switching patients to a different product can lead
to additional, clinically relevant, long-term beneficial effects that are best observed
using FRI.
The fourth part aims to bring FRI a step further, outside the clinical trails. It
is known that air pollution has an associated increase in morbidity and mortality.
The behavior of individual airborne particles in the human lung is however not yet
understood. Current research is mostly based on generalized casts or computer
models obtained from morphometric analysis of the lungs. In chapter 10, it is
determined how the composition of individual particles, obtained with micro-
analytical techniques, can be combined with patient specific simulations of particle
deposition in the airways. When performing clinical trails, most results are obtained
using statistical analysis. However, it is not because a treatment works for the mean
of the population, that it will work for an individual patient. Chapter 11 aims to be
a first step in using FRI as a tool for personalized medicine. This chapter tries to
demonstrate the clinical value of FRI in describing a new clinical presentation of
the anatomical and physiological abnormalities in two subjects with an idiopathic
unilateral diaphragmatic paralysis. It is examined how FRI can help the clinician in
his decision process.
As large amounts of data are processed in this thesis, a lot of work is put in
improving the scalability of FRI by designing robust automation algorithms and by
reducing the turnaround time of the simulations. At the beginning of each individual
chapter, the contributions of the author and main challenges in engineering that are
tackled in that chapter are given. Some of these are explained in detail in chapter
12, including some advanced algorithms that can possibly be used in future work.
The thesis ends with chapter 13 where the conclusions that can be drawn from this
work are listed. The strengths en weaknesses of FRI are described and the future
research directions are pointed out.
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Functional respiratory imaging
Functional respiratory imaging (FRI) is the process of extracting patient specific
physiological data of the respiratory system from medical images. The purpose of
FRI is to assess the influence of a certain biological or mechanical process on the
respiratory system of a certain subject.
The medical images that are used as input data for FRI can originate from a
variety of imaging techniques (Figure 2.1). These techniques can be divided in two
large groups:
• Anatomical imaging techniques such as radiography, computed tomography
(CT), cone beam computed tomography (CBCT) and magnetic resonance
imaging (MRI)
• Functional imaging techniques such as ultrasonography, scintigraphy, positron
emission tomography, single-photon emission computed tomography and
hyperpolarized gas MRI
Figure 2.1: Images of the respiratory tract obtained from different imaging modalities
(radiography [4], MRI [1], CT, helium MRI [8], scintigraphy [10], PET [11], SPECT [5])
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In this thesis, the techniques from the first group are used as input data.
Although it seems contradictory to extract functional data from anatomical images,
a lot of information can be obtained when making the images in an intelligent way
and combining them with computational techniques. The main building blocks of
the FRI workflow are: medical imaging, image processing and computational fluid
dynamics.
2.1 Medical imaging
To be able to start the FRI workflow, the medical images must satisfy some con-
ditions. It is important that the images have a high quality and that they are taken
at the right moment. Furthermore, the risks for the patient has to be as low as
reasonably achievable and it has to be possible to obtain the images in a normal
clinical setting.
In this thesis, CT is used as primary imaging modality (Figure 2.2). With CT,
cross-sectional images (slices) are made by rotating an X-ray source and detector
around a subject as shown in figure 2.3.
Figure 2.2: A patient inside a CT-scanner [12]
The source sends out a beam of X-rays with known intensity and the detector
measures the radiation intensity on the opposite side. The difference between these
two values is the mean attenuation of the signal due to the line of tissue between the
source and detector. When rotating the source and detector, it is possible to get the
attenuation values (measured in Hounsfield units) for all the pixels in a cross-section
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Figure 2.3: Principles of computed tomography [9]
of the subject. As different tissues have different attenuation properties, it is now
possible create an anatomical cross-sectional image by applying a tomographic
reconstruction algorithm to the signal. When performing helical rotations, it is
even possible to get three-dimensional images. In order to improve the speed and
accuracy of CT scanners, modern CT scanners use fan beam X-ray sources and
multiple detector rows that make it possible to scan multiple slices at the same time
(Figure 2.4).
A variation of CT that is used in chapter 6 is CBCT. In this type of scanner, the
X-ray beam is conical shaped and the detector is able to perform two-dimensional
measurements. This makes it possible to construct three-dimensional images using
a single rotation.
Because air functions as a natural contrast agent, CT has the highest signal
to noise ratio and spatial resolution of all pulmonary imaging tools. On top of
that, the acquisition time is very short, allowing the whole lungs to be imaged
during breath hold to rule out motion artifacts. Furthermore, this technique allows
analyzing the region of interest in three dimensions. The disadvantage is that
CT produces ionizing radiation, possibly resulting in adverse health effects for
the patient. However, due to the high signal to noise ratio when imaging air, the
radiation dose needed for FRI is much lower as compared to conventional CT
scans [3]. With today’s technology, it is possible to perform a thorax scan with
an effective radiation dose for a patient of around 2 mSv. The next generation CT
scanners will be using more advanced iterative imaging reconstruction algorithms
and it is expected that the effective dose will be reduced to the level of a normal
chest radiography. As children are more sensitive to radiation than adults, they were
scanned with adapted protocols in order to decrease the dose even more.
Even more important than the quality of the image is the moment at which
it is taken. This is a prerequisite for extracting functional data and also allows
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Figure 2.4: Computed tomography with multiple detectors [7]
comparing a pre and post situation. The moment is here defined as the lung
level or the moment during the breathing cycle. For upper airway geometries this
moment was set depending on the purpose, as the image has to give an optimal
representation of the process one wants to investigate. Since obstructive sleep apnea
is an expiratory phenomenon, it was hypothesized that the end inspiratory geometry
is the main driver for collapsibility. Since inhalation medication is mostly taken
during a slow inhalation, the scan was also taken during that maneuver. For the
lower airways, the CT images were taken during breath hold at two distinct lung
levels: at the end of a normal exhalation (functional respiratory capacity or FRC)
and at maximal inspiration (total lung capacity or TLC). In this way, functional
information is generated as it is now possible to assess how airway geometry and
lobar volumes change over the breathing cycle. In order to scan (diseased) subjects
at breath hold, the acquisition time needs to be as low as possible. In general, any
scanner that is able to scan the whole lung in around 6 s with a voxel size of around
0.6 mm can generate high quality input data for FRI. Most modern 64-slice CT
scanners fulfil these requirements.
As it is necessary to scan at the correct moment, the breathing signal has to
be monitored while the patient is on the table. Using a pneumotach device, it is
possible to get a real time measurement of the breathing pattern and lung levels.
In this way, it is guaranteed that the images are taken at the moment that was
predefined for the study.
The only devices that are needed to create the correct input data for FRI
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analyses are a modern CT scanner and a pneumotach device. Since these devices
are available in most clinical settings, FRI is not limited to academic research but is
applicable in clinical trails and medical practice.
2.2 Image processing
After the acquisition of the medical images, the regions of interest are extracted
using segmentation algorithms. A combination of automatic algorithms and manual
correction is used to correctly select the voxels. The automatic airway segmentation
algorithm that is used in this thesis is a proprietary algorithm based on the work of
Tschirren et al. [13]. Although this approach is not ideal due to possible variability
in the manual part, it is the only possibility at this moment. The results that
were presented at the fourth international workshop on pulmonary image analysis
in Toronto after a segmentation challenge showed that human interaction is still
necessary when segmenting airways and lobes [2]. The biggest challenge is the
automatic detection of fissure lines that are needed to make a distinction between
the lobes as these are easily lost due to the noise in the images (Figure 2.5). An
internal sensitivity study showed that the influences of the manual interventions are
quite small when people are well trained (a maximal difference of less than 3 %).
With this workflow, it is possible to segment down to bronchi with a diameter of
about 1 – 2 mm. To obtain the most patient specific information, the lower airways
are extracted at TLC level as the larger airway lumen allows segmenting more
airway generations.
After the segmentation, the extracted voxels are converted to a triangulated
three-dimensional model (Figure 2.6) on which anatomical measurements can
be performed. Furthermore, this model can be post-processed by labeling the
correct anatomical regions and defining inlets and outlets for the computational
fluid dynamics simulations.
2.3 Computational fluid dynamics
Computational fluid dynamics (CFD) is a computer simulation technique that allows
to determine the behavior of a flow in a model [6]. In this method, flow is described
by the Navier-Stokes equations and is numerically solved on a computational grid
(the mesh). This method makes it possible for the system of mathematical equations
to be solved iteratively. The result is that flow features such as speed, pressure and
density are known everywhere in the model.
The theory around CFD is described in previous work of the author [14] and
is given in appendix A. For the integration with FRI, the Navier-Stokes equations
can be adapted to be optimal for the study. These adaptations are described in the
different chapters.
In most cases, adaptation is a synonym for simplification. CFD can be made
very simple and very complicated, depending on the requirements. If one wants
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Figure 2.5: Axial CT-slice of the lung. The white arrows indicate the fissure lines
Figure 2.6: Reconstructed models of the upper airway, lower airways, lung lobes and
pulmonary blood vessels
Figure 2.7: A detail of a meshed airway, the Navier-Stokes equations, two results of CFD
calculations (pressure contours and particle deposition)
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to design a car, it is useful to use very complex models that mimic the reality as
good as possible as insights in every vortex can be used to optimize the design. As
the car will be produced in mass, every small optimization can have large financial
consequences. Furthermore, the computational grid can be manually optimized for
the given geometry and boundary conditions can be defined exactly. If one wants to
simulate a patient, it is useful to use models that are as simple as possible for the
phenomenon one wants to investigate. As time is critical for making simulations
clinically relevant, it is counterproductive to use complex models that do not add any
clinical relevance as compared to much simpler models. One of the main reasons is
that the numerical precision is not the limiting factor for a correct simulation, but
the uncertainties in the boundary conditions are.
The largest problem when simulation biological flows is the correct definition
of boundary conditions as it is very difficult to measure these in a patient in a non-
invasive way. However, to make the simulations fully patient specific, physiological
correct boundary conditions are a must.
Upper airways are the easiest to simulate (Figure 2.8). As there is only one inlet
and one outlet, a simple physiological pressure difference or mass flow is sufficient
to obtain good results. Although the possibility exists that upstream and downstream
regions have an effect on the exact results, these will be very small making it difficult
to justify the taking of additional scans to obtain more information about these
regions. Also, upper airway simulations are mostly performed to simulate changes
in upper airway functionality before and after an intervention that only affects that
region.
When simulating lower airways, things become more complicated. A normal
airway branch consists of one inlet and multiple outlets that are connected to
different anatomical regions (the lobes) in the lung. While the boundary conditions
at the inlet are straightforward (a physiological pressure or a mass flow) and are
easy to measure, the boundary conditions at the outlets are unknown. The problem
is that these conditions need to reflect the impedances of the downstream regions,
which are not visible on the CT-scanner due to resolution limitations. However, as
scans are taken at FRC and at TLC, some functional information concerning the
downstream bronchial resistances and alveolar stiffness can be extracted. Although
it is not possible to extract all individual features, it is possible to segment the
envelop of the lobe. When segmenting the different lobes at the two levels, it is
possible to compare the volumes. The volume difference between TLC and FRC of
a certain lobe is then a measure for the flow that goes to that lobe. As it is known
which outlet goes to which lobe, it is possible to define the flow that goes through
that outlet. This is defined as the internal airflow lobar distribution (Figure 2.9). As
outflow conditions are numerically not stable in these irregular geometries and as
the flow per lobe is known but not the flow per outlet, an iterative algorithm is used
that calculates the under pressures that are needed to obtain that flow.
The main advantage of this method is that it is fully patient specific, even
incorporating the dynamics of diseased anatomical areas.
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Figure 2.8: Pressure values from an inspiratory flow simulation in an upper airway. The
under pressure at the larynx (blue) drives the air at atmospheric pressure (red) from the
nostrils to the downstream regions, resulting in a pressure drop over the upper airway
Figure 2.9: Lobes at FRC and TLC and the resulting internal airflow lobar distribution
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2.4 Clinical relevance
In the previous sections, statements are made about the clinically relevant results
that can be obtained with FRI. However, how are the clinically relevant outcome
parameters defined? A clinically relevant parameter is a parameter that can be linked
to the wellbeing of the patient. One of the problems in biomedical engineering
is that clinicians and engineers have a different expertise and that communication
between them can be confusing. As the clinician is in the end responsible for the
patient, he will not make any decision based on data where he has no confidence in.
That is why the engineers have to provide the clinician with parameters that
can be directly translated to the physiological status of the respiratory system. It is
therefore not useful to provide him with local measures of turbulent kinetic energy
if one wants to test if a certain inhalation compound has an effect in a patient
suffering from asthma. More useful parameters are the changes in volume and
resistance as it easy to see how these parameters correspond to lung function. When
providing these parameters on a lobar level, the clinician can have more insight into
the heterogeneity of the disease and the mode of action.
Especially these local insights make FRI so valuable. The human body adapts
so well to new situations that traditional pulmonary function tests, which generate
global outcome parameters covering the whole respiratory system, are not able
to detect lung diseases in an early stage. In this way, the possibility exists that
irreversible damage has occurred before any test has given an indication. That also
emphasizes the importance of time. The goal of FRI is become a technique that is
more sensitive than the traditional techniques, but with a speed that is similar.
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Obstructive sleep apnea
syndrome

3
Anatomical and functional changes in
the upper airways of sleep apnea
patients due to mandibular
repositioning: A large scale study
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3.1 Abstract
The obstructive sleep apnea-hypopnea syndrome (OSA) is a sleep related breathing
disorder. A popular treatment is the use of a mandibular repositioning appliance
(MRA) which advances the mandibula during the sleep and decreases the collapsi-
bility of the upper airway. The success rate of such a device is, however, limited and
very variable within a population of patients. Previous studies using computational
fluid dynamics have shown that there is a decrease in upper airway resistance in
patients who improve clinically due to an MRA. In this article, correlations between
patient specific anatomical and functional parameters are studied to examine how
MRA induced biomechanical changes will have an impact on the upper airway
resistance. Low-dose computed tomography (CT) scans are made from 143 patients
suffering from OSA. A baseline scan and a scan after mandibular repositioning
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(MR) are performed in order to study variations in parameters. It is found that
MR using a simulation bite is able to induce resistance changes by changing the
pharyngeal lumen. The change in minimal cross-sectional area is the best parameter
to predict the change in upper airway resistance. Looking at baseline values, the
ideal patients for MR induced resistance decrease seem to be women with short
airways, high initial resistance and no baseline occlusion.
3.2 Contributions of the author
The author of this thesis was the principal researcher in this study. He performed
the segmentation of the airways, investigated the meshing strategy and determined
the setup of the computational fluid dynamics simulations. He was involved in
the choice of outcome parameters, and performed all measurements manually.
Furthermore, he was responsible for all statistical analyses and the interpretation
of the results. The main challenge in this study was to extract and combine the
large amounts of data, originating from different sources and having different file
structures.
3.3 Introduction
The obstructive sleep apnea-hypopnea syndrome (OSA) is a sleep related breathing
disorder that is characterized by repeated partial or complete closure of the pharynx
[1]. To overcome this abnormal situation, the respiratory reflexes will activate the
upper airway muscles in order to restore the flow to the lungs. These so-called
arousals disturb the patient’s sleep, causing excessive sleepiness at daytime [12].
The physiologic consequences of these episodes of airway collapse are repetitive
bursts of sympathetic activity, hypoxia, hypercapnia, increased left ventricular
afterload, and acute hypertension [5]. This pathology is often associated with
increased risk of cardiovascular co-morbidity [29]. The golden standard in assessing
the severity of OSA is the Apnea Hypopnea Index (AHI), which is the sum of all
occurring respiratory events during the night, expressed on a hourly basis. This
value can be measured by performing polysomnography in a sleep clinic [12, 19].
Previous studies showed that anatomical markers are not able to differentiate
healthy individuals from OSA patients [35]. However, within the population of
OSA patients, several of these do correlate with the severity of the pathology. The
size of the pharyngeal airway lumen has been measured using different imaging
techniques [7, 20, 28, 34, 36, 38]. Correlations are found between OSA severity and
velopharyngeal airway size, minimal cross-sectional area [36], minimal posterior
airway space [25, 30], reduced minimum palatal airway widths [17], airway volume
and several other parameters describing the narrowness of the pharyngeal airway
[34]. It is thought that these parameters can help to select the ideal treatment on a
patient specific basis.
One of the possible treatments for OSA is the use of a mandibular repositioning
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appliance (MRA). This device repositions the mandibula during the sleep and
decreases the collapsibility of the upper airway. The major drawback of this
treatment is that the success rate is limited and very variable within a population
of patients [32]. A technique to predict the patient specific success would be of
significant clinical importance [8]. Previous studies have shown that functional
respiratory imaging, by means of computational fluid dynamics, can predict the
efficiency of the MRA treatment. The percentage change in upper airway resistance
correlates very well with a change in AHI [10, 11, 34].
In this study, relationships between patient specific anatomical and functional
parameters will be studied. In this way, it is possible to examine how the mandibular
repositioning (MR) induced biomechanical changes will have an impact on the
upper airway resistance. The hypothesis is that these insights can help future clinical
research.
3.4 Methods
3.4.1 Patient data
Low-dose computed tomography (CT) scans are made from 143 patients suffering
from OSA, lying on their back. Patients are selected as possible candidates for MRA
treatment after standard ENT clinical examination and standard polysomnography.
The patients are then referred to the dental sleep professional for a clinical and radi-
ological dental examination. Patients with active temporo-mandibular disfunction
are excluded from the study as well as patients suffering from untreated caries and
periodontal disease, edentulous patients and those having an insufficient number of
remaining teeth. If no further contraindications for MRA treatment are present, the
patients are included [26, 32]. A baseline scan and a scan with the mandibula in an
advanced position using a prefabricated bite registration are performed so variations
in parameters before and after MR can be studied. The registration bites used in
this study can be seen in Figure 3.1 and are prepared by a dental technician and
fitted as well as adjusted intraorally by the dentist titrating mandibular advancement
to the maximal comfortable protrusion (MCP).
This position differs from the maximal protrusion (MP) in that the MP is
an extreme protrusion where no other movements in lateral and/or cranio-caudal
direction is possible anymore. The MCP is determined by having the patient in
the MP from which the mandible is gently moved backwards, retruded, until the
patient does not experience any more the constraints of the MP [6]. This procedure
is repeated three times and the MCP is taken as the average of these measurements.
The advantage of this procedure is furthermore that one does not start with an
arbitrary position of, e.g. 50% of the MP, but with an individually determined
position. This will furthermore increase the patients therapy compliance.
Institutional review board approval is obtained and all patients signed an
informed consent.
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Figure 3.1: Registration bite as used in this study: (a) Registration bite, (b) Placed in an in
situ model
3.4.2 Computational domain and grid
The CT-images of a patient are loaded into Mimics (Materialise, Leuven, Belgium)
and are ordered in a way that correct sagittal, transverse and coronal views are
reconstructed. On these reconstructed views, the region of interest is defined in
a mask. A mask is defined as a part of the image where the gray values lie in
a specified interval of Hounsfield units (HU). For upper airways, a range of HU
between -1024 and -400 is seen to give very good results while a range between 226
and 3071 is used for the skull [16, 39]. The masks are extracted from the images
and patient specific 3D reconstructions of the upper airway (the region behind the
tongue, from the hard palate to the vocal cords, as seen in Figure 3.2(a) and skull
are obtained.
To prepare the segmented upper airway for CFD calculations, a computational
grid is created using TGrid 4.0.16 (Ansys, Lebanon, USA). A sensitivity study
showed that a computational grid between 500,000 and 1,000,000 tetrahedral cells
is sufficient for reaching mesh convergence.
3.4.3 Physical models and boundary conditions
Computations are done with a commercial Navier-Stokes solver (Fluent 6.3.26,
Ansys, Lebanon, USA). As the air velocity in the upper airways is smaller than a
Mach number of 0.2, the compressibility of air can be neglected [4]. Also, the flow
in the upper airways is considered adiabatic. The Navier-Stokes equations are now
given by the continuity (Equation 3.1) and momentum (Equation 3.2) equations for
an incompressible flow with constant dynamic viscosity [2, 31, 33].
∇ ·U = 0 (3.1)
ρ
(
∂U
∂t
+ U ·∇U
)
= −∇p+ µ∇2U (3.2)
In this equation, U is the velocity vector, ρ is the density, t is the time, p
is the pressure and µ is the dynamic viscosity. The values for ρ and µ are taken
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(a) Location of the upper airway (b) Computational grid and pressure drop
Figure 3.2: Three-dimensional upper airway model
for air at 15 ◦C. Flow simulations are performed by solving Equation 3.1 and
Equation 3.2 numerically. The pressure-based solver is used with a node-based
Green-Gauss gradient treatment as it achieves higher accuracy in unstructured
tetrahedral grids compared to the cell-based gradient evaluation. Second-order
discretization schemes are used for the pressure and momentum equations. The
pressure-velocity coupling is solved using the SIMPLE scheme.
In order to enable proper comparison between the models the applied pressures
at the in- and outlet are equal for all models. The steady boundary conditions are
chosen, so that a laminar approach is possible. At the inlet, a total pressure of 0 Pa
is set and at the outlet, a static pressure of -20 Pa is applied. Pressure boundary
conditions are chosen for realistic inter-patient comparison as a constriction of the
upper airway will not change the static pressure difference between atmosphere and
lungs, but will restrict the airflow.
3.4.4 Outcome parameters
3.4.4.1 Upper airway morphology
All measurements on the upper airways are done before and after MR. In this way
it is possible to detect morphological changes due to the treatment. The anatomical
parameters that are measured are:
• The volume of the upper airway (Vair).
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• The length of the upper airway (L). This is kept constant inter-patient.
• The minimal cross-sectional area of the upper airway (Smin).
• The position of the minimal cross-sectional area (PosSmin ). This is done by
measuring the distance between the top of the upper airway and the minimal
cross-sectional area. This value is divided by L in order to obtain a parameter
that is normalized for the length of the airway.
Starting from these measurements, other parameters are calculated. The mean
cross-sectional area of the upper airway is calculated by means of Equation 3.3.
Savg =
Vair
L
(3.3)
The ratio Smin/Savg is calculated as it is to be investigated whether upper
airways with a rather uniform area distribution react differently from airways which
are more concave and thus have a lower Smin/Savg .
3.4.4.2 Skull morphology
To determine if the morphology of the skull has an influence on the MR, the angulus
mandibulae (AM) is measured. Therefore, two construction lines are created. One
line connects the midpoint of the arc formed by the AM with the center of the
condylus. The other line contains the same midpoint and acts as a tangent line to
the lower part of the mandibula. The angle between both lines is considered the
AM as seen in Figure 3.3 [11].
Figure 3.3: Angulus mandibulae
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3.4.4.3 Functional parameters
The airway resistance R is given by Equation 3.4 [21, 23].
R =
∆p
m˙
(3.4)
In this equation, ∆p is the total pressure drop and m˙ is the mass flow rate in the
upper airway. The resistance can be converted to a resistance-based radius rres by
combining the Poiseuille equation, given as Equation 3.5, with Equation 3.4.
∆p =
8µLm˙
piρr4res
(3.5)
⇔ rres = 4
√
8µL
piρR
(3.6)
This parameter, given by Equation 3.6, is an approximation as the Poiseuille
equation is only valid for straight, rigid tubes [3, 37]. However, rres is calculated
for statistical purposes as R can become infinite. Finally, it is investigated if men
and women respond differently to the MR treatment.
3.4.5 Statistics
The data are tested for normality by using the Shapiro-Wilk W Test. It is found
that none of the measured parameters and none of the calculated evolutions due
to the treatment are normally distributed. Therefore, non-parametric techniques
are needed to perform correct statistical analysis [27]. Statistical analysis was
performed using commercial statistical software (Statistica 7.0, Statsoft). The
techniques used in this paper are Spearman rank correlation and Mann-Whitney
U-test. The significance level is chosen to be p < 0.05.
3.5 Results
3.5.1 Correlations between changes in functional and anatomi-
cal parameters
From here on, the symbol ∆ is used to define the percentage difference between the
parameter before and after MR. Figure 3.4(a) shows that there is a significant inverse
correlation between the percent change in upper airway volume and the percent
change in upper airway resistance. As L is held constant inter-patient, the exact
same result is found when comparing ∆Savg . There is a highly significant inverse
correlation between ∆Smin and the percent change in resistance, as illustrated in
3.4(b). The resistance also tends to decrease when the airway becomes less concave.
Detailed results are found in Table 3.1.
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(a) Correlation between change in volume and change in resistance
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(b) Correlation between change in Smin and change in resistance
Figure 3.4: Correlations between changes in functional and anatomical parameters
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Parameter1 Parameter2 n rs p
∆R ∆Vair 111 -0.61 < 0.001
∆Savg 111 -0.61 < 0.001
∆Smin 111 -0.93 < 0.001
∆Smin/Savg 111 -0.78 < 0.001
∆rres ∆Vair 123 0.56 < 0.001
∆Savg 123 0.56 < 0.001
∆Smin 123 0.94 < 0.001
∆Smin/Savg 123 0.84 < 0.001
Table 3.1: Correlations between changes in functional and anatomical parameters
3.5.2 Correlations between changes in functional and baseline
parameters
There seems to be a significant difference between men and women, as seen in
Figure 3.5. In women, resistance tends to decrease while this is not the case in
men. The baseline resistance, L and Smin can give an indication of the change
in resistance, but the correlations are weak. No correlations with AM are found;
however, it has to be mentioned that the AM data are missing for some patients
as their CT-scan did not include the condylus, making it impossible to perform
measurements. Detailed results are found in Table 3.2.
Better correlations between anatomical baseline parameters and resistance
changes are found when patients with a baseline occlusion are excluded. Especially
baseline L and rres are promising parameters. Detailed results are found in Table
3.2. Also here, the gender differences are visible (see Table 3.3), but the resistance
tends to decrease in both sexes. It is discovered that patients with smaller and more
concave anatomical structures at baseline tend to occlude more after MR. Especially
a smaller Smin and a smaller Smin/Savg (see Figure 3.6(a)) are risk factors. Also,
when Smin is closer to the tongue, there is a higher chance of obstruction, as seen
in Figure 3.6(b). Detailed results are shown in Table 3.4.
3.6 Discussion
Details of the mode of action of MRAs in the treatment of snoring and OSA remain
uncertain. Several studies suggest that the tongue, soft palate, lateral pharyngeal
walls and mandibula interact to control airway size. It is thought that mandibular
advancement induces complex changes in these structures, resulting in improved
airway stability [9]. The goal of this study is to understand the MR induced
biomechanical changes, in order to support future clinical research. The strength
of this study is the fact that measurements are done on a very large patient data
set. In this way, it is possible to confirm or reject hypotheses that were formulated
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Figure 3.5: Difference between the sexes in change in resistance
Parameter1 Parameter2 All Patients Patients without baseline collapse
n rs p n rs p
∆R Vair 111 0.16 NS 96 0.29 0.004
Savg 111 0.13 NS 96 0.25 0.016
Smin 111 0.20 0.040 96 0.39 < 0.001
Smin/Savg 111 0.18 NS 96 0.37 < 0.001
L 111 0.15 NS 96 0.22 0.029
rres 111 0.21 0.029 96 0.41 < 0.001
AM 100 0.16 NS 86 0.14 NS
∆rres Vair 123 -0.13 NS 108 -0.19 0.048
Savg 123 -0.10 NS 108 -0.19 0.048
L 123 -0.21 0.018 108 -0.26 0.006
rres 123 -0.11 NS 108 -0.20 0.036
AM 112 -0.09 NS 98 -0.07 NS
Table 3.2: Correlations between changes in functional and baseline parameters
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(a) Comparison of baseline Smin/Savg in patients without and with MR induced obstruction
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(b) Comparison of baseline PosSmin in patients without and with MR induced obstruction
Figure 3.6: Correlations between changes in functional and baseline parameters
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All patients
Parameter nMen nWomen Median [quartile] men Median [quartile] women p
∆R (%) 84 27 -0.34 [-45.48/41.41] -38.08 [-61.08/-11.08] 0.008
∆rres (%) 95 28 0 [-16.88/13.69] 12.55 [2.15/24.62] 0.003
Patients without baseline collapse
Parameter nMen nWomen Median [quartile] men Median [quartile] women p
∆R (%) 71 25 -19.02 [-52.06/72.97] -39.17 [-61.08/-20.39] 0.023
∆rres (%) 82 26 0.43 [-26.89/16.86] 12.98 [3.75/26.61] 0.007
Table 3.3: Relationship between sex and the change in resistance
Parameter n median p
no obstruction obstruction no obstruction obstruction
Vair [mm3] 116 27 8676.88 5837.18 < 0.001
Savg [mm2] 116 27 138.12 86.55 0.002
Smin [mm2] 116 27 39.04 0 < 0.001
Smin/Savg [-] 116 27 0.25 0 < 0.001
PosSmin [-] 116 27 0.28 0.13 0.009
Table 3.4: Risk factors for an MR induced obstruction
Number Description
143 The total number of patients
123 Patients where ∆rres can be calculated. This excludes patients with ∆rres = ±∞
108 The same as above, but also excludes patients with a baseline occlusion
112-98 The same as the above two, but excludes patients where the AM could not be measured
(CT-scan did not include the condylus)
111 Patients where ∆R can be calculated. This excludes patients with ∆rres = ±∞
96 The same as above, but also excludes patients with a baseline occlusion
100-86 The same as the above two, but excludes patients where the AM could not be measured
(CT-scan did not include the condylus)
Table 3.5: Description of the amount of patients
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in small-scaled studies. The different subgroups of patients that are used in the
statistics are described in Table 3.5.
For this patient dataset, the upper airway resistance decreases in 58.7% of the
cases, which is in the same range as the clinical success rate [24, 32]. It is found
that the change in the upper airway resistance due to MR is determined by the
change in pharyngeal lumen. This confirms the results of De Backer et al. [10] and
Vos et al. [34] in small patient populations. However, in 20.3% of the patients, the
resistance increases or stays the same while the volume increases. The changes in
Smin and Smin/Savg are better parameters to deal with this effect. In only 3.5% of
the patients, the resistance increases or remains unchanged while these parameters
increase. Especially a MR induced change in minimal cross-sectional area is a
good parameter to predict the change in upper airway resistance. This is a very
interesting finding and can be explained by the fact that the MR induces a rotation
of the tongue in some patients. This rotation causes a partial or full occlusion of the
upper airway and thus an increase in its resistance. The change in minimal cross
sectional area is much more sensitive to this rotation than the change in volume,
making it a better parameter to predict the resistance change. This strong link
between CFD calculated resistance and the minimal cross-sectional area confirms
the observations of Yu et al. [40].
It is discovered that baseline parameters can also give some indications about
the change in resistance. Women tend to have a larger resistance decrease compared
to men, which is confirmed by the clinical results of Marklund et al. [22]. Also,
patients with a high initial resistance tend to improve more. However, people with
a baseline occlusion or very concave airways have a higher chance of an occlusion
while wearing the protrusive bite registration. This is especially true if Smin is
close to the tongue. This is logical as even a small rotation of the tongue can cause
an occlusion in these patients. This confirms clinical observations as an occlusion
at baseline indicates that the patient suffers from severe OSA, while MRAs are only
suited for patients with mild-to-moderate OSA [18].
No correlations using the angulus mandibulae are found, despite the fact that
De Backer et al. [11] found a weak correlation between the AM and ∆Vair , making
it a promising parameter for this larger scale patient study. A possible explanation
is that a baseline value of the skull is only indirectly related to the soft tissue
morphology. For future research, it would be interesting to check for correlations
between resistance changes and mandibular protrusion. Mandibular protrusion has
shown to have an effect on the pharyngeal cross-sectional area [13]. In a study
using video endoscopy, the mandibular protrusion resulted in a significant increase
in airway diameter, primarily in the oropharyngeal cross-sectional area, in both
obese and nonobese subjects [14]. It is thought that protrusion is necessary to make
the MRA work because placebo MRAs that do not perform a mandibular protrusion
do not decrease AHI [15].
When excluding the patients with a baseline occlusion, better correlations are
found. The ideal patients for MR induced resistance decrease seem to be women
with short airways and high but finite initial resistance. However, one should take
care about interpreting baseline resistance values. Due to the major and minor losses
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in the geometry, the resistance will change with changing boundary conditions. The
boundary conditions have to be exactly the same for all patients in order to get a
resistance value that is only geometry dependent.
In this study, upper airway walls are assumed rigid. On longterm, it should
be intriguing to develop a fluid structure interaction model of the upper airway
in order to investigate the relationship between structural and flow parameters.
In this way, the behavior of the surrounding tissue can be analyzed, opening
possibilities to create predictive techniques for a whole range of treatments for OSA.
Using rigid walls, the laminar approach is the most appropriate for calculating the
geometrical resistance. A sensitivity study showed that there is no difference in
resistance when using a turbulence model. The nasal cavity was not segmented
as no geometrical changes are expected in this region as a result of mandibular
repositioning. Furthermore, one would reduce the sensitivity to pick up change
that are specifically induced by the device by including the nasal resistance in the
CFD calculations. Another reason to exclude the nasal cavity was to limit radiation
exposure as much as possible. Considering the limited influence of this region to
describe MR related changes, it was judged to be better not to expose the retina to
X-rays.
The largest limitation of this study is that the biomechanical observations
cannot be mapped directly to clinical outcome. However, it is thought that the
results of this study, using patient specific computer models, can provide an added
value for the MR treatment of OSA. The gained biomechanical insights can be used
to interpret results from future clinical research.
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Functional respiratory imaging as a
tool to assess upper airway patency in
children with obstructive sleep apnea
Sleep Medicine 2013; 14(5): 433 – 439
Cedric Van Holsbeke, Wim Vos, Kim Van Hoorenbeeck, An Boudewyns, Rodrigo
Salgado, Pascal Verdonck, Jose Ramet, Jan De Backer, Wilfried De Backer and
Stijn Verhulst
4.1 Abstract
Objective: To investigate if anatomical and functional properties of the upper
airway using computational 3D-models derived from CT images better predict
obstructive sleep apnea (OSA) severity than standard clinical markers.
Methods: Consecutive children with suspected OSA underwent polysomnography,
clinical assessment of upper airway patency and a CT scan while being awake.
A 3D-reconstruction of the pharyngeal airway was built from these images, and
computational fluid dynamics modelling of low inspiratory flow was performed
using open source software.
Results: 33 children were included (23 boys, mean age was 6.0 ± 3.2 years).
OSA was diagnosed in 23 patients. Children with OSA had a significantly lower
volume of the overlap region between tonsils and adenoids (median volume of
1408 mm compared to 2173 mm; p = 0.04), a lower mean cross-sectional area at
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this location (median of 69.3 mm2 compared to 114.3 mm2; p = 0.04) and a lower
minimal cross-sectional area (median of 17.9 mm2 compared to 25.9 mm2; p =
0.05). Various significant correlations were found between several imaging parame-
ters and the severity of OSA, most pronounced for upper airway conductance (r =
-0.46; p < 0.01) for correlation between upper airway conductance and the apnea
hypopnea index. No differences or significant correlations were observed with clin-
ical parameters of upper airway patency. Preliminary data after treatment showed
that none of the patients with residual OSA had their smallest cross-sectional area
located in segment 3 and this frequency was significantly lower than in their peers
whose sleep study normalized (64%; p = 0.05).
Conclusion: Functional respiratory imaging parameters are highly correlated with
OSA severity and are a more powerful correlate than clinical scores of upper air-
way patency. Preliminary data also showed that we could identify differences in
the upper airway of those subjects who did not benefit from a local upper airway
treatment.
4.2 Contributions of the author
The author of this thesis was the principal technical researcher in this study. He was
involved in the study design, scanning protocol and cooperated in the segmentation
of the airways. While a commercial computational fluid dynamics (CFD) software
package was used in chapter 3, he investigated how these problems could be
solved using open source software. He created his own CFD solver based on
OpenFOAM and tuned boundary conditions, solver settings and mesh settings to
give similar results to the validated commercial software. The complex geometry
of the nasal region and the need for automation (see section 12.2) made this a
very challenging topic. Furthermore, the author designed algorithms to extract the
outcome parameters in an automated way (see section 12.3). He was also involved
in the statistical analyses.
4.3 Introduction
Obstructive sleep apnea (OSA) is a prevalent disorder affecting 1 to 4% of the
general pediatric population [18]. However, this prevalence is much higher ex-
ceeding 50% in children with specific risk factors including obesity and Down
syndrome [24, 26]. OSA in children is also associated with significant compli-
cations affecting the developing nervous and cardiovascular systems and should
therefore be correctly treated [8].
The main anatomical risk factor for pediatric OSA is adenotonsillar hypertro-
phy but other factors such as craniofacial abnormalities, obesity and alterations in
neuromotor tone may also play a role. Second, residual disease after adenotonsillec-
tomy is present in a large proportion of children [6]. Although indices of nocturnal
breathing improve in the majority of patients after adenotonsillectomy, there is a
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subset of patients who do not significantly improve to have justified surgery. In
view of several non-surgical alternatives, one of the challenges in this field will be
to closely match the anatomical characteristics of an individual patient with the
most appropriate treatment. A meta-analysis showed that the association between
a clinical score of tonsillar hypertrophy and the severity of OSA is weak [21].
A number of imaging studies, mainly using magnetic resonance imaging (MRI),
have investigated the relation between upper airway structural anatomy and OSA
severity [1–5, 12, 14, 23]. Converting these images to three-dimensional (3D)
models enables calculation of specific volumes of the upper airway, but also allows
the application of computational fluid dynamics (CFD) too. This method can derive
additional functional and quantitative properties of the upper airway such as local
resistances.
It was shown that these CFD parameters predict the severity of OSA in adult
patients as well as a response to treatment [10, 25, 27]. In children, CFD has
mainly been used to investigate physiological changes in intra-luminal pressures
and resistances during obstruction rather than as a parameter of OSA severity or as a
tool for treatment selection [22, 28]. The aim of this study was therefore to evaluate
upper airway characteristics by use of ultra low dose computed tomography (CT)
and computational fluid dynamics in children with sleep-disordered breathing. Fur-
thermore using preliminary data, we also investigated if these imaging parameters
could predict treatment outcome.
4.4 Materials and Methods
4.4.1 Study population
Consecutive children and adolescents between 3 to 16 years referred to the Pediatric
Sleep Lab of the Antwerp University Hospital for suspected OSA were included
between January 2011 and May 2012. All children had to be free of any acute
disease at the moment of sleep screening and subjects with neuromuscular disease
or any genetic or craniofacial syndrome were excluded. The Ethical Committee of
the Antwerp University Hospital approved this study and informed consent was
obtained from the subjects and their parents.
4.4.2 Questionnaire and physical examination
The parents completed a standardized questionnaire regarding sleep and respiratory
co-morbidities. Tonsillar size was rated by two authors (A.B. and S.V.) using
the Brodsky scale [7]. A score “0” was given in case of tonsillectomy. Tonsillar
hypertrophy was scored with tonsil size > 2. Modified Mallampati scale was
also assessed [19]. Height and weight were measured according to standardized
techniques. Body mass index (BMI) was calculated as weight in kilograms over
height in m2, and was further analyzed as z-scores.
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4.4.3 Polysomnography
All subjects underwent polysomnography (Brain RT, OSG, Rumst, Belgium) ac-
cording to standardized criteria. All tracings were manually scored using the AASM
guidelines [15]. OSA was defined if obstructive apnea index (OAI) ≥ 1 or obstruc-
tive apnea hypopnea index ≥ 2. Other parameters of interest included mean oxygen
saturation (<SaO2>), SaO2 nadir, oxygen desaturation index (ODI) and arousal
index.
4.4.4 CT scan
All patients underwent a CT scan to evaluate upper airway geometry. Scanning was
performed with patients in supine and neutral position. The scan was performed
using a GE LightSpeed 64-slice CT scanner with an average acquisition time
between two to five seconds. This resulted in a dataset containing an average of 350
– 400 DICOM images, all images having an in-plane spatial resolution of 0.3 mm
and reconstructed with a slice increment of 0.5 mm. Since the main interest was to
obtain images discriminating air in the airways from the surrounding soft-tissue, all
CT examinations were performed with an adapted low-dose scan protocol. This was
achieved using an 80 kV setting, a modulated mA dosage depending on anatomic
configuration (less dose in anatomic short-axis and more dose in the long-axis
direction) and by limiting the scan range to the strictly minimal anatomic limits.
4.4.5 Upper airway morphology extraction from CT
The acquired DICOM images were processed using a commercial software package
(Mimics 15.0, Materialise). Subsequently a segmentation of the upper airway
was done using the Hounsfield Unit (HU) of each voxel in the DICOM images
as a discriminatory parameter, making a binary distinction between air and solid
structures. The HU is a value for the radiodensity of the tissue and reaches from
-1024 to 3071. Characteristic values on the Hounsfield scale are -1024 HU and 1000
HU respectively corresponding with air and bone. Segmentation was performed
from the nares to the first thoracic vertebra. The segmented region was then
converted to a 3D model using a contour interpolation algorithm. Since this model
is based on a segmentation of (near) cubic pixels, a staircasing-effect can result.
Using an appropriate smoothing algorithm with volume compensation the 3D
model was converted to a smooth realistic model without loss of patient specific
morphology of the upper airway. This model was then used for detailed analysis of
the anatomical parameters, volume meshing and CFD simulation. The following
parameters were calculated: effective upper airway volume, minimal and mean
cross-sectional area. Effective upper airway volume is defined as the total upper
airway volume excluding the regions where there is almost no flow such as the
sinuses and the air pockets close to the vocal cords. The upper airway was then
divided in the following regions (Figure 4.1): nostril to bottom of inferior turbinate
(segment 1), bottom of inferior turbinate to choanae (segment 2), choanae to tip of
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uvula (segment 3); uvula to epiglottis (segment 4) and epiglottis to the first thoracic
vertebra (segment 5). Volumes of these segments were also calculated and the
location of the minimal cross-sectional area was recorded.
Figure 4.1: Studied regions of the upper airway: nostril to bottom of inferior turbinate
(segment 1), bottom of inferior turbinate to choanae (segment 2), choanae to tip of uvula
(segment 3), uvula to epiglottis (segment 4), and epiglottis to the first thoracic vertebra
(segment 5).
4.4.6 Upper airway characteristics extraction from CFD
The 3D model obtained after segmentation was then divided into discrete cells
to form a hexahedral dominant computational domain (SnappyHexMesh 2.0.1,
OpenCFD Ltd, UK). The cells volumes were in the order of 1e-14 to 1e-8 m3. The
mesh was not aligned to the axial flow direction and the cells were extra refined
near the boundaries. This resulted in a computational grid of the upper airway
typically consisting of approximately 800,000 computational cells. This 3D mesh
was exported and read into a custom Reynolds Average Navier Stokes CFD solver
based on OpenFOAM 2.0.1 (OpenCFD Ltd, UK). Here the following boundary
conditions were set to the model:
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• a pressure outlet at the outlet surface in the larynx of -20 Pa
• a pressure inlet at the inlet surface at the nostrils of 0 Pa,
• non-impermeable walls (no-slip condition) for the sides of the upper airway.
Pressure based boundary conditions were used as this enables the simulation
of the flow demand for the wide range of patient ages and sizes. Second-order
discretization schemes were used and the pressure-velocity coupling was solved
using the SIMPLE scheme. A steady, laminar simulation of the inspiratory airflow
was then performed until convergence of the mass flow rate through the upper
airway was achieved. From the outcome of the CFD analysis the resistance of the
upper airway was calculated. Some patients expressed an obstruction during the
CT-scan. Therefore, this value was transformed to the inverse of the resistance to
the fourth power and defined as the conductance.
4.4.7 Statistical analysis
Statistical analysis was performed using IBM SPSS 20.0. Normally distributed data
are presented as mean ± standard deviation (SD) and skewed data as median and
range. Consecutive patients referred for possible OSA were classified as normal or
OSA based on the results of the sleep study. No individual matching was performed.
Groups were compared using Mann-Whitney or chi-square analyses. Spearman
correlation analysis was also performed. A multiple regression analysis for the
logarithm of oAHI was also performed. All analyses are two-tailed and significance
was set as p < 0.05.
In view of our hypothesis that CFD analysis of the upper airway would be a
more sensitive correlate of the severity of OSA, we based a sample size calculation
on the correlation between upper airway conductance and oAHI. The correlation
coefficient was set on 0.48 based on preliminary data. Based on this coefficient
with alpha set at 0.05 and power at 0.80, the requested sample size was 25 subjects.
4.5 Results
4.5.1 Patient characteristics
33 children were included. There were 23 boys and mean age was 6.0 ± 3.2
years. Mean BMI z-score was 0.65 ± 1.50 and 11 children were overweight or
obese. Respiratory allergy was diagnosed in 5 patients and asthma in 4 patients.
Seven children had a prior history of adenotonsillectomy and 3 had a history
of adenoidectomy. OSA was diagnosed in 23 patients (70%). There was no
difference in characteristics between subjects with and without OSA except for
several polysomnographic characteristics (Table 4.1).
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Normal sleep study OSA p
N 10 23
Age (y) 7.2± 3.1 6.5± 3.8 0.2
Sex (% males) 60% 74% 0.4
BMI z-score 1.1± 1.2 0.8± 1.6 0.5
Respiratory Allergy (%) 30% 10% 0.1
Asthma (%) 20% 10% 0.6
Previous Adenotonsillectomy (%) 20% 22% 0.9
Previous Adenoidectomy (%) 20% 4% 0.2
OAI 0.0 (0.0 – 0.1) 0.8 (0.0 – 2.6) <0.001
oAHI 0.6 (0.2 – 1.9) 8.2 (3.7 – 34.0) <0.001
RDI 1.5 (0.8 – 5.0) 14.3 (5.1 – 35.6) <0.001
ODI 0.3 (0.0 – 0.9) 2.8 (0.7 – 5.0) <0.001
<SaO2> (%) 97.0 (96.4 – 98.3) 96.9 (95.8 – 97.8) 0.4
SaO2 nadir (%) 87.0 (82.0 – 92.0) 88.0 (85.0 – 92.0) 0.9
Arousal Index 8.4 (0.5 – 43.6) 18.7 (2.8 – 29.0) 0.1
Table 4.1: Patient and sleep characteristics of subjects with and without OSA
4.5.2 Correlation between imaging parameters and OSA
Children with OSA had a significantly lower volume of segment 3, a lower mean
cross-sectional area of segment 3 and a lower minimal cross-sectional area (Table
4.2). Various significant correlations were found between imaging parameters and
OSA severity, most pronounced for conductance, followed by the minimal cross-
sectional area, mean cross-sectional area of segments 3 and 5, volumes of segments
3 and 5, mean cross-sectional area and effective upper airway volume (Table 4.3 and
Figure 4.2). The minimal cross-sectional area was located in segment 3 (overlap
region of tonsils and adenoids) in half of the studied patients (52%), followed by
segment 5 (30%), segment 2 (9%), segment 1 (6%) and segment 4 (3%).
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Figure 4.2: Scatterplot between the mean cross-sectional area of segment 3 and OAI (part a)
and conductance and oAHI (OAI and oAHI were log-transformed).
Normal sleep study OSA p
Upper airway volume (mm3) 29718.6 (13551.2 – 55091.6) 17387.4 (2610.4 – 62025.7) 0.2
Effective upper airway volume (mm3) 25834.7 (9802.3 – 46853.0) 14717.5 (2447.7 – 52655.3) 0.1
Volume of segment 1 (mm3) 2438.8 (961.5 – 4278.6) 1966.2 (393.6 – 3810.4) 0.09
Volume of segment 2 (mm3) 12805.2 (1656.3 – 34553.0) 5343.4 (246.3 – 35710.2) 0.2
Volume of segment 3 (mm3) 2172.5 (1077.2 – 2769.8) 1407.9 (0.0 – 2699.9) 0.04
Volume of segment 4 (mm3) 960.6 (289.3 – 2315.2) 1317.9 (0.0 – 3301.0) 0.9
Volume of segment 5 (mm3) 5539.5 (2297.8 – 7476.8) 3896.5 (2297.8 – 7476.8) 0.1
Mean cross-sectional area (mm2) 185.5 (75.99 – 320.91) 116.20 (23.31 – 318.35) 0.2
Mean cross-sectional area of segment
1 (mm2)
130.72 (50.60 – 225.19) 92.28 (20.71 – 200.55) 0.09
Mean cross-sectional area of segment
2 (mm2)
317.81 (40.40 – 803.56) 171.36 (9.47 – 849.77) 0.1
Mean cross-sectional area of segment
3 (mm2)
114.34 (56.70 – 145.78) 69.29 (0.00 – 142.10) 0.04
Mean cross-sectional area of segment
4 (mm2)
151.55 (83.04 – 605.85) 159.90 (0.00 – 287.34) 0.5
Mean cross-sectional area of segment
5 (mm2)
93.87 (52.22 – 145.00) 72.49 (25.66 – 145.42) 0.2
Minimal cross-sectional area (mm2) 25.9 (11.2 – 58.0) 17.9 (0.0 – 77.9) 0.05
Conductance [(L/kPas)
1
4 ] 301.6 (6.1 – 5521.9) 92.2 (0.0 – 4096.0) 0.2
Table 4.2: Imaging parameters in subjects with and without OSA
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4.5.3 Correlation between clinical assessment of upper airway
patency and OSA
There was no difference in parameters reflecting the clinical assessment of upper
airway patency between subjects with or without OSA (Table 4.4). Spearman
correlation analyses between these parameters and OSA severity is presented in
Table 4.5. Several trends were observed for Mallampati score that reached statistical
significance only with SaO2 nadir.
Normal sleep study OSA p
Mallampati score 2 (1 – 3) 2 (1 – 3) 0.2
Tonsillar size 2 (0 – 3) 3 (0 – 4) 0.6
Tonsillar hypertrophy 20% 48% 0.2
Table 4.4: Clinical assessment of upper airway patency in subjects with or without OSA
Mallampati Tonsillar size
OAI 0.34 0.11
oAHI 0.35 0.27
RDI 0.34 0.29
ODI 0.10 0.28
<SaO2> -0.18 -0.15
SaO2 nadir -0.39* -0.28
Arousal index 0.17 -0.08
Table 4.5: Correlation analyses between clinical parameters of upper airway patency and
OSA severity (*p < 0.05)
4.5.4 Correlation between imaging and clinical assessment of
upper airway patency
Tonsillar size significantly correlated with the volume of segment 3 (r = -0.49; p =
0.004), the mean cross sectional area of segments 2 (r = -0.35; p = 0.04) and 3 (r =
-0.49; p = 0.004), the minimal cross-sectional area (r = -0.34; p = 0.05) and upper
airway conductance (r = -0.50; p = 0.004). No significant correlations were found
for Mallampati score.
4.5.5 Correlation analyses for upper airway conductance and
minimal cross sectional area
Upper airway conductance was correlated with the volumes of segment 1 (r = 0.68;
p < 0.001), segment 2 (r = 0.71; p < 0.001), segment 3 (r = 0.58, p = 0.001) and
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segment 5 (r = 0.45; p = 0.009) and with the mean cross-sectional area (r = 0.69;
p < 0.001), the mean cross-sectional area of segment 1 (r = 0.68; p < 0.001), 2 (r =
0.73; p < 0.001) and 3 (r = 0.58; p = 0.001). The minimal cross-sectional area was
correlated with the volumes of segment 1 (r = 0.68; p < 0.001), segment 2 (r = 0.59;
p < 0.001), segment 3 (r = 0.67, p = 0.001) and segment 5 (r = 0.54; p = 0.009),
and the mean cross-sectional area (r = 0.60; p < 0.001), mean cross-sectional of
segments 1 (r = 0.68; p< 0.001), 2 (r = 0.59; p< 0.001) and 3 (r = 0.67; p< 0.001).
Multiple regression analysis was not possible because of multicollinearity between
these parameters.
4.5.6 Final model for oAHI
In multiple regression analysis, only the volume of segment 5 was significantly
correlated with oAHI. Volume and mean cross-sectional area of segment 3, the
minimal cross-sectional area, upper airway conductance, Mallampati score and
tonsil size did not reach sufficient significance to remain in a stepwise model.
However, results should be interpreted with caution because of multicollinearity
between these parameters.
4.5.7 Post-treatment data
Post-treatment data was available for 15 patients diagnosed with OSA: 8 patients
underwent adenotonsillectomy, 2 patients adenoidectomy and 5 patients were
treated with montelukast. A control polysomnography showed residual OSA in
4 out of 15 patients. None of the patients with residual OSA had their smallest
cross-sectional area located in segment 3 and this frequency was significantly lower
than in their peers whose sleep study normalized (percentage of subjects with the
smallest cross-sectional area in segment 3 was 64% in this group; p = 0.05). There
were no other differences between these two groups.
4.6 Discussion
This study investigated upper airway dimensions during wakefulness by means
of computational fluid dynamics in children with sleep-disordered breathing. Our
study clearly showed that upper airway dimensions are correlated with OSA severity.
Furthermore, preliminary data showed that 4 subjects with residual OSA after
treatment had their smallest cross-sectional area, prior to surgery, outside of the
overlap region between adenoids and tonsils (segment 3) suggesting that imaging
could predict the effect of treatment outcome.
Our study agrees with previous imaging studies that children with OSA have
smaller airways. In our study, children with OSA had a significantly lower volume
and mean cross-sectional area of segment 3 (overlap region between adenoids and
tonsils) and a lower minimal cross-sectional area. Second, multiple significant
correlations were found between upper airway volume, the minimal cross-sectional
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area, mean cross-sectional area, mean cross-sectional area and volumes of segments
1, 2, 3 and 5 and several markers of OSA severity indicating that a smaller upper
airway was related to more severe OSA. Fregosi et al. found similar differences and
correlations in 18 children with OSA studied by MRI [13]. Similarly, Arens et al.
demonstrated a smaller minimal and mean cross-sectional area and a smaller airway
volume. Furthermore, the most restricted segment of the airway was the overlap
region [2, 3]. Donnelly et al. also observed similar differences in another MRI
study [12]. Our study also showed that CFD-based parameters are even stronger
correlated with OSA severity. The CFD-calculated conductance expressed the
highest correlation coefficient with oAHI, RDI, ODI and SaO2 nadir suggesting
that CFD brings additional value to imaging-based upper airway analysis. This
finding confirms previous data in adults with OSA [10]. Although we have to
note that the volume of segment 5 was the only significant variable in a multiple
regression analysis of oAHI. This could indicate that the narrowing or loss of
tone of the upper airway extends into the trachea as shown in adults [17] or that
there is less tracheal traction on the upper airway. However, this finding should
be confirmed in follow-up studies because multiple regression was difficult to
perform because of multicollinearity between these variables. CFD has only been
applied in a limited number of studies in pediatric OSA. Xu et al. studied the
influence of pharyngeal airway shape in children on internal pressure distribution
in children with OSA [28]. Another study by Persak et al. applied CFD to estimate
pharyngeal airway resistance and compliance in children with and without OSA.
They showed that the airways of subjects with OSA were more compliant and that
this method could also characterize differences along the pharynx and between
OSA subjects. These studies clearly show the additional value of this technique.
CFD allows not only for a non-invasive estimation of functional characteristics
of the upper airway but also allows for more detailed segmental analyses. 3D-
airway reconstruction and/or CFD analysis can identify that part of the airway
that is most likely responsible for OSA in an individual patient. Resistance and
conductance are ideal CFD endpoints as these incorporate both flow and pressure
measurements in a given geometry and thus provide a lot of information in one
single number. Furthermore, clinicians are familiar with these terms, giving them
more insight in the clinical relevance of CFD. It could be interesting to investigate
local flow parameters such as maximum velocity and minimal pressures. However,
it is difficult to assess what the influence of these very local effects is in a complex
biological system. The results are promising and future studies should use these
techniques to predict the effect of adenotonsillectomy for instance prior to the actual
surgery. In this prospect, we demonstrated that there was a difference in the location
of the smallest cross-sectional area in subjects who did not benefit from local upper
airway treatment. This study therefore warrants more and larger scale studies to
investigate the usefulness of imaging coupled with CFD in predicting treatment
response. Furthermore, these studies should include other subpopulations where
other anatomical factors than adenotonsillar hypertrophy and especially neuromotor
factors are playing a more dominant role such as Down syndrome, cerebral palsy
and obesity.
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In spite of the limited applications of CFD in pediatric sleep apnea, CFD has
been validated on in vitro models both in children as in adults [9, 11, 16, 28]. Our
present study did not include such a validation arm, but there was a significant
correlation between the degree of tonsillar hypertrophy and airway conductance.
Significant correlations were also observed between the Brodsky scale and the
minimal cross-sectional area and the volume of segment 3. In spite of these
correlations, there was no significant relation between clinical assessment of upper
airway patency and OSA severity. Whether this will still hold in future studies
identifying predictors of treatment will need to be confirmed. In this view, it is
important to note that more easily obtained techniques could also be of value. For
instance, it was demonstrated that parameters obtained from a lateral cephalogram
are also valid measures of upper airway dimensions. Clinical assessment of tonsillar
size correlated with imaging parameters in this study as well [23]. Therefore, future
studies should compare the usefulness of these and other techniques including
clinical assessment, plain radiographs, CT or MRI images, CFD, sleep endoscopy,
etc.
Limitations of our study include the absence of a control group without symp-
toms of OSA. However, our aim was to characterize the severity of OSA and
differences with a normal control group have been described before. A limited
number of patients had a history of upper airway surgery although this percentage
was not significantly different between both studied groups. Although this probably
reflects the population referred to a pediatric sleep lab for OSA, our study sample
cannot be considered as a homogeneous population. Second, we did not use sequen-
tial images to characterize the upper airway during inspiration and expiration. It has
been shown that the airway of subjects with OSA is more compliant [1, 4]. Our goal
was to identify markers that could be obtained from a relatively straightforward
protocol in order to use it in large-scale studies to identify predictors of treatment
success. We have therefore chosen to obtain cross-sectional images only. Future
studies with this goal should also incorporate other clinical parameters related to
OSA severity including questionnaire data or more easily obtainable radiographic
measures with for instance a lateral neck radiograph. Finally, this study used CT-
imaging, which requires radiation. However, we could significantly reduce the
radiation dosage due to specific protocols as described previously [20].
In conclusion, this study showed that parameters obtained from 3D recon-
struction of CT-images of the upper airway post-processed with CFD are highly
correlated with OSA severity and are a more powerful correlate than clinical scores
of upper airway patency. Preliminary data also showed that we could identify
differences in the upper airway of those subjects who did not benefit from a local
upper airway treatment. Future large scale studies, also in subpopulations with
other risk factors besides adenotonsillar hypertrophy, are needed to confirm the
usefulness of these techniques in predicting treatment response.
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Part II
Simulation of inhalation
medication

5
Lung deposition analysis of inhaled
medication: Effect of upper airway
morphology and comparison with in
vivo data
Inhalation Toxicology 2012; 24: 81 – 88
Samir Vinchurkar, Lieve De Backer, Wim Vos, Cedric Van Holsbeke, Jan De Backer
and Wilfried De Backer
5.1 Abstract
Background: Asthma affects 20 million Americans resulting in an economic
burden of approximately $18 billion in the US alone [2, 37]. Research studies based
on differences in patient specific airway morphology for asthma and the associated
effect on deposition of inhaled aerosols are currently not available in the literature.
Therefore, the role of morphological variations such as upper airway occlusion is
not well documented. Furthermore, no studies were found that compared numerical
studies on patient specific lung deposition with in vivo data.
Methods: Functional respiratory imaging based computational fluid dynamics
(CFD) of the respiratory airways for five asthmatic subjects is performed in this
study using computed tomography (CT) based patient specific airway models and
boundary conditions. The CFD simulations were used for obtaining lung deposition
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using beclomethasone/formoterol® HFA metered dose inhaler.
Results: The lung deposition obtained using CFD was in excellent agreement with
available in vivo data using the same product. Specifically, CFD resulted in 30%
lung deposition, whereas in vivo lung deposition was reported to be approximately
31%.
Conclusion: It was concluded that a combination of patient specific airway models
and lobar boundary conditions can be used to obtain accurate lung deposition
estimates. Additionally, lower lung deposition can be expected for patients with
higher extrathoracic resistance. Novel respiratory drug delivery devices need to
accommodate population sub-groups based on these morphological and anatomical
differences in addition to subject age.
5.2 Contributions of the author
From all studies that are described in this thesis, the author was least involved in
this one. However, the author cooperated in the segmentation of the airways, setup
of the computational fluid dynamics simulations and post processing of the discrete
phase.
5.3 Introduction
Inhalation therapy has become a popular therapeutic technique for diseases such
as asthma and chronic obstructive pulmonary disease (COPD). Particle deposition
characteristics in respiratory airways are needed to develop and improve systemic
and local drug delivery using inhalation medication [15, 24]. Additionally, these
studies can be useful to assign risk factors to corresponding particle size groups
for inhalation toxicology [5, 26, 39, 50]. Experimental investigations are widely
performed to evaluate the particle size groups of interest [40, 43, 44] as well as
evaluate pre-clinical dosimetry [14, 31]. Numerical analyses assist in selection of
pre-clinical criteria and comparison with in vitro and in vivo data [38, 47]. The
advantage of performing numerical studies lies in the fact that models and boundary
conditions can be created and modified without much difficulty as compared to in
vitro and in vivo studies.
Particularly, computational fluid dynamics (CFD) has been extensively applied
to study flow characteristics and particle deposition in idealistic [8, 33], physio-
logically realistic [7, 17] and patient specific [20, 46] airway models. While the
models studied were mathematically detailed to capture the airway morphology,
very few studies have considered the actual airway morphology without any mod-
ifications [20]. Furthermore, the available studies have related the quantitative
effect of specific numerical conditions including inlet velocity profiles and turbu-
lent models on deposition in simple, mathematically detailed and user developed
airway models [16, 32, 49]. These results need to be validated using models with
a higher degree of morphological accuracy since relatively smaller changes in the
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morphology can lead to a significant effect on deposition characteristics in the
airways [30, 41].
Recently, De Rochefort et al. [22] performed CFD analysis of patient specific
airway models by integrating the airway reconstruction process from in vivo thoracic
scans with the velocity field calculation. Volumetric CT based images were used to
perform airway segmentation of an ovine and human lung. A significant correlation
was shown between the airway flow patterns, and local and global geometrical
factors. Kabilan et al. [29] studied flow characteristics in a CT based ovine lung
model. The study showed asymmetric and highly vortical flow patterns as compared
to idealized bipodial flow [29]. These studies show that airway morphology can
significantly affect deposition in the respiratory airways.
It is well known that subjects suffering from asthma are characterized by
high airway resistance as compared to normal subjects [1, 3, 27]. Therefore,
some studies have modelled the airway structure for asthma by constricting the
downstream diameters of smooth pipe models representative of respiratory airways
[35]. However, using the complete patient specific airway morphology can play a
significant role in respiratory airway deposition [30, 41]. Available studies show
that patient specific airway segmentation can be obtained down to the level of the
small airways with diameters between 1 and 2 mm which is around the 5th – 9th
generation [4]. This information can be applied to analyze the effect of airway
morphology on lung dose and identify sub-group populations based on important
airway structure parameters, for example the diameter of the trachea, the dimensions
of the laryngeal opening etcetera.
Changes in airway morphology can significantly affect local deposition leading
to hotspot formations [30]. Additionally, numerical factors including flow condi-
tions, turbulence model and boundary conditions employed can affect the accuracy
of numerical calculations. For example, (a) steady state conditions are not entirely
representative of actual breathing conditions [28], (b) Initial particle injection time
can be a significant factor for dosimetry analysis in airway models [19, 28], (c)
Reynolds averaged turbulence models are inadequate to accurately model particle
deposition for turbulent conditions [44]. To obtain accurate deposition estimates,
the effects of different morphological, numerical and boundary conditions including
lobar flow distribution needs to be studied for patient specific airway models.
Very few studies employed anatomical based models for performing deposition
in the upper airways [34, 42, 45]. However, no studies were found on variability
in upper airway morphology and associated effects on lung dose for a targeted
patient-population. The objective of the current study was to assess the effect of
upper airway geometry on lung deposition in asthma patients by using a combina-
tion of patient specific models as well as boundary conditions. The airway models
for asthmatic subjects were derived from high resolution computed tomography
(HRCT) images. Subsequently numerical analyses were performed to obtain parti-
cle deposition patterns in these models using the inhalation formulation employed in
an in vivo study [21]. In this in vivo study, lung deposition of a beclomethasone/for-
moterol formulation in asthmatic patients was assessed using gamma scintigraphy.
With gamma scintigraphy, radioisotopes (here the radioactive technetium labelled
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formulation) are inhaled and the emitted gamma radiation is captured by external
detectors. In this way two-dimensional images of the location of the radioisotopes
in the lungs are obtained. The numerical results obtained in the current study were
evaluated against this in vivo data for lung deposition. Special attention was given
to the deposition in the upper respiratory tract as this is a determining factor for the
dosage effectively delivered to the thoracic region [9, 12].
5.4 Materials and methods
5.4.1 High resolution CT scans
For this study, imaging information of 5 asthmatic patients was retrospectively used.
The subjects’ age used for the CFD study was 52 ± 10 years as shown in Table
5.1. The protocol was approved by the ethics committee at the Antwerp University
Hospital (Wilrijkstraat 10, Edegem 2650). All patients gave their written informed
consent. The HRCT scans were performed at a low dose radiation level using a
multi-slice CT scanner with 64 receptors (GE VCT Lightspeed). Scanning of the
thoracic region was performed at functional residual capacity (FRC) which is the
lung level attained after normal expiration and at total lung capacity (TLC). The
scanning region started at the larynx and extended down to the diaphragm. These
imaging sequences took between 2 and 8 seconds per scan. The lung volumes were
controlled using adapted spirometry during the CT procedure. The radiation dose
was reduced by reduction of the tube current and voltage [10, 51]. Additionally,
there was an increase in noise factor on further reduction of the radiation dose.
Images of the extrathoracic region, ranging from the soft palate down to the larynx,
were obtained in a separate scan and fused together with the thoracic region. Total
radiation exposure was below 5 mSv per patient. The resulting images had a pixel
size of approximately 0.5 mm and a slice thickness of 0.3 mm.
Patient no Age sex
1 38 M
2 60 M
3 57 F
4 63 F
5 42 M
Table 5.1: Patient’s demographic details
5.4.2 Three-dimensional airway models
The HRCT mages were subsequently used for accurate 3D reconstructions of the
airway geometries using a semi-automatic algorithm of the airways up to the point
where no distinction could be made between the intra-luminal and alveolar air (5th
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– 9th bifurcation). The segmentation and three-dimensional reconstruction was
performed with a commercially developed and validated software package (Mimics
version 13.1, Materialise nv, Belgium). The segmented airway model was then
smoothed with a volume compensation algorithm. A fully developed 3D model is
illustrated in Figure 5.1. These models were divided in Parts 1 – 5 as shown in the
figure. The Parts 1 – 5 represented the extrathoracic region, the tracheal region, the
right lung (right airway region), the left lung (left airway region) and the fraction
entering the deep lung region (beyond the segmented airway region), respectively.
Figure 5.1: Representative patient specific airway model attached with inhaler illustrating
division of parts 1 to 5 for obtaining local particle deposition results
5.4.3 Flow simulations
Flow behavior in the airway models could be mathematically described by the
Navier-Stokes equations. These governing equations are based on the conservation
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of mass and momentums and are given by:
δui
δxi
= 0 (5.1)
δui
δt
+ uj
δui
δxj
= −1
ρ
δp
δxi
+
δ
δxj
[
(ν + νT )
(
δui
δxj
+
δuj
δxi
)]
(5.2)
Where ui is the time-averaged velocity in three coordinate directions, i.e., i = 1, 2,
and 3, p is the time-averaged pressure, ρ is the fluid density, ν is the kinematic vis-
cosity, and νT is the turbulent viscosity. An important flow feature, especially when
considering aerosol interaction, is turbulence. The Large Eddy Simulation tech-
nique (LES) is an intermediate approach to model turbulence between the Reynolds
Averaged Navier Stokes (RANS) turbulence models wherein the fluctuating part of
the flow is ensemble averaged and Direct Numerical Simulation (DNS) wherein
the fluctuating part of the flow is fully resolved. The LES technique solves the
larger eddies carrying most of the energy, whereas the remaining smaller eddies are
modelled using a sub-grid scale model such as a RANS k- model. LES solutions
provide a higher numerical accuracy as compared to the RANS models [11, 13].
Additionally, LES has been shown to provide better solutions for respiratory models
due to the nature of the flow separation in such models [36]. Despite the larger
computational cost, the LES method has been used in this study. Further details
on the turbulent viscosity νT for LES with dynamic kinetic energy subgrid scale
model can be obtained in the User’s manual for Fluent 6.3.
5.4.4 Aerosol transport
For the discrete phase or particle transport, the governing transport equation can be
written as:
dvi
dt
= α
Dui
Dt
+
f
τp
(ui − vi) + gi (1− α) + filubrification+lift (5.3)
dxi
dt
= vi (t) (5.4)
where vi and ui are the components of the particle and local fluid velocity, respec-
tively, and gi denotes gravity. The drag factor is given by ’f ‘, the response time for
particles is denoted by τp = ρpdp2/18µ , and the density ratio α = ρ/ρp ≈ 10−3.
Particles are typically initiated at user-specified start and end time. In this study the
particles were initiated at two points: At beginning of the inhalation cycle between
0 and 0.3 second (case A) and at the peak of the inhalation cycle between 0.5 to
0.8 seconds (case B). The exact temporal injection time were 0 – 0.3 seconds for
actuation ’A‘ at the beginning of inhalation, and and 0.5 – 0.8 seconds for actuation
’B‘ at peak of inhalation. The particles were initiated as a solid cone injection with
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a half angle of 18 ◦ approximately which is representative for metered dose inhalers.
The particle diameter distribution for the injections in the CFD models was equal
to the aerosol size distribution of the formulation used in the study by De Backer et
al. [21] in order to allow for proper comparison of the results. The formulation had
a mass median aerodynamic diameter of 1.30 ± 0.10 µm with a geometric standard
deviation of 1.97 ± 0.12 µm.
5.4.5 Computational grid and boundary conditions
In order to solve the governing equations in the flow domain, hence the respiratory
system, a computational grid must be created. For the geometry and the flow rates
under consideration a grid size of approximately 6 million cells is required in
combination with a time-step of 0.005 s. Further details on grid convergence are
reported in a previous study by De Backer et al [18]. This grid was created using a
commercial grid generation package (TGrid version 5.0.6, Ansys Inc.). This grid
was then imported in a commercial flow solver to perform the numerical simulations
(Fluent 6.3, Fluent Inc). Adequate grid convergence studies were performed for the
airway models. The inhalation profiles for this study were modelled based on data
measured for an asthma patient with a sample inhalation device. Three breathing
patterns with average flow rates of 15, 30 and 60 L/min were employed representing
sedentary, light and heavy breathing conditions, respectively as shown in Figure 5.2
together with the measured profile. Internal mass flow distributions for individual
lobes were based on the volume changes between the FRC and TLC scans. The
lobar mass flow distributions are calculated as a ratio of the difference between
the total lung capacity (TLC) and functional residual capacity (FRC) volume of an
individual lobe to the sum of the differences in TLC and FRC volumes for all lobes.
Based on the mass flow distribution, patient specific lobe under-pressures were
calculated using an in-house algorithm. These under-pressures were then employed
as outlet boundary conditions for CFD simulations. The latter ensured that besides
the airway geometry also the internal airflow distribution was patient specific. (Pat.
pend. EU 09161455.2 US 61/182.493 [25]).
Finally, the imaging algorithms used in the current study were validated
earlier in a separate study which compared the functional respiratory imaging
methods applied in the current study with CT and single-photon emission computed
tomography (SPECT). It was shown by De Backer et al. [18] that lung ventilation
results obtained using functional respiratory imaging based CFD were in good
agreement (± 3%) with results obtained using SPECT-CT. Further details on the
validation of the imaging and CFD techniques used in the current study are available
in De Backer et al [18].
5.5 Results
The CFD simulations yield aerosol deposition patterns in different regions of the
airway model. Of particular interest to developers of inhalation medication is the
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Figure 5.2: Modelled inhalation profile using three flow rates shown together with the
measured profile from an asthmatic subject
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fraction of the nominal inhaled dose that reaches the thoracic airways (part 3 – 5)
as this determines the biological availability of the product to a large extent. The
current study showed that for patients 1, 2, 4 and 5 the thoracic or lung deposition
for the 30 l/min case was relatively similar with 28.6%, 32.9%, 28.7% and 30.1%
respectively when considering the actuation of the inhaled particles at the beginning
of the inhalation cycle (case A). Patient 3 however demonstrated a significantly
lower fraction of aerosols depositing in the lower airways with only 11.4% of the
nominal dose deposited beyond the trachea for case A. On further analyzing all five
patients’ morphological characteristics it was found that patient 3 was characterized
by a narrow laryngopharynx as shown in Figure 5.3. Additionally, a higher upper
airway resistance was obtained via CFD simulations for patient 3 as compared to
the other patients as illustrated in Table 5.2. Therefore the extrathoracic deposition
for patient 3 was significantly higher as compared to other patients. The resistance
values show an order of magnitude increase for patient 3 as compared to the other
patients. Deposition in the thoracic region was consistently lower for actuation
of particles at the peak of the inhalation (case B) for all cases studied due to
enhanced extrathoracic deposition caused by increased particle impaction as shown
in Figure 5.4. The average lower thoracic deposition for the CFD-based models
was 26.3 ± 8.6% for case A and 23.0 ± 7.3% for case B.
Figure 5.3: Upper airway region for the five asthmatic patients studied showed a partial
occlusion for Patient 003 characterized by lower lung dose
Considering all three flow rates including 15, 30 and 60 l/min, the lowest flow
rate resulted in the highest thoracic deposition of 28.3 ± 8.3% and 25.4 ± 7.9% for
cases A and B, respectively. Due to higher impaction losses in the extrathoracic
region, the highest flow rate resulted in the lowest thoracic deposition obtained
as 22.9 ± 8.6% and 17.5 ± 7.5% for cases A and B, respectively. Overall, the
thoracic deposition was inversely proportional to the inhalation flow rate. Patients
with occluded upper airway regions, for example patient 3 in this study, show even
higher effect of the flow rate. For this patient the thoracic deposition reduced from
approximately 15% for 15 l/min flow rate to approximately 5% for 60 l/min flow
rate.
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Figure 5.4: Lung deposition obtained in the current study for five asthmatics with actuation
at the beginning of inhalation (A) and peak of inhalation (B) shown as a function of the
inhalation flow rate
Patient no Upper airway resistance [Pa/kg/s]
1 91852.2
2 73216.7
3 1561266.7
4 170183.3
5 102004.2
Table 5.2: Upper airway region resistance for the five asthmatic patients analyzed in this
study
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The comparison of results obtained in the current study using CFD with the in
vivo results by De Backer et al. [21] are shown in Figure 5.5 for all patients studied,
and excluding patient 3 for the CFD study in the same figure. The in vivo study
showed a deposited thoracic fraction of 30.8% on average with a standard deviation
of 8.8%. The difference between the average deposition in the CFD models and
the in vivo scintigraphy study is therefore 5% where the standard deviations are
almost equal. When only considering the deposited thoracic fraction of patients
1, 2, 4 and 5 the average difference between the CFD and in vivo study reduces
to approximately 1% as shown in Figure 5.5. The averaged thoracic deposition
obtained for these four patients is 30.2% with a standard deviation of 2%.
Figure 5.5: Comparison of lung deposition results obtained in the current study using CFD
at 30 l/min with the in vivo study performed by De Backer et al. [21]. Exclusion of patient
03 from the CFD analysis (avg CFD (-3)) provides a good comparison with the in vivo data
(avg in vivo). The error bars represent standard deviation.
Furthermore, hotspot formations were observed in the upper airway region
from the pharynx through the larynx. However, the carinal ridge and subsequent
bifurcations showed relatively mild or no hotspot formations as compared to previ-
ous studies reporting deposition in pipe lung models [6, 52]. Specifically, even the
largest particles with 9 µm diameter resulted in less than 4% of the total deposited
particles at the carinal ridge (first bifurcation).
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5.6 Discussion
Gamma scintigraphy has been extensively used in the past to assess the deposition
location of inhaled drugs. By labeling the drug with a radioactive tracer the location
in the respiratory system could be determined afterwards using a non-invasive
approach. Although this method could be used to assess the deposited aerosol
fraction in the extrathoracic region, the central and peripheral airways, there remain
some limitations. The labeling of the product under consideration is not always
straightforward and usually time consuming. Furthermore, the scintigraphy test is
typically used as an evaluation tool rather than a design tool as it is difficult to repeat
the measurements with different parameters. In this regard, the in-silico method
could offer a number of advantages to complement the existing tools. Patient
specific models could be constructed with minimal patient involvement (e.g., a low
dose CT scan at FRC and TLC) and subsequently be used to assess the influence of
several parameters on global and local deposition patterns. These parameters can
include pharmaceutical and device components such as aerosol size distribution
and injection velocities as well as clinical characteristics such as inhalation profiles.
The current study showed a good agreement between the CFD results and
in vivo data in terms of thoracic deposition at similar flow rates and inhalation
conditions. The same aerosol size distribution was employed for both studies.
However, the asthmatic patients included for the CFD study were different than
the in vivo study. The results in the current study show that lower inhalation flow
rates lead to higher thoracic deposition for all patients considered. Patient 3 showed
very low thoracic deposition as compared to the averaged deposition data for the
remaining 4 patients since the subject was characterized by a narrow laryngeal
region resulting in relatively high upper airway resistance further leading to low
thoracic deposition. Additionally, lower thoracic deposition would be expected
for patients characterized by a narrow oropharyngeal region accounting to an
associated high velocity zone. These airway occlusions resulted in higher particle
deposition downstream of the occlusion characterized by impaction as well as
upstream of the occlusion due to recirculation zones characterized by dispersion.
An example of the downstream deposition is the laryngeal jet region, whereas an
example for the upstream deposition is the recirculating region below the uvula
adjoining the epiglottis. The overall maximum variability in deposition is obtained
to be 26%, which can be highly significant considering that average deposition for
asthma inhalation medication is on the order of 30%. The current results present a
case study for inter-patient variability in lung dose. More patients with differing
morphological features need to be studied for accurate estimation of inter-subject
variability. These need to be validated with clinical studies for realistic lung dose
variability in asthmatics.
Furthermore, the prevalence of a narrow upper airway in asthmatics should
be investigated. Sleep apnea is associated with narrow upper airway regions
[48], which occurs on the order of 5% in the population. It was also reported
that obesity played a role in sleep apnea particularly in pediatrics. However, a
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straightforward relation between obesity and sleep apnea was not demonstrated
indicating that further studies were essential to evaluate the effect of obesity on
sleep apnea and association with upper airway narrowing. Although upper airway
morphological data was not found for asthmatics, obesity and asthma are understood
to be interlinked with possibly multiple mechanisms involved [23]. Uncontrolled
asthma population needs to be studied for obesity and associated patient specific
inhaler performance. Only then can a meaningful correlation be sought between
asthma, obesity and upper airway narrowing. There is a possibility that significant
uncontrolled asthma population may be receiving lower inhaled medication due to
a narrow upper airway, which can be related to obesity or as an inherently existing
independent physiological condition. Further studies on asthmatics are needed to
evaluate the role of upper airway narrowing independently and concomitant with
obesity.
Previous studies [32] report hotspot formations at the carinal ridge and subse-
quent bifurcations for smooth airway models. However, these were not obtained in
the current study since the flow was driven by under-pressure at the lobes instead of
a velocity inlet thus leading to smaller stagnation points at the bifurcations resulting
in lower impaction. Furthermore, these under-pressures were calculated based on
the fraction of air entering the individual lobes. The lobar mass distribution for
a patient can be obtained by using lobar volume data for the TLC and FRC as
explained in the methods section. It is assumed that these boundary conditions lead
to lesser hotspot formation at sites previously reported. Further studies need to be
performed to validate these findings.
5.7 Conclusions
This study illustrated that patient specific lung morphology can play a significant
role in lung deposition of inhaled medication. The upper airway morphology was
the most important factor affecting lung deposition. However, the prevalence of
narrow upper airway as an independent physiologic condition and concurrent with
obesity need to be studied for additional asthma patients, particularly the uncon-
trolled population. A good agreement was obtained between imaging based CFD
simulations and in vivo data on lung dose for asthmatics. In general, CFD provides
an invaluable method to analyze lung dose variability based on patient morphology,
device properties, inhalation patterns and aerosol size distribution characteristics.
A few examples include patient morphology with narrow upper airway structure,
subjects suffering from COPD and asthmatics. Device properties that can be stud-
ied include actuation time, jet velocity and spray cone angle. Inhalation patterns
together with an aerosol size distribution can be studied for a combination of the
other properties to obtain lung dose. These results can be used to identify sub-group
populations for targeted drug delivery. Additionally, device design and size distribu-
tion can be optimized for specific sub-population groups. CFD can provide a faster
and cheaper way to study effect of one or a combination of these characteristics
on respiratory dosimetry. However, satisfactory CFD results need to be followed
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by in vitro and in vivo tests to validate the results before clinical implementation.
Additional asthma patients with narrow upper airways and a spectrum of body mass
index need to be included in future studies. These studies can assist in developing
novel delivery devices and particle formulation characteristics which can be used in
treating uncontrolled asthma and COPD patients.
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6.1 Abstract
Background: As the upper airway is the most important limiting factor for the
deposition of inhalation medication in the lower airways, it is interesting to assess
how its morphology varies between different postures. The goal of this study is to
compare the upper airway morphology and functionality of healthy volunteers in
upright and supine position during tidal nasal breathing and to search for baseline
indicators for these changes. This is done by performing three-dimensional mea-
surements on computed tomography (CT) and cone beam computed tomography
(CBCT) scans.
Methods: This prospective study was approved by all relevant institutional review
boards. All patients gave their signed informed consent. In this study, twenty
healthy volunteers (mean age, 62 years; age range, 37 – 78 years; mean body mass
index, 29.26; body mass index range 21.63 – 42.17; 16 men, 4 women) underwent
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a supine low dose CT scan and an upright CBCT scan of the upper airway. It was
examined if the (local) average (Savg) and minimal (Smin) cross-sectional area, the
position of the latter, the concavity and the airway resistance changed from upright
to supine position. If changes were found, baseline parameters were sought that
were indicators for these differences.
Results: There were 5 drop-outs due to movement artifacts in the CBCT scans.
Savg and Smin were respectively 9.76% and 26.90% larger in the CBCT scan
than in the CT scan while the resistance decreased with 26.15% in the upright
position. The Savg of the region between the hard palate and the bottom of the
uvula increased the most (49.85%). In people with a high BMI, this value changed
the least. The airway resistance in men decreased more than in women.
Conclusions: This study demonstrated that there are differences in upper airway
morphology and functionality between supine and upright position and that there
are baseline indicators for these differences.
6.2 Contributions of the author
The author of this thesis was the principal technical researcher in this study. He
was involved in the study design and investigated the feasibility. Similar to the
study in chapter 4 the computational fluid dynamics simulation were performed
using a custom solver based on OpenFOAM and sensitivity studies on meshing and
turbulence were performed. While the measurements in chapter 3 were performed
manually, the author designed algorithms to extract the outcome parameters in an
automated way (see section 12.3). He was responsible for all statistical analyses
and the interpretation of the results.
6.3 Introduction
Small airway diseases such as asthma and chronic obstructive pulmonary disease
(COPD) are treated with inhaled compounds according to the Global Initiative
for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines [1, 4]. Delivering the drugs to the inflamed airway regions
is critical as under-treatment can cause exacerbations [20, 24]. However, simply
increasing the dosage to counter this issue can cause systemic side effects [25]
and still not guarantee adequate treatment. Computational fluid dynamics (CFD)
in patient specific airway models can predict where the particles of an inhaled
compound deposit in a certain patient. This technique has been validated and has
promise in assessing patient specific treatment [5, 6, 13].
In order to perform the particle simulations correctly, patient specific boundary
conditions and airway anatomy are needed. Upper airway morphology is the most
important factor in assessing particle deposition in the lower airways [10, 33, 34]
and is mostly obtained using computed tomography (CT) or magnetic resonance
imaging scans, as these scanners are widely available. The problem with these
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scanning techniques is that the images are taken when the subject or patient is
in the supine position. Inhaled medication is however mostly administered in an
upright position. Posture is thought to be an important determinant of upper airway
dimension [12, 29, 36] and can thus have an influence on the CFD results.
Another interesting item is that most oropharyngeal casts and models that
are used for in vitro deposition modelling are based on scans in a supine position
such as those by McRobbie et al. [19]. A larger insight in posture dependent
differences could possibly help them to optimize the throat models currently used
by the industry.
A scanning device that has the possibility to scan a subject in an upright
position is the cone beam computed tomography (CBCT) scanner. CBCT is nowa-
days widely used in dentistry and maxillofacial surgery due to its low radiation
dose [15], and has already been used to make upper airway models in an upright po-
sition [9, 28, 31]. Also, a phantom study has shown that CBCT is a valid technology
for accurately quantifying air volumes [35].
As most particle simulations in realistic airway structures are performed on
models obtained with a CT scanner [5, 14, 16, 34], it is interesting to assess if there
is a possibility that these simulations under- or over-predict the lung deposition.
The purpose of this prospective open cross-over study is to quantify the differences
in airway morphology and functionality between supine and upright position using
CT and CBCT scans of healthy volunteers. The study also investigates which
anatomical regions are more prone to possible position dependent changes and if
there are baseline morphological or clinical parameters that have an influence on
these.
6.4 Materials and Methods
6.4.1 Subject Data
A total of 20 adult healthy volunteers (mean age, 62 years; age range, 37 – 78 years;
mean BMI, 29.26; body mass index range 21.63 – 42.17) were included from 18
March 2011 to 29 April 2011. The population consisted of 16 male and 4 female
subjects and was divided in three BMI groups. There were 7 subjects with a BMI
lower than 25, 6 subjects with a BMI between 25 and 30 and 7 subjects with a
BMI higher than 30. The detailed inclusion and exclusion criteria can be found in
Table 6.1. Institutional review board approval was obtained, a written informed
consent was signed by all subjects and the study was submitted to ClinicalTrials.gov
(NCT01594164).
6.4.2 CT and CBCT
All subjects underwent one low-dose CT scan in supine position and one CBCT
scan in upright position on the same day. Both scans were taken during tidal nose-
breathing to prevent any patient-induced occlusion of the glottis. A pneumotach
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Inclusion criteria
• Written informed consent obtained.
• Male or female subject aged≥ 18 years.
• BMI < 25 kg/m2 (group 1), BMI ≥ 25 kg/m2 and < 30 kg/m2 (group 2) and
BMI≥ 30 kg/m2 (group 3).
• Female subject of childbearing potential who confirms that a contraception
method was used at least two months before scan.
Exclusion criteria
• Subject is under the age of legal consent.
• Subject who is pregnant or is breast-feeding.
• Subject with a history of surgery of the upper airway.
• Subject with a history of any illness that, in opinion of the investigator, might
confound the results of the study or poses an additional risk to the subject by
participation in the study.
• Subject is unlikely to comply with the protocol or unable to understand the
nature, scope and possible consequences of the study.
• Subject who received any investigational new drug within the last 4 weeks prior
to scan.
• Subject who has claustrophobia.
Table 6.1: Inclusion and exclusion criteria
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device was used to make sure that the subject breathed consistently and to detect if
the subject swallowed during the scan. The scanning region started at the beginning
of the palatum and extended down to the sternum.
A Lightspeed VCT scanner (GE Healthcare, Milwaukee, Wisconsin) was used
to obtain supine images. The images had a pixel size of approximately 0.5 mm2
and were reconstructed with a slice thickness of 0.3 mm. The scan took around
1 second and was triggered to start at the beginning of the inspiration. The subject
received a radiation dose around 0.1 mSv. An i-CAT CBCT scanner (Imaging
Sciences International, Hatfield, Pennsylvania) was used for the upright images.
The images had a voxel size of approximately 0.4 mm3. The scan took around
9 seconds and the effective dose was approximately 68 µSv.
Every volunteer in this study was thus exposed to a total radiation dose around
0.2 mSv.
6.4.3 Airway segmentation
Both CT and CBCT scans were loaded into the Mimics 13.1 (Materialise, Leuven,
Belgium) software suite. This validated package (Food and Drug Administra-
tion, K073468; Conformité Européenne certificate, BE 05/1191.CE.01) allowed
to segment the anatomical region of interest and to generate a three-dimensional
representation of it. The scans were first resliced so that the central sagittal slice of
the hard palate was positioned horizontally. This enabled to take the same region of
interest for both CT and CBCT which was important for a correct comparison. The
region of interest was chosen as the space of air posterior to the tongue, from the
hard palate to the larynx (Figure 6.1) as this region is most prone to airway collapse
due to the weight of the surrounding tissue [11]. The segmented region consisted
of pixels in a Hounsfield units region between -1024 and -400 [7]. Subsequently,
the segmented mask was converted to a three-dimensional object using a contour
interpolation algorithm.
Figure 6.1: Sagittal slice of a CT scan (left) and a CBCT scan (right), taken without contrast
material. The region of interest is indicated in white
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6.4.4 Computational fluid dynamics
Computational fluid dynamics simulations were performed on the three-dimensional
objects in order to generate extra functional data. A hexahedral dominant com-
putational grid was created using SnappyHexMesh 2.0.1 (OpenCFD Ltd, UK). A
sensitivity study showed that a computational grid between 300,000 and 1,400,000
cells was sufficient for reaching mesh convergence. This convergence was ob-
tained using differences in mass flow and total pressure drop for increasing mesh
refinement levels. The final flow simulations were performed using the mesh size
based on a difference of less than 1% between the coarse and fine grids. The
computations were performed using a custom made Navier-Stokes solver based
on the OpenFOAM 2.0.1 library (OpenCFD Ltd, UK). As the air velocity in the
upper airways is smaller than a Mach number of 0.2, an incompressible solver
could be used [3]. Also, the flow in the upper airways was considered adiabatic.
Second-order discretization schemes were used for the pressure and momentum
equations and the pressure-velocity coupling was solved using the SIMPLE scheme.
In order to enable proper comparison between the models, the boundary condi-
tions were set equally for all models. At the inlet, a total pressure of 0 Pa was set
and at the outlet, a static pressure of -20 Pa was applied. Sensitivity analyses on
turbulence showed that no inaccuracies were introduced by employing a laminar
flow approach. The mass flow and the total pressure drop were similar between
laminar and k-ω SST turbulence boundary conditions (considering 5% turbulence
intensity at the inlet) with a maximum difference of less than 1% for the model
with the highest Reynolds number. Pressure boundary conditions were chosen for
realistic inter-patient comparison as morphology changes in the upper airway will
not change the pressure difference between atmosphere and lungs, but will restrict
the airflow. The resulting flows were between 6.5 l/min and 50 l/min.
6.4.5 Outcome parameters
All measurements on the upper airways were done on the three-dimensional objects
that were extracted from the CT and CBCT scans. In this way it was possible to
detect morphological differences. The anatomical parameters that were measured
were:
• The average cross-sectional area of the upper airway (Savg)
• The minimal cross-sectional area of the upper airway (Smin)
• The position of Smin, measured from the hard palate (PosSmin )
• In order to see if the potential differences between CT and CBCT are due
to very local movements or due to global movements, the Savg was also
measured in three anatomical zones:
– In the region between the hard palate and the end of the uvula (Savgtop )
– In the region between the end of the uvula and the epiglottis (Savgcentral )
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– In the region between the epiglottis and the larynx (Savgbottom )
The different zones and cross-sectional areas are shown in Figure 6.2. The
ratio Smin/Savg was defined as the concavity and has been calculated as it was
to be investigated whether upper airways with a uniform area distribution react
differently from airways which are more concave and thus have a lower Smin/Savg .
Figure 6.2: The different airway zones and the definition of the cross-sectional areas
From the computational fluid dynamics simulations, the upper airway resis-
tance R was extracted. The resistance was defined as the ratio of the total pressure
drop over the upper airway and the mass flow rate through it [17, 18].
Finally, it was investigated if men and women respond differently to the change
in posture.
6.4.6 Statistics
The data were tested for normality using the Shapiro-Wilk W Test. Depending
on the outcome of these tests, parametric or non-parametric statistical techniques
were used. In this study correlations were calculated using the Spearman rank
test and differences between CT and CBCT were analyzed using the Wilcoxon
Matched Pairs test. Differences between sexes were investigated using the Mann-
Whitney U test. Statistical analysis was performed using Statistica 10 (Statsoft,
Tulsa, Oklahoma) and the significance level was set at 0.05.
6.5 Results
6.5.1 Drop-outs
From the 20 healthy volunteers that were included, only 15 valid CBCT scans
could be analyzed as the rotating gantry of the CBCT touched the shoulders of the
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broad-shouldered subjects, causing motion artifacts. These subjects were especially
found in the highest BMI group (1 male with a BMI lower than 25, 1 male with a
BMI between 25 and 30, 3 males with BMIs above 30).
6.5.2 Differences between CBCT and CT
Values of Savg and Smin were significantly larger in the CBCT scan than the same
parameters in the CT scan (respectively 9.76% and 26.90%) while the concavity and
the PosSmin did not change significantly. A good example can be seen in Figure
6.3. Also, the resistance R was found to be 26.45% smaller in upright posture than
when lying down.
When looking more in detail at the diameter distribution, it can be seen that
there was a very significant increase (49.85%) in Savgtop when the subject changed
from supine position to upright position. However, the values of Savgcentral and
Savgbottom were not influenced by this action. Detailed statistical results can be
found in Table 6.2.
Median (Lower/upper quartile)
Parameter CT CBCT Difference [%] p-value
Savg [mm2] 196.55 (126.84/216.91) 216.44 (170.01/378.69) +9.76 0.005
Savgtop [mm
2] 135.53 (94.45/202.50) 230.34 (154.35/364.53) +49.85 < 0.001
Savgcentral [mm
2] 178.52 (107.06/248.65) 195.88 (125.22/285.31) -14.16 0.820
Savgbottom [mm
2] 193.45 (178.66/270.28) 223.32 (192.02/382.69) +4.25 0.112
Smin [mm2] 57.31 (35.49/84.91) 78.70 (60.66/173.06) +26.90 0.027
PosSmin [mm] 27 (23/57) 41 (24/61) +6.67 0.177
Smin/Savg [-] 0.326 (0.270/0.418) 0.388 (0.336/0.463) +15.98 0.100
R [kPas/L] 0.084 (0.055/0.116) 0.054 (0.025/0.071) -26.45 0.004
Table 6.2: Differences between CT and CBCT
6.5.3 Indicators for the differences between CBCT and CT
From here on, the symbol ∆ is used to define the percentage change between the
parameter measured with CBCT and the parameter measured with CT. A positive
value means that the CBCT value is larger than the CT value. The significant
results in the previous section showed that the median values of ∆Savg, ∆Smin
and ∆Savgtop are positive, while the median value of ∆R is negative.
BMI was not found to be an indicator for ∆Savg , ∆Smin and ∆R. However,
it was found that in people with a higher BMI, ∆Savgtop became smaller (Table 6.3).
There was an inverse correlation between BMI and Savgtop in an upright position
(Spearman R: -0.664 p-value: 0.007), but BMI had no relation with Savgtop when
lying down (Spearman R: -0.282 p-value: 0.308).
There was a significant difference between the sexes for ∆R (Table 6.4). In
males, ∆R decreased 42.98% (p-value: 0.006) while this value was not different
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Figure 6.3: These two images show the same upper airway. On the left is the CT scan, on the
right is the CBCT scan. It can be seen that the cross-sectional areas are much larger in the
CBCT airway scan
Parameters Spearman R p-value
BMI & ∆Savg -0.357 0.191
BMI & ∆Savgtop -0.625 0.013
BMI & ∆Smin 0.032 0.909
BMI & ∆R 0.111 0.694
Table 6.3: BMI versus difference between CBCT and CT
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from zero for women (p-value: 0.715). The closer the upright PosSmin was to the
hard palate, the more ∆Smin increased and ∆R decreased (Spearman R: 0.611
p-value: 0.016).
Parameters Mean rank men Mean rank women Mann-Whitney U p-value
Sex & ∆Savg 8.55 6.50 16.00 0.489
Sex & ∆Savgtop 7.64 9.00 18.00 0.661
Sex & ∆Smin 9.00 5.25 11.00 0.177
Sex & ∆R 6.55 12.00 6.00 0.040
Table 6.4: Sex versus difference between CBCT and CT
6.6 Discussion
Particle deposition simulations are mostly performed on airway models that are
segmented from CT scans as this technique results in the best visualization of upper
and lower airways. As it is possible to decrease the radiation dose for an upper
airway scan to 0.1 mSv, the possible negative side effects can be minimized [22].
However, due to the fact that inhalation medication is mostly taken in upright
position while the CT scan is taken in supine position, there is a possibility that the
simulated geometry will not correspond completely to the real geometry.
The first aim of this study was to compare the upper airway morphology in
supine and upright position in order to see if this is the case. This was done by
scanning healthy subjects with a CT scanner while lying down and with a CBCT
scanner while sitting straight. As both scanning techniques are known to provide
good quantitative results when measuring spaces of air, the segmented voxels of
both techniques could be compared. We could demonstrate that there is indeed
a difference in airway morphology between these postures: the airway becomes
significantly smaller and its resistance increases when lying down. This can be
explained by the fact that the gravity vectors of the surrounding tissues are aligned
perpendicular to the airway walls in this position, increasing the load on the airway
muscles. It seems that the tension in the airway muscles does not increase enough
to counter the increased load completely, resulting in a smaller airway lumen. The
fact that the average airway diameter only decreased in the part posterior to the
uvula suggests that, in a population of healthy subjects, this is the region that is
most prone to airway collapse. This is supported by previous findings in healthy
subjects and sleep apnea patients [2, 11, 32] and is probably due to a posterior
displacement of the soft palate and the tongue [21, 30].
The second aim of this study was to find baseline parameters that are indicators
for these morphology changes. The closer the position of the minimal cross
sectional area to the hard palate when upright, the more the minimal cross sectional
area will decrease and the resistance will increase when lying down. This is in line
with the fact that the region of collapse is mostly posterior to the uvula.
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No correlations were found between the BMI and the global changes in
morphological and functional airway parameters. This is an important outcome
and implies that in healthy subjects, no large morphological or functional changes
occur due to an increased weight of the surrounding tissue. It was even found that
in people with a high BMI, there is less area change posterior to the uvula. It can
be suspected that in healthy subjects, the airway muscles apply enough force to
guarantee a certain airway lumen.
Men and women responded significantly differently to the change in posture.
The airway resistance decreases in men while there is no significant change found
in women. Although there is a sex imbalance in the included subjects (11 males, 4
females), this is an interesting finding as will be discussed further.
This study had a number of limitations. There were a significant amount
of drop-outs in the broad shouldered subjects due to the small diameter of the
CBCT rotating gantry that interfered with the region of interest. As this gave some
imbalance in the BMI groups, one has to approach the correlations that were found
with BMI carefully. The above mentioned sex imbalance is also a limitation. A
higher number of women would open the possibility to perform more detailed
comparisons. A previous study found no significant differences between CT and
CBCT when measuring spaces of air in a phantom [35], so in a static context no
differences will be observed due to the different imaging modalities. However, it is
known that the upper airway geometry changes during tidal breathing [26] which
can introduce movement related errors. As the CT scan only took 1 second and was
triggered at the start of the inhalation, the breath induced geometry changes were
considered to be very small. However, the long scanning time of the CBCT could
have introduced some motion artifacts as the subject performed multiple breaths
during the scan. Although there were no visible motion artifacts, the possibility
exists that the upright volumes were underestimated as these artifacts would be
excluded from the Hounsfield range. As the significant geometrical percentage
changes between CBCT and CT were all positive, it is possible that these are
underestimated. The effect of the upstream nasal regions were neglected in the
CFD simulations. Although this zone was not a part of our region of interest, the
exclusion could have had an influence on the results. It was not possible to quantify
this influence as the field of view of the CBCT was not large enough to scan both
the nasal region and the upper airway in one movement. The skewness of the data
had the effect that non-parametric tests were used and no multivariate analyses were
performed.
In future studies, it would be interesting to perform this methodology in a
population of obstructive sleep apnea (OSA) patients. The first reason is that
this would open possibilities to gain insights in the pathology and to help with
diagnostics. Another reason is the fact that there are a lot of patients that suffer
from both OSA and asthma/COPD [23, 27] and that the conclusions of this study
are possibly not valid for them. The most important insight of the current study is
that the largest area changes occur at the region posterior to the uvula. As most
inhalation compounds are administered through the mouth, it would be interesting
to see if the upper airway behavior changes due to mouth breathing. An open mouth
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can possibly induce a movement of the uvula, which can influence the local or
global airway morphology and functionality. There are plans for a future study
where this will be investigated. The insights of the current and future studies can
lead to more accurate lung deposition estimates.
The large inter- and intra-subject variation in upper airway morphology shows
that there is a need for a subject specific approach when assessing deposition of
inhalation medication. Several predictive models exist, as described in a review of
Warren H. Finlay and Andrew R. Martin [8], that are very valuable but are based
on statistical models en are not able to tell if an individual subject behaves like the
fitted deposition curve predicts.
This study demonstrated that there are differences in upper airway morphology
and functionality between supine and upright position and that there are baseline
indicators for these. The upper airway behavior that was extracted from the CT and
CBCT scans is in line with clinical observations and shows the usefulness of these
techniques. This is especially true as the large variability within and between the
subjects emphasizes the added value of subject specific models.
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7.1 Abstract
Small airways disease, related to chronic Pseudomonas aeruginosa (Pa) infection,
plays a key role in cystic fibrosis (CF) lung disease. Inhaled antibiotics are the
cornerstones of Pa treatment. Unfortunately despite their use, small airways dis-
ease progresses and antibiotic-resistant Pa develops, suggesting small airways
receive less than the minimal inhibitory concentration. Comprehension of the
impact of structural lung changes and breathing profile on local antibiotic concen-
trations is needed to prevent sub-inhibitory concentrations. We used functional
respiratory imaging (FRI) to predict local Aztreonam lysine for inhalation (AZLI)
concentrations in CF lungs. FRI was applied to 40 patient-specific chest computed
tomography airway models. In most simulated conditions, concentrations were
above the minimal inhibitory concentration. However, more diseased lobes were
likely to receive less AZLI. Structural lung disease and high tidal volumes greatly
reduced small airways concentrations. FRI allows further optimization of anti-Pa
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treatment within the small airways.
7.2 Contributions of the author
The author of this thesis was the principal technical researcher in this study. He
cooperated in the segmentation and coupling of the different models and determined
the optimal boundary conditions and simulation strategy for the particle simulations.
This included the generation of lognormal distributions for the aerosol cloud. He
automated the complete trajectory from three-dimensional models to computational
fluid dynamics results. The main challenge in this chapter was the post-processing
of the results. The author programmed the construction of the individual Phalen
models and the coupling with their patient specific three-dimensional airway models.
He was responsible for the automated extraction of the outcome parameters, semi-
automated statistical analyses in the R software environment and cooperated in the
interpretation of the results.
7.3 Introduction
Cystic fibrosis (CF) is a severe hereditary and life-threatening disease in the Cau-
casian population [8], affecting 70,000 patients in the European Union and United
States. Life expectancy is restricted to approximately 37 years. The main cause
of morbidity and mortality (> 90% of deaths) in CF patients is due to progressive
lung disease [42]. An important component in the pathophysiology of CF lung
disease is small airways disease which starts early in life [13, 37, 43, 50]. The
main pathogen that contributes to lung disease progression in CF is Pseudomonas
aeruginosa (Pa) [19, 25, 33]. Inhaled antibiotics play a central role in the eradication
and chronic suppressive therapy of Pa infections.
Unfortunately, commonly used therapies to eradicate Pa do not prevent pro-
gression of CF lung disease, especially in the small airways. Significant mucus
accumulation and wall thickening in the small airways has been found in patients
with severe lung disease [43, 50]. Pa has been associated with these changes,
mainly in airways smaller than 1 mm in diameter [3]. Hence, further improve-
ment of these anti-Pa therapies is needed. Based on high concentrations of drug
in sputum of patients, it has been assumed that inhaled antibiotics result in high
concentrations within the airways [24, 27, 35, 44, 59]. However, it is questionable
whether concentrations in sputum samples are representative for the concentrations
in the small airways. First of all, the overall surface area of the small airways is
much larger than that of central airways [43]. As a result, drug bypassing cen-
tral airways is distributed over a large surface area. Second, sputum originating
from the small airways always pass through the central airways before it can be
expectorated, taking along the drug deposited in these central airways, what is
likely to increase the initial sputum concentration. Unfortunately, very little is
known about the concentrations of anti-Pa antibiotics in the small airways because
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they are extremely difficult to measure in vivo. The progression of small airways
disease in patients with chronic Pa infection despite anti-Pa antibiotics suggests that
concentrations of these inhaled antibiotics are perhaps inadequate due to insufficient
small airway deposition. To optimize eradication and chronic suppression of Pa
with inhaled antibiotics, it is important to obtain local concentrations equal to,
or above the minimal inhibitory concentration (MIC). Concentrations below the
MIC are thought to result in suboptimal killing of Pa and could contribute to the
development of antibiotic resistance [24] and to failure of eradication. When the
Pa infection persists, nonmucoid variants are mostly replaced by mucoid forms [8].
These are considered the hallmark of chronic infection [25], as they are to date
impossible to eradicate using current therapies. Mucoid Pa are associated with a
more rapid decline in lung function and increased treatment burden [33].
To improve inhaled therapy, extensive research has been done to understand the
mechanisms of aerosol deposition. It has been established that aerosol deposition
is strongly dependent on particle size [12] and airflow. An appropriate airflow is
necessary to transport the aerosol to the site of infection. Inhalation technique and
factors influencing airflow distribution in the lungs such as structural lung changes
and airway obstruction by mucus are known to affect deposition of aerosols [21, 28].
For CF it is known that patients suffering from more severe lung disease have more
central airway deposition compared to healthy individuals [28]. This suggests that
CF patients might benefit from specific dose adjustments based on their disease
severity. Adjusting dose, particle size or inhalation technique to the patient’s lung
disease status could improve efficiency of aerosol delivery to the site of infection,
resulting in more effective treatment. However, to maximize drug delivery to the
small airways, the relation between age, structural changes and inspiratory flow
profile and antibiotic concentrations in different compartments of the bronchial tree
needs to be better understood.
Unfortunately, it is difficult to investigate the simultaneous influence of these
factors on deposition in vivo. However, many aspects of aerosol deposition can
nowadays be modelled. Functional respiratory imaging (FRI) has been developed to
assess the behaviour of inhalation medication in the airways and lungs of a specific
patient [15]. This technique has been validated using Single Photon Emission
Computed Tomography [16]. So far, this technique has been used to study lung
drug deposition in asthma patients [51], and, both in asthma and chronic obstructive
pulmonary disease, to assess airflow distribution [15, 16] and the bronchodilating
effects of β2-agonists [14, 17, 53]. There are three essential steps in applying
FRI to CT data. These steps involve image processing (specifically, segmentation
and trimming), three-dimensional image reconstruction and definition of boundary
conditions required for simulation of inhalation therapy, such as breathing profile,
internal lobar flow distribution and drug characteristics.
FRI can increase our understanding of deposition mechanisms in diseased
airways as this technique makes it possible to estimate local measurements of an
individual patient. By using patient specific anatomical models obtained from their
CT scans, in combination with a flow simulation method, aerosol concentrations
in both the central and small airways can be computed. Moreover, by using CT
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scans from patients who differ in disease severity, the relationship between airway
morphology and airway deposition can be assessed. Additionally, by repeating
simulations and changing important variables one at a time, FRI can provide more
information on how to optimize small airway aerosol deposition in CF patients
with structural lung changes. To our knowledge, patient specific airway models
were never used before to estimate local concentrations of inhaled antibiotics in CF
patients.
For our current study we aimed to study the relation between structural lung dis-
ease and deposition of a recently developed inhaled antibiotic used for suppressive
treatment of chronic Pa infections; Aztreonam lysine for inhalation (AZLI). AZLI
is a monobactam antibiotic, delivered by the e-Flow® electronic nebuliser [59].
In our study we aimed to use FRI to predict AZLI concentrations in CF lungs.
We hypothesized firstly that there is great variation in AZLI concentrations due
to differences in airway geometry between subjects and CF lung disease severity.
Secondly, we hypothesized that AZLI concentrations in the small airways would
be below the MIC for Pa in patients with more severe lung disease. Thirdly, we
hypothesized that AZLI concentrations in the small airways could be improved by
increasing the dose of AZLI or by modifying the inhalation technique.
7.4 Materials and methods
7.4.1 Study population
We included CF patients who had a volumetric in- and expiratory high resolution
CT scans with a slice thickness of 1 mm or less performed as part of their routine
annual check up in the Erasmus MC-CF centre (Rotterdam, Netherlands) in the
period from 2008 to 2012. Patients were diagnosed as having CF by a positive
sweat test and/or genotyping for known CF mutations. For all patients (ages 5 – 17
years), demographic data and pulmonary function tests were collected. Pulmonary
function test results were expressed as percentages of predictive values, according
to Stanojevic for the forced vital capacity (FVC) and FEV1, and Zapletal for the
forced expiratory flow at 75% (FEF75) [46, 58]. Written informed consent for the
use of de-identified data was obtained from the parent/guardian and subjects = 12
years prior to inclusion in the study. This retrospective study was approved by the
Institutional Review Board of our hospital (MEC-2013-078).
7.4.2 Chest Computed Tomography
For this study 40 consecutive CT scans were included. All CT scan sets were
acquired using a 128-slice CT scanner (Somatom Definition Flash, Siemens). Thirty-
nine (98%) volumetric CT scans were spirometer controlled (Jaeger AG). For one
patient the spirometer was not tolerated and a technician-controlled technique was
used.
Before performing the CT scan, a lung function technician trained the study
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subjects by practicing the required spirometry manoeuvres in supine position with
the children half an hour prior to the CT scan. Children were trained to obtain
a breath-hold at maximal inspiration (total lung capacity, TLC) and maximal
expiration (residual volume, RV) for 5 – 15 seconds. The inspiratory and expiratory
slow vital capacities (SVC) achieved during the training were used as the reference
values for the spirometric results during the CT scan. The reference SVC’s were
performed according to the ATS/ERS criteria [36]. Breathing instructions during
the CT scan were given by the same lung function technician. During CT scanning,
the lung technician monitored in real time the inspired and expired volumes on the
computer screen of the CT-compatible spirometer setup. When the patient obtained
the correct TLC (inspiratory scan) or RV (expiratory scan) breath hold level, the
lung function technician signalled the CT-technician to start scanning. For the
technician-controlled technique the same breathing instructions were given during
the CT scan; however, the inspired and expired volumes were not measured using
spirometry.
7.4.3 CT settings
Tube voltages of 80 kV (patients < 35 kg) or 110 kV (patients = 35 kg) were
used with a 0.6s rotation time. Scanning was done from apex of the lung to
base at 1.5 pitch and 6x2 mm collimation. Images were reconstructed with a
slice thickness = 1.0 mm, a slice increment = 0.6 mm and kernel B75f. For the
inspiratory protocol, a modulating current was used (Siemens) with a reference
tube current-time product of 20 mAs for optimal image quality. For expiratory CTs,
a tube current fixed at 25mA with an effective tube current-time product of 10 mAs
(the typical value for a 5-year-old child) was used producing a lower radiation dose
than the inspiratory protocol with sufficient image quality. Total radiation dose was
in the order of 0.75 mSv for children below the age of 6 years and 1 mSv in older
children.
7.4.4 CT evaluation
To quantify chest CT abnormalities, we used the validated CF-CT scoring system
[54]. This scoring method evaluates the 5 lung lobes and the lingula as a sixth
lobe for the following components: 1) severity, extent of central and peripheral
bronchiectasis; 2) airway wall thickening; 3) central and peripheral mucus plugging;
4) opacities (atelectasis, consolidation, ground glass pattern); 5) cysts and bullae
on inspiratory CTs and 6) the pattern and extent of trapped air on expiratory CTs.
The maximal possible composite CT score is 207 points and the components scores
are expressed as a percentage of this maximal possible score. The component
scores for bronchiectasis, airway wall thickening and air trapping were used for
analysis. To examine the relation between structural changes in the airways and
AZLI concentrations in that area, CF-CT scores were also computed for each of the
5 lobes.
Prior to scoring, all CT scans were de-identified (Myrian®, Intrasense). Next,
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scans were scored in random order by an experienced observer, with more than 2
years’ experience in scoring, and who was blinded to clinical background. To assess
inter-observer agreement, a second observer, with 4 months scoring experience,
scored all CT scans. Both observers were initially trained in CF-CT scoring using
a standardized instruction module and training sets and started scoring the study
CT scans after establishing good intra- and inter-observer agreement. To establish
the intra-observer agreement, observer 1 rescored 25 random selected scans after 3
months. CF-CT scores of observer 1 were used for analysis.
7.4.5 Reconstruction of three-dimensional airway models
Based on the inspiratory scan, a semi-automatic algorithm was used to reconstruct
patient specific three-dimensional (3D) model of the intra-thoracic region, which
we defined arbitrarily as the lower airway. The automatic segmentation could
be performed up to the point where no distinction could be made between the
intra-luminal and alveolar air. Following automated segmentation of the bronchial
tree, the airways were manually checked. Missing branches were added to the
bronchial tree and incorrect branches were deleted when necessary; 3.39 ± 2.51%
[0.63 – 10.97] of the branches needed to be manually altered. The respiratory tract
was reconstructed down to the level of airways with a diameter of 1 – 2 mm. The
segmented airway tree was converted into a 3D model that was smoothed using a
volume compensation algorithm. The smoothed model was trimmed perpendicular
to the airway centreline at the trachea (using the middle point of the superior side
of the sternum as a landmark) and at each terminal bronchus. Remaining noise in
this model was then manually removed.
For the upper (extrathoracic) airways, a generic average adult upper airway
model was selected and scaled down in such a way that both the anteroposterior
and lateral dimension of the scaled model’s trachea, at the location of the sternum,
matched the average anteroposterior (1.25cm) and lateral (1.19cm) dimension for
the 40 patients. The upper airway model was connected with a reverse engineered
mouthpiece of the Pari eFlow®. Reverse engineering was done based on a CT scan
of the mouthpiece taken on a GE LightSpeed VCT (80 kV, 18.25 mAs, 0.311 mm
slice increment, 0.188 mm pixel size, STANDARD reconstruction algorithm). The
mouthpiece/upper airway model was trimmed perpendicular to the centreline of
the trachea (again using the middle point of the superior side of the sternum as a
landmark).
For each of the 40 CT scan sets, the patient specific lower airway model was
connected to the selected nebulizer mouthpiece/upper airway model, maximizing
the amount of patient specific information. All segmentation and 3D model op-
erations were performed in commercially available validated software packages
(Mimics 15.0 and 3-Matic 7.0, Materialise nv, Food and Drug Administration,
K073468; ConformitÈ EuropÈenne certificate, BE 05/1191.CE.01).
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7.4.6 Meshing
The triangulated, mouthpiece/upper-/lower airway surface models had a maximum
triangle edge length of 0.5 mm and a minimum triangle aspect ratio of 0.4. These
models were converted to tetrahedral 3D volume meshes using TGrid 14.0 (Ansys
Inc). A boundary layer with a growth rate of 1.4 was included in the models. Maxi-
mal tetrahedral volume was set to 2 mm3 and maximal equilateral volume-based
skewness to 0.9. Grid convergence demonstrated that a mesh size of 2.9 ± 0.7M
[1.9 – 4.6] cells is appropriate for the study, depending on the size of the patient
specific lower airway model. Meshing was done on 1 CPU and meshing time was
below 200 s.
7.4.7 Reconstruction of three-dimensional lung lobes
From both the inspiratory and expiratory CT scans, the patient specific lung lobes
were extracted using a semi-automated tool that identifies the fissures separating the
lung lobes. The internal lobar flow distribution could be calculated based on the lo-
bar volume change from expiration to inspiration. Lung lobe identification has been
performed in a commercially available validated software package (Mimics 15.0,
Materialise nv, Food and Drug Administration, K073468; Conformité Européenne
certificate, BE 05/1191.CE.01).
7.4.8 Breathing profile
The average age of the patient population (11 years) was used to generate a generic
breathing profile based on the following parameters: median weight of 11 year old
Dutch children is 38 kg (boy: 37 kg, girl 38.5 kg) [47]; tidal volume of 10 mL/kg
(380 mL); respiration rate (18 breaths per minute) [55]. The resulting profile had
an inspiration/expiration ratio of 1:2 and a sinusoidal shape, see Figure 7.1.
To be able to examine the flow dependency of the simulated results, 2 addi-
tional breathing profiles were generated: 1) a high breathing profile, consisting of a
higher tidal volume of 14 mL/kg (532 mL) and the respiratory rate of the youngest
age (5 years: 22 breaths per minute), and 2) a low breathing profile, consisting of a
lower tidal volume of 6 mL/kg (228 mL) and the respiratory rate of oldest age (17
years: 14 breaths per minute). These additional profiles can also be found in Figure
7.1.
7.4.9 Aerosol characteristics
Eleven different trials (Anderson Cascade impactor n = 6, next generation impactor
n = 2, and laser diffraction n = 3) studied the diameter distribution of AZLI nebulized
via the Pari eFlow® (Gilead data on file). The extremes and the median were selected
for use in the FRI simulations: smallest diameter (2.81± 1.47 µm), median diameter
(3.18 ± 1.63 µm) and largest diameter (4.35 ± 2.05 µm). Furthermore, an in vivo
characterization of the eFlow® showed that 35% of the nominal fill volume is either
trapped in the mouthpiece or exhaled.
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Figure 7.1: Inhalation part of breathing profiles. Small breathing profile: tidal volume of
6 mL/kg (228 mL) and respiration rate of 14 breaths per minute. Average breathing profile:
tidal volume of 10 mL/kg (380 mL) and respiration rate of 18 breaths per minute. Large
breathing profile: tidal volume of 14 mL/kg (532 mL) and respiration rate of 22 breaths per
minute.
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7.4.10 Flow simulation
Computational fluid dynamics (CFD) flow simulations were performed in Fluent
14.0 (Ansys Inc). All simulations were transient using a second order time stepping
algorithm and a time step of 0.005s. Turbulence was evaluated through large eddy
simulations with a turbulent kinetic subgrid model. Aerosol transport was modelled
by an implicit Runge-Kutta Lagrangian discrete particle model, with a one-way
coupling of the forces from the flow to the particle and taken into account the
Saffman lift forces. Particles were considered deposited the moment they hit the
airway wall.
The nominal dose of 75 mg AZLI was corrected for the 35% combined inhaler
loss and exhaled fraction. Due to the incorporation of the exhaled fraction, only
the inhalation was modelled. The boundary condition at the inhaler mouthpiece
was represented by the inhalation part of the mean breathing profile in Figure 7.1.
The downstream boundary conditions at the terminal bronchi were set such that the
percentage of flow exiting the model towards a lobe did match with the internal
lobar flow distribution obtained from the expiratory and inspiratory CT data.
To investigate the influence of the inhalation manoeuvre on local concen-
trations, additional simulations were performed in a subset of the population (2
tallest, 2 smallest, 2 median sized patients). These additional CFD simulations were
performed with the altered breathing profiles described in section 7.4.8.
7.4.11 Aerosol deposition analyses
To be able to perform regional analyses, the respiratory tract was subdivided in
multiple regions. For the airways with a diameter >1 – 2 mm these regions were
obtained from the mouthpiece/upper-/lower airway model, see Figure 7.2. In figure
7.2, the upper airway is divided in two parts: the oral cavity and the pharynx;
and the lower airway is divided in a central part and distal parts representing the
lung segments. Conducting airways with a diameter < 1 – 2 mm could not be
distinguished from the CT images and have been added to the patient specific
model by using Phalen’s description of the airway tree in infants, children and
adolescents [41]. For every simulation, a Phalen model was constructed based on
the height of the specific patient.
Regional AZLI deposition was evaluated for both the particles depositing
inside the model, in every separate zone indicated in Figure 7.2; as well as for the
particles exiting the model at the terminal bronchi, in the small airways represented
by the Phalen model on a lobar basis. Once the aerosol entered the Phalen model of
a certain lobe, it was assumed that it was distributed homogeneously.
7.4.12 Airway surface liquid
To compute AZLI concentration in the airway surface liquid (ASL) throughout the
bronchial tree we used a range of thicknesses based on studies in CF. Three different
ASL scenarios were considered: thick ASL (7 µm) [49], thin ASL (3 µm) [48] and
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Figure 7.2: Coupled mouthpiece/upper-/lower airway model subdivided in multiple regions.
Airways are segmented up to the 5th – 9th generation. The different regions are: mouthpiece
(turquoise), mouth (dark grey), upper airway (light grey), central airways (white), distal
airways (colored)
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the mean ASL (5 µm).
7.4.13 AZLI concentrations
For each reconstructed airway and for each lung lobe, the area was calculated and
the CFD simulations provided data on the drug deposition in that region. The
regional AZLI concentration was computed as follows: the mass of the deposited
drug in an airway was divided by the thickness of the lining fluid multiplied by the
surface area of that airway.
Finally, this regional AZLI concentration is expressed relative to the MIC
of AZLI required to inhibit the growth of 90% of Pa strains multiplied by 10
(10xMIC90 = 10x128 µg/ml = 1280 µg/ml), since this is the most stringent effective
AZLI level reported in literature [27, 40, 44].
7.4.14 Statistical analysis
Inter- and intra-observer agreements of component CF-CT scores were calculated
using intraclass correlation coefficients (ICC). Although no universally accepted
standards are available for what constitutes good reliability, ICC values between
0.4 and 0.6, 0.6 and 0.8, and = 0.8 are generally considered to represent moderate,
good and very good agreement, respectively. Systematic errors in component scores
were evaluated using Bland-Altman plots, expressing the differences between two
observers as a function of their mean [5].
To establish the correlation between age and disease severity expressed in
CF-CT scores and pulmonary function tests, we used Spearman’s correlation test.
According to Cohen’s criteria (1988), correlations between 0.10 and 0.29 are
considered weak, between 0.30 and 0.49 moderate and above 0.50 are considered
strong.
Differences between multiple groups were investigated using a Kruskal-Wallis
test, after which two by two comparisons were made using Mann-Whitney tests.
The effect size was noted as r. To search for correlations between parameters that
were measured in the different lobes, a generalized estimating equation using an
autoregressive covariance matrix was used to account for within-subject correlations.
All data are presented as the median (range). Significance level was set at 0.05
and p-values were corrected for multiple testing using Benjamini and Hochberg
correction [4]. All statistical computations were performed using the open-source
statistical environment R 2.15.3.
7.5 Results
7.5.1 Study population
Forty consecutive inspiratory and expiratory chest CT scans were selected. Baseline
characteristics are shown in Table 7.1. Thirty-nine (98%) CT scans were spirometer
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controlled, and for 1 CT scan the breathing during the scan was controlled by the
technician. There were no significant differences between the sexes for demograph-
ics, pulmonary function tests and CF-CT sub scores (Table 7.1), meaning that the
dataset did not have to be split in sex groups. ICCs for within-observer agree-
ment ranged from 0.85 (CF-CT air trapping score) to 0.93 (CF-CT bronchiectasis
score), whereas between-observer agreement ranged from 0.67 (CF-CT airway wall
thickening score) to 0.77 (CF-CT air trapping score).
Value p-value
N 31
Male 11 35%
Age 11.4 (5.8 – 17.3) 0.51
Bronchiectasis score % of max CF-CT score 2.8 (0.0 – 16.0) 0.41
Airway wall thickening score % of max CF-CT score 3.7 (0.0 – 18.5) 0.99
Air trapping score % of max CF-CT score 22.2 (11.1 – 85.2) 0.41
FEV1% pred 93.5 (70.0 – 115.0) 0.1
FVC% pred 104 (78.0 – 127.0) 0.69
Table 7.1: Baseline characteristics: Data are presented as nr. (%) or median (range), unless
otherwise indicated. P-values represent differences between the sexes
7.5.2 Correlations
There was a moderate positive correlation between bronchiectasis scores and age
(r = 0.481, p = 0.005). Correlations between age and airway wall thickness
(r = 0.302, p = 0.087) and air trapping (r = 0.096, p = 0.554) were not signifi-
cant. Furthermore, there were no significant correlations between age and pul-
monary function tests (FVC% pred: r = 0.053, p = 0.885; FEV1% pred: r = -0.024,
p = 0.885).
7.5.3 Deposition analyses
Significant differences between the lobes were found for all tested CF-CT sub scores
(bronchiectasis score: χ2 = 24.04, p < 0.001; airway wall thickness: χ2 = 23.90,
p < 0.001; and air trapping: χ2 = 18.77, p < 0.001). It was found that CF-CT sub
scores were generally higher in the right upper lobe than in the other lobes (Table
7.2).
There was a deposition difference of AZLI between the different lobes (Table
7.3). The highest AZLI concentrations were found in the lower lobes. For the lower
lobes, AZLI concentrations were always higher than 10xMIC90 independent of
the scenario tested. An inverse correlation between AZLI concentration in a lobe
and the CF-CT scores was observed, indicating that more diseased lobes received a
lower concentration of AZLI (Table 7.4).
When expressing this regional AZLI concentration relative to 10xMIC90,
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CF-CT sub score Lobe Score (% of total score) Comparison with other lobes (p-values)
RUL RML RLL LUL LLL
Bronchiectasis
RUL 0 (0 – 33.33) - 0.005 0.004 0.058 0
RML 0 (0 – 29.17) 0.005 - 1 0.235 0.235
RLL 0 (0 – 29.17) 0.004 1 - 0.235 0.235
LUL 0 (0 – 18.75) 0.058 0.235 0.235 - 0.017
LLL 0 (0 – 25.00) 0 0.235 0.235 0.017 -
Airway wall thickness
RUL 11.11 (0 – 27.78) - 0.045 0.049 0.472 0.029
RML 0 (0 – 13.89) 0.045 - 0.43 0.034 0.661
RLL 0 (0 – 16.67) 0.049 0.43 - 0.023 0.469
LUL 2.78 (0 – 16.67) 0.472 0.034 0.023 - 0.006
LLL 0 (0 – 22.22) 0.029 0.661 0.469 0.006 -
Air trapping
RUL 11.11 (0 – 50.0) - 0.045 0.049 0.472 0.029
RML 11.11 (0 – 33.33) 0.045 - 0.43 0.034 0.661
RLL 11.11 (0 – 50.0) 0.049 0.43 - 0.023 0.469
LUL 11.11 (0 – 50.0) 0.472 0.034 0.023 - 0.006
LLL 11.11 (0 – 33.33) 0.029 0.661 0.469 0.006 -
Table 7.2: Comparison of CF-CT sub scores per lobe: Data are presented as median
(range), unless otherwise indicated. P-values in bold represent significant differences. RUL
= right upper lobe, RML = right middle lobe. RLL = right lower lobe, LUL = left upper
lobe, LLL = left lower lobe.
Lobe AZLI concentration (µg/ml) Comparison with other lobes (p-values)
RUL RML RLL LUL LLL
RUL 1332 (888 – 1787) - 0.002 1.40E-09 0.156 2.70E-10
RML 966 (636 – 1608) 0.002 - 2.70E-10 5.60E-06 2.70E-10
RLL 2070 (1387 – 2782) 1.40E-09 2.70E-10 - 6.80E-11 5.30E-10
LUL 1391 (468 – 1943) 0.156 5.60E-06 6.80E-11 - 3.30E-13
LLL 2623 (1942 – 3280) 2.70E-10 2.70E-10 5.30E-10 3.30E-13 -
Table 7.3: Differences between lobes in AZLI concentrations for the scenario of thick lining
fluid with largest aerosol diameter. Data are presented as median (range), unless otherwise
indicated. P-values in bold represent significant differences. RUL = right upper lobe, RML
= right middle lobe. RLL = right lower lobe, LUL = left upper lobe, LLL = left lower lobe.
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ASL Diameter (µm) CF-CT score Estimate Std.err Wald p-value
T
hi
n
(3
µm
Smallest (2.9)
Bronchiectasis -439 115 14.6 0.00013
Airway wall thickness -466 142 10.7 0.0011
Air trapping -237.5 85.3 7.76 0.0053
Median (3.18)
Bronchiectasis -387 108 12.8 0.00034
Airway wall thickness -421 133 10 0.0016
Air trapping -229.7 78.5 8.56 0.0034
Largest (4.35)
Bronchiectasis -278.8 86.5 10.4 0.0013
Airway wall thickness -316.8 106.2 8.9 0.0029
Air trapping -190.3 61.4 9.6 0.0019
M
ed
ia
n
(5
µm
)
Smallest (2.9)
Bronchiectasis -263.7 69 14.6 0.00013
Airway wall thickness -279.6 85.4 10.7 0.0011
Air trapping -142.5 51.2 7.76 0.0053
Median (3.18)
Bronchiectasis -232 64.8 12.8 0.00034
Airway wall thickness -252.7 79.9 10 0.0016
Air trapping -137.8 47.1 8.56 0.0034
Largest (4.35)
Bronchiectasis -167.3 51.9 10.4 0.0013
Airway wall thickness -190.1 63.7 8.9 0.0029
Air trapping -114.2 36.9 9.6 0.0019
T
hi
ck
(7
µm
)
Smallest (2.9)
Bronchiectasis -188.3 49.3 14.6 0.00013
Airway wall thickness -199.7 61 10.7 0.0011
Air trapping -101.8 36.5 7.76 0.0053
Median (3.18)
Bronchiectasis -165.7 46.3 12.8 0.00034
Airway wall thickness -180.5 57.1 10 0.0016
Air trapping -98.5 33.7 8.56 0.0034
Largest (4.35)
Bronchiectasis -119.5 37.1 10.4 0.0013
Airway wall thickness -135.8 45.5 8.9 0.0029
Air trapping -81.6 26.3 9.6 0.0019
Table 7.4: Inverse correlation between AZLI concentration in a lobe and the CF-CT scores,
shown for the different scenarios and different aerosol diameters. P-values in bold represent
significant correlations. ASL = airway surface liquid, Estimate = the estimation of the slope
of the linear model, Std.err = the robust standard error estimate, Wald = the Wald statistic
(outcome of the Wald test)
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differences were observed when using different ASL thicknesses. The combination
of the thin lining fluid and smallest diameter of aerosols resulted in AZLI concentra-
tions above 10xMIC90 for all lobes. For the combination of thick lining fluid and
largest diameter of aerosols, up to 28% of the lobes received AZLI concentrations
below 10xMIC90. The lowest AZLI value that was observed in all the lobes for the
tested population was 468.14 µg/ml or 3.66xMIC90. Table 7.5 summarizes the pa-
tients and lobes that receive a concentration lower than 10xMIC90 for the different
modelling conditions. In figures 7.3 and 7.4, the relative AZLI concentrations in 2
patients are shown for 3 different scenarios. In the central and distal airways, AZLI
concentrations 10 – 100x above the threshold of 1280 µg/ml were observed. In the
small airways (visualized per lobe in the images), lower concentrations were seen.
ASL Diameter (µm) Nr of patients with at least 1
lobe with AZLI < 10xMIC90
Nr of lobes with AZLI <
10xMIC90
Thin (3 µm)
Smallest (2.9) 0 0
Median (3.18) 0 0
Largest (4.35) 1 (2.5%) 1 (0.5%)
Median (5 µm)
Smallest (2.9) 1 (2.5%) 1 (0.5%)
Median (3.18) 3 (7.5%) 3 (1.5%)
Largest (4.35) 10 (25%) 15 (7.5%)
Thick (7 µm)
Smallest (2.9) 6 (15%) 7 (3.5%)
Median (3.18) 14 (35%) 19 (9.5%)
Largest (4.35) 32 (80%) 56 (28%)
Table 7.5: Number of patients and lobes with AZLI <10xMIC90: Data are presented as nr.
(%). ASL = airway surface liquid, Nr = number.
Decreasing the tidal volume decreased the deposition in the extrathoracic
region. These reductions subsequently resulted in significantly more areas with a
concentration above 10xMIC90 in the lungs (Table 7.6).
ASL Diameter (µm) % Area with AZLI < 10xMIC90
Low flow Average flow High flow
Thin (3 µm)
Smallest (2.9) 0 0 0
Median (3.18) 0 0 0
Largest (4.35) 0 0 0
Median (5 µm)
Smallest (2.9) 0 0 0
Median (3.18) 0 0 0
Largest (4.35) 0 (0 – 10.92) 0 (0 – 10.92) 16.51 (0 – 27.37)
Thick (7 µm)
Smallest (2.9) 0 (0 – 10.92) 0 (0 – 10.92) 0 (0 – 10.92)
Median (3.18) 0 (0 – 10.92) 0 (0 – 10.92) 16.51 (0 – 27.37)
Largest (4.35) 0 (0 – 10.92) 27.40 (0 – 49.79) 49.40 (27.25 – 49.79)
Table 7.6: Influence of inhalation technique on AZLI concentrations: Data are presented as
median (range), unless otherwise indicated. ASL = airway surface liquid.
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7.6 Discussion
This study demonstrates the ability of FRI to give insight in patient specific inhaled
antibiotic concentrations throughout the bronchial tree. The most important finding
was that the concentrations of the inhaled antibiotic delivered to the airways were
highly dependent on patient related factors.
Another important finding of this study was that for the tested inhaled antibi-
otic (AZLI), effective concentrations above the 10xMIC90 threshold for Pa were
observed throughout the lung in most simulated conditions. However, variables,
such as particle diameter and lining fluid thickness, had an important impact on
the results. Under certain assumptions of these variables, it was shown that the
concentration would drop below 10xMIC90 in up to 28% of the lobes. The most
critical scenario was the combination of a thick lining fluid and the largest aerosol
diameter. However, the lowest observed AZLI concentration in the lobes of the
studied population was still above 3xMIC90 for Pa. For this particular patient, an
increase of 2.7 times the standard nebulized AZLI dose would have resulted in
sufficiently high concentrations in all lobes. In the “best-case” scenario, all lobes
received AZLI concentrations above 10xMIC90. The observation that regional
low concentrations can exist is of great importance since suboptimal concentra-
tions could result in suboptimal killing and are associated with the development of
antibiotic resistance [24].
As in previous studies we observed that the upper lobes were more severely
affected relative to the other lobes [31, 56]. The reason for this distribution however
is still largely unknown. Our findings suggest that uneven distribution of inhaled
drugs could contribute to this inequality. We observed that even in CF patients with
relative little structural damage the upper lobes received lower AZLI concentrations
than the lower lobes. Furthermore, an inverse correlation between the CF-CT score
and the AZLI concentration for a lobe was shown. These findings match deposition
studies in CF patients showing that the deposition pattern is more heterogeneous in
diseased lungs than in healthy lungs [12, 23, 29]. In addition, it supports previous
studies showing that penetration of inhaled drugs in deformed or partial obstructed
airways is restricted [23, 29]. These results suggest that upper lobes are more
vulnerable to be undertreated and that this effect is stronger once structural damage
is present.
With our simulations we showed that lower inhalation flows lead to higher
AZLI concentrations in the small airways, due to decreased extrathoracic deposition.
This finding is in line with previous studies showing that high flows lead to high
extrathoracic and upper airway deposition of drug [12]. Using patient specific
airway modelling we were able to study the impact of inhalation flow rate and
inhaled volume on local airway drug concentrations in all lobes for individual
patients. This information can subsequently be used to set smart nebulisers in such
a way that adequate small airways concentrations can be obtained [2]. Or to define
the required medication dose for a patient that, independent of the breathing pattern,
results in sufficient drug delivery to critical areas of the lung.
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FRI could offer a number of advantages to complement available techniques for
studying aerosol deposition. First, non-imaging techniques, e.g. pharmacokinetic
methods, lack the ability to identify dose deposition into different zones of the
lungs [10]. Scintigraphic methods do assess the deposition location of inhaled drugs.
However, in these studies the lung is divided into several large regions of interests
and aerosol deposition patterns and distribution is compared between these regions
[6, 11, 23, 30, 42]. In contrast, FRI enabled us to determine detailed information on
aerosol deposition at specific anatomical sites. Second, FRI information allowed us
to estimate AZLI concentrations throughout the bronchial tree. In vivo this kind
of data are extremely difficult to obtain. To date, great emphasis has been given
to sputum concentrations in clinical studies investigating inhaled antibiotics. It is
highly likely that these concentrations are primarily reflective of central airway
concentrations. The central airway concentrations found in this study were in the
range of the fitted sputum concentrations from clinical studies, taking into account
that published sputum concentrations were collected at later time points compared
to this study (data on file). As suggested by our findings, high concentrations in
central airways result in lower concentrations in the small airway compartment,
challenging the validity of sputum samples as a useful indicator to explain the
failure or success of inhaled antibiotics. Third, our method utilized CT scans that
were acquired as part of routine clinical care [32]. Hence, extra clinically relevant
information could be extracted from the chest CT beyond lung morphology without
the need for additional radiation. Fourth, the model allowed us to study the impact
of multiple variables, e.g. particle size distribution, on lung deposition within the
same patient. Thus, FRI opens up new pathways to further optimize inhalation
therapies even at a personalized level.
To allow modelling of AZLI and estimation of concentrations, several as-
sumptions were made. These assumptions do limit the implementation of our
results.
The first assumption was that the antibiotic concentration in the ASL is the
most important determinant for effective killing of Pa [7, 9, 57]. To estimate ASL
concentrations we had to consider three different scenarios for lining fluid thickness.
These scenarios were based on in vitro data of CF bronchial epithelial cultures and
covered the complete range of ASL thickness found in CF [48].
While ASL concentration is considered to be a reliable marker of alveolar
antibiotic concentration [7, 9, 57], there are several limitations to this assumption.
First, we did not take the uptake of drug by alveolar macrophages into considera-
tion as a measure of intracellular penetration in the lungs [45]. Especially in the
chronically infected lung, macrophages may play a substantial role in the phar-
macodynamics of anti-infective agents. Second, we did take into account binding
of AZLI to sputum [45]. Only unbound drug concentrations are considered to
be microbiologically active. The significance and the amount of protein binding
of AZLI in ASL are unknown and, to our knowledge, have not been studied. In
plasma, protein binding for AZLI is around 42 – 56% [34, 52]. Hence, due to
sputum binding, estimated concentrations of unbound AZLI could be dramatically
lower, increasing the percentage of airways with insufficient ASL concentrations.
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Third, we did not account for mucociliary and cough clearance which further re-
duces AZLI concentrations in the airways within minutes after inhalation [18].
Fourth, the microbiological effect of a β-lactam antibiotic, such as AZLI, is best
predicted using function of time above the MIC (T > MIC) [38, 39]. Unfortunately,
the half-life of AZLI in the airways is largely unknown. The half-life of AZLI in
serum is approximately two hours. Therefore, a prediction of efficacy of AZLI
in the airways based on a single time point immediately after inhalation has clear
limitations. Thus, even though the concentration of AZLI was well above MIC90
for most simulated conditions immediately after nebulization, concentrations may
decrease below MIC90, especially in diseased areas, before a new dose of AZLI is
nebulized.
The second assumption was the AZLI concentration that could be considered
effective for killing Pa strains. This assumption has limitations as the ideal AZLI
concentration for effective killing of Pa in vivo is actually not well defined. First,
terms indicating the efficacy level of antibiotics, e.g. MIC and MIC90, are used
interchangeably in previous studies [38, 39]. Second, the MIC90 values range
between 32 and 128 µg/ml [20, 22, 27, 40, 44]. Third, for AZLI, most susceptible
bacteria are killed at concentrations 1 to 4-fold their MIC. However, in some cases
an AZLI concentration of 4 to 16-fold the MIC was required to achieve bacteri-
cidal killing of Pa [1]. For two other antibiotics, ceftazidime and imipenem, it
was shown that mucoid Pa strains required higher antibiotic concentrations as the
time-dependent killing pattern for nonmucoid Pa strains changed to concentration-
dependent killing [26]. Studies on the efficacy of AZLI mostly use the conservative
threshold of 10-fold MIC90, but without clear explanation [20, 22]. This conserva-
tive threshold, using 128 µg/ml as MIC90, was also used for our analyses in this
manuscript, but no speculations could be made concerning its clinical relevance.
The final limitation of the model is that we did not use patient specific breathing
profiles and upper airway models for this study since they were not available.
Clearly, this would have improved the precision of the simulations.
In conclusion, it was shown that inhaled antibiotic concentrations in the lung
lobes are highly patient specific. Using FRI, we were able to gain insight in the
relation between patient specific characteristics such as severity of localized CF
lung disease and concentrations of the inhaled antibiotic throughout the lung. This
method opens up the possibility of personalizing the medication dose on a patient
specific basis.
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Effects of inhalation
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8
The acute effect of
budesonide/formoterol in COPD: a
multi-slice computed tomography and
lung function study
European Respiratory Journal 2011; 40:298 – 305
Lieve De Backer, Wim Vos, Jan De Backer, Cedric Van Holsbeke, Samir Vinchurkar
and Wilfried De Backer
8.1 Abstract
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification
of chronic obstructive pulmonary disease (COPD) does not always match with
other clinical disease descriptors such as exacerbation frequency and quality of
life, indicating that forced expiratory volume in 1 s (FEV1) is not a perfect de-
scriptor of the disease. The aim of this study was to find out whether changes in
airway geometry after inhalation of the most commonly used inhalation therapy
in severe COPD can more adequately be described with an image-based approach
than with spirometry. 10 COPD GOLD stage III patients were assessed in a
double-blind crossover study. Airway volumes were analysed using segmentation
of high resolution computed tomography (HRCT) images; airway resistance was
determined using computational fluid dynamics (CFD). Distal airway volume signif-
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icantly increased (p = 0.011) in patients 4 h after receiving a budesonide/formoterol
combination from 9.6 ± 4.67 cm3 to 10.14 ± 4.81 cm3. Also CFD-determined
airway resistance significantly decreased (p = 0.047) from 0.051 ± 0.021 kPas/L to
0.043 ± 0.019 kPas/L. None of the lung function parameters showed a significant
change. Only functional residual capacity (FRC) showed a trend to decline (p =
0.056). Only the image-based parameters were able to predict the visit at which
the combination product was administered. This study showed that imaging is a
sensitive, complementary tool to describe changes in airway structure.
8.2 Contributions of the author
The author of this thesis was involved in the design of the double-blind crossover
study. He determined the imaging and computational fluid dynamics strategy
in order to perform the longitudinal comparisons in the most optimal way and
cooperated in the generation of the three-dimensional models. The author designed
algorithms to extract the outcome parameters and perform the comparisons in an
automated way, including the conversion from blinded to unblinded results. He was
involved in the statistical analyses and sample size calculation.
8.3 Introduction
Chronic obstructive pulmonary disease (COPD) is characterised by chronic airway
inflammation (bronchitis) and the destruction of lung parenchyma in combination
with the loss of vascular structures (emphysema). A hallmark of COPD is the
relatively irreversible nature of the airway constriction. In clinical practice, patients
are diagnosed with COPD if the decrease in forced expiratory volume in 1 s (FEV1)
is not fully reversible after the administration of bronchodilating products and when
the ratio between the FEV1 and the forced vital capacity (FVC) remains below
70%. It is, however, possible that a substantial degree of reversibility of bron-
choconstriction in COPD can be detected. This reversibility of bronchoconstriction
tends to vary over time and with disease severity as well as with the method and
product of treatment [5, 25]. It would be interesting to predict this response and
categorise patients according to bronchodilating capacity. FEV1 represents the
whole of the bronchial tree, so cannot show local bronchodilation, which can be
important for the medication to be effective. As COPD is such a heterogeneous
disease, bronchodilating capacity is only part of the patient assessment. The severity
of COPD is defined by the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines [24] consisting of four categories. Patients are subdivided into
these groups based on their post-bronchodilator FEV1 value. Even though FEV1
remains the primary outcome parameter to describe respiratory diseases in clinical
studies and practice, only weak correlations have been found between this parameter
and patient-reported outcomes such as the St George’s Respiratory Questionnaire
(SGRQ) [16–20]. The FEV1-based categorisation can still be improved [16]. Today,
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the standard treatment of COPD includes inhaled corticosteroids (ICS) and short-
(SABA) and long- (LABA) acting β2-agonists. However, the inherent black-box
approach of the spirometry parameters in combination with the above-mentioned
weak clinical correlations often causes difficult and very costly development and
registration processes for new compounds targeted at treating COPD [1]. Even
in very large clinical trials the beneficial effect of therapies on FEV1 or even
survival is difficult to demonstrate [4, 7, 8]. Given the increasing prevalence of
COPD [23], the need for new outcome parameters that more adequately describe
the influence of inhalation medication on the respiratory system becomes apparent.
These outcome parameters should ideally facilitate development of novel effective
therapies that relieve the burden primarily on the patient but also on the social
healthcare structure. Within the field of COPD, imaging and in particular high
resolution computed tomography (HRCT), has emerged as a complementary tool
to spirometry and body plethysmography, predominantly to assess the extent of
emphysema [13, 15, 22]. The severity of emphysema is typically correlated with a
decrease in local Hounsfield units (HU), indicating a destruction of pulmonary lung
tissue. Recent developments have extended the use of HRCT scans by adding more
functionality to the static images by means of airway segmentation and computa-
tional fluid dynamics (CFD) [21]. Patient specific assessments of the airway volume
and airflow in the respiratory system can be obtained by solving mathematical flow
equations within the segmented airway structures [12]. Several studies have in-
dicated the possible applications of this method and have validated the approach
through comparison with in vitro and in vivo data [10, 11]. The current study used
the same approach where patient specific computer models are constructed based
on HRCT images using segmentation principles and flow parameters are derived
using CFD. The aim of the present study was to find out whether in GOLD stage
III COPD patients, treated with inhalation of routinely used inhalation therapy or
placebo, changes in airway structure and function are more adequately described
with this new imaging technology than with spirometric data. Fixed combinations
were chosen as the study medication to reflect the real-life situation. We also
performed a sample size calculation to calculate the number of patients in clinical
trials needed when using more sensitive, image-based outcome parameters.
8.4 Materials en Methods
8.4.1 Ethics
The study was conducted according to all ethical principles. Approval from the eth-
ical committee was obtained and all patients gave their informed consent (EudraCT
2009-016502-16, PML_DOC_0905_/_ISSSYmB0020).
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8.4.2 Patient population
In this study 10 COPD patients (six male/four female) were included. All patients
were categorised by the GOLD guidelines as GOLD stage III with a mean ± SD
FEV1 of 34.8 ± 7.7% predicted. The mean ± SD age of the patients was
65.1 ± 3.3 years with a mean ± SD height of 170 ± 7 cm and weight of 93 ± 5 kg.
8.4.3 Study design
This was a double-blind, placebo-controlled crossover study designed to investigate
a number of topics. A first aim was to demonstrate how functional respiratory
imaging parameters such as changes in airway volumes and CFD-determined
resistance can assess changes induced by a combination product compared to
placebo. Subsequently these changes could be compared to other lung function
parameters. Furthermore a comparison could be made between the combination
product and placebo. A final aim of the study was to analyse whether the different
outcome parameters could distinguish between placebo and active product. The
latter was possible considering the double-blind design of the study.
At baseline (V1), patients received full lung-function testing and low-dose
inspiratory and expiratory HRCT scans. A low-dose computed tomography (CT)
scan reduces the radiation by lowering the current and increasing the pitch com-
pared to a normal thoracic CT. Due to the natural contrast between air and the
surrounding airway tissue, a significant reduction, up to six-fold, in the radiation
dose can be obtained [2]. The lung function tests yielded the following parameters:
FEV1, FEV1/FVC and peak expiratory flow (PEF) from the spirometry; and airway
resistance (Raw), specific airway resistance (sRaw), functional residual capacity
(FRC) and total lung capacity (TLC) from body plethysmography. After the initial
tests and scans the patients were randomised to receive either placebo or budes-
onide/formoterol combination (Symbicort®, AstraZeneca, Södertälje, Sweden). In
this study a combination product (ICS/LABA) was used as suggested by the GOLD
guidelines for the treatment of COPD GOLD stage III patients. The lung function
and imaging tests were repeated 4 h after the administration of the product or
placebo (V2). Patients returned to the hospital 1 week later, and the lung function
tests were repeated pre-dose (V3). To limit radiation dose, no baseline HRCT
scan was taken at this point. Subsequently patients received either the combination
product or placebo. Again, 4 h after the administration of the formulation, both
lung function and imaging tests were performed (V4). To limit the radiation dose
given to the patient as much as possible a dose-reduction protocol was applied. The
natural contrast between the intraluminal air and the surrounding tissue allows for
a significant reduction in dose without compromising image quality. The scanner
used was a General Electric VCT Lightspeed scanner (GE Healthcare, Chalfont
St Giles, UK) with 64 detector rows. The HRCT settings were as follows: tube
voltage, 120 kV; tube current, between 10 mAs (low-weight patients) and 100 mAs
(high-weight patients); noise factor, 28; collimation, 0.625 mm; rotation time, 0.6 s;
and pitch factor, 1.375. The field of view was indicated by the CT technician based
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on the scout image and was positioned closely around the thorax to optimise in-
plane image resolution which was around 0.5 mm. The resulting radiation dose was
in the order of 1 – 2 mSv per scan. Images were reconstructed to a slice thickness
of 0.6 mm to attain near cubic voxels. Respiratory gating was used to ensure the
proper lung volume. CT examinations were performed blindly.
8.4.4 Image post-processing
Post-processing of the HRCT images included segmentation of the airway tree
structure and CFD flow simulations. Segmentation can be defined as the grouping
of voxels that belong to an anatomical structure (e.g. tracheobronchial tree, lung).
This group of voxels or mask can subsequently be used to create a patient specific
three-dimensional model of the anatomical structure under consideration. For this
study the focus was placed on the tracheobronchial tree, with HU ranging from
-1024 to -824 [11], and in particular the smaller airways starting from the segmental
level (generation 2 – 4). Using state-of-the-art imaging equipment it is possible to
distinguish, in the HRCT images, airways with a diameter as low as 1 mm. Smaller
airways cannot be further detected since the in-plane resolution of the scanner
(512x512) is typically not sufficient to distinguish between the intraluminal and the
alveolar air. Consequently the analysis was performed on all airways starting from
generation 2 – 4 down to the smallest detectable airways. The DICOM (Digital
Imaging and Communications in Medicine) images obtained in this clinical study at
the different measurement instances were assessed using the commercially available,
US Food and Drug Administration approved, software package Mimics (Materialise,
Leuven, Belgium). The tracheobronchial tree was subsequently segmented using
a semi-automatic approach where the central airways up to around generation 4
– 5 are automatically generated and the smaller branches are added manually. A
total of three airway tree models were obtained per patient: the model from V1 was
based on pre-bronchodilation images, the airway constructed at V2 was either after
administration of placebo or the combination, and the model based on V4 was again
either after administration of placebo or the combination depending on what was
used in V2. After segmentation, all models of the same patient were superimposed
using a least-squares method. Subsequently all models were trimmed such that
the branches extended equally far and a comparison could be made between the
different geometries excluding the variability induced by the manual segmentation.
The main outcome parameter of the segmentation procedures is the distal airway
volume (iVaw) (Figure 8.1). In addition to the changes in volume, the changes in
resistance were determined using CFD (iRaw). CFD is a computer method that
provides flow characteristics throughout the entire reconstructed airway model.
Flow simulations were performed using Fluent v6.3 (Ansys Inc, Lebanon, NH,
USA), which solved the Reynolds-averaged Navier–Stokes (RANS) equations.
Steady flow was considered at 30 L/min. More details on the flow simulation
principles can be found in De Backer et al. [10]. The CT and CFD analysts were
blinded with respect to the randomisation to avoid any bias.
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Figure 8.1: HRCT-based airway models indicating distal airway branches (iVaw) at baseline
and visits 2 and 3
8.4.5 Statistics
Differences were assessed using the Wilcoxon matched-pairs test. Sample size
calculations were performed using t-test for dependent samples. A p-value < 0.05
was considered to be statistically significant. Results are presented as mean ± SD.
8.5 Results
iVaw significantly increased (p = 0.011) in patients 4 h after they received budes-
onide/formoterol in combination (Table 8.1). The distal airway volumes increased
from 9.6 ± 4.67 cm3 to 10.14 ± 4.81 cm3. The airway resistance decreased from
0.051 ± 0.021 kPas/L to 0.043 ± 0.019 kPas/L.
Figure 8.2 illustrates changes in distal airway volumes after the administra-
tion of the placebo and the combination product. No lung function parameter
showed a significant change. The FEV1 did increase slightly from 34.8 ± 7.69%p
to 35.9 ± 7.89%p but not significantly (p = 0.34). The sRaw decreased from
5 ± 2.87 kPas to 4.65 ± 2.29 kPas but again not significantly (p = 0.14). Although
both iRaw and sRaw declined, there was no correlation between the parameters
(r = 0.45, not significant). A decreasing trend in FRC was observed after adminis-
tration of budesonide/formoterol indicating a reduction in hyperinflation.
The bronchodilating effect, defined as an increase in iVaw and a decrease in
iRaw, seems higher in a limited number of patients (n = 7); this effect seems not
to be systematic. This appears more clearly in the functional imaging parameters
(Table 8.2).
A sample size calculation revealed that in order to have a well-powered study
(power goal of 90%) with iVaw as primary outcome parameter, a total of 16 patients
would be required. When using iRaw, 34 patients were needed. Were FEV1 used as
the primary end-point, the number of required patients would go up to 93. The least
sensitive parameter in this regard is the PEF, with a total of 217 patients required to
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Budesonide/Formoterol
pre post p
iVaw [ cm3] 9.60± 4.67 10.14± 4.81 0.011∗
iRaw [kPas/L] 0.05± 0.02 0.04± 0.02 0.047∗
FEV1 [L] 0.95± 0.33 0.98± 0.33 0.34
FEV1 [% pred] 34.80± 7.69 35.90± 7.89 0.34
FEV1/VC [%] 34.32± 6.99 34.72± 6.67 0.51
PEF [L/s] 3.00± 1.26 3.12± 1.22 0.71
Raw [kPas/L] 1.00± 0.50 0.92± 0.45 0.20
sRaw [kPas] 5.00± 2.87 4.65± 2.29 0.14
FRC [% pred] 155.90± 35.6 151.00± 32.44 0.056
TLC [% pred] 115.80± 21.64 114.20± 19.03 0.13
∗ indicates statistical significance;◦ indicates a trend
Table 8.1: Comparison of lung function and imaging parameters before and after the
administration of budesonide/formoterol
Figure 8.2: Illustration of distal airway volume changes [%] after administration of placebo
(left) or combination product (right)
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Patient ∆iVaw% ∆iRaw%
01 14.11± 9.07 -27.09± 21.74
02 2.79± 7.89 8.24± 49.17
03 -4.55± 3.88 24.83± 53.04
04 6.21± 5.03 -11.67± 36.77
05 -2.53± 14.82 51.02± 118.36
06 19.52± 27.85 -34.71± 43.05
07 17.40± 26.14 -19.57± 40.66
08 5.36± 10.87 -9.21± 37.27
09 35.38± 134.81 -6.48± 39.89
10 13.24± 10.82 -38.45± 20.81
Table 8.2: Average changes and standard deviations in iVaw (distal airway volume) and
iRaw (airway resistance determined by computational fluid dynamics) for all patients after
administration of budesonide/formoterol indicating the level of inhomogeneity in
bronchodilation
attain statistically significant results.
When considering the effect of placebo a significant decline in iVaw (p = 0.025)
and PEF (p = 0.025) was observed (Table 8.3). A downward trend was depicted
by FEV1 (p = 0.09). CFD-based resistance increased significantly (p = 0.005);
bodyplethysmography showed a significant increase in sRaw (p = 0.026) and an
upward trend in Raw (p = 0.07). Figure 8.3 illustrates the individual changes in
iVaw and iRaw after the administration of the combination product and placebo.
Placebo
pre post p
iVaw [ cm3] 9.60± 4.67 9.16± 4.37 0.025∗
iRaw [kPas/L] 0.05± 0.02 0.057± 0.031 0.047∗
FEV1 [L] 0.96± 0.31 0.93± 0.33 0.07◦
FEV1 [% pred] 34.9± 6.71 33.70± 7.24 0.09◦
FEV1/VC [%] 33.68± 7.36 33.89± 6.80 0.74
PEF [L/s] 3.07± 0.95 2.77± 1.03 0.025∗
Raw [kPas/L] 0.94± 0.46 1.01± 0.43 0.07◦
sRaw [kPas] 4.89± 2.72 5.33± 2.48 0.026∗
FRC [% pred] 151.30± 32.46 155.10± 30.95 0.15
TLC [% pred] 114.10± 19.3 116.00± 18.25 0.058
∗ indicates statistical significance;◦ indicates a trend
Table 8.3: Comparison of lung function and imaging parameters before and after the
administration of the placebo
A significant difference between placebo and the budesonide/formoterol com-
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Figure 8.3: Individual changes in a) iVaw (distal airway volume) and b) iRaw (airway
resistance determined by computational fluid dynamics) after administration of combination
product and placebo
8-10 BUDESONIDE/FORMOTEROL IN COPD PATIENTS
bination was observed in two lung function parameters: PEF (p = 0.027) and FEV1
(p = 0.037). The sRaw also indicated a significant difference (p = 0.036), as did TLC
and FRC. The image-based peripheral airway volumes showed a highly significant
difference between placebo and the active combination (p = 0.0005) (Table 8.4).
change [%] Budesonide/Formoterol Placebo p
iVaw +6.48± 7.46 -4.29± 4.45 0.0005∗
iRaw -7.02± 23.72 9.04± 18.37 0.005∗
FEV1 +3.56± 10.49 -3.63± 6.10 0.037∗
FEV1/VC +1.53± 5.81 +1.02± 6.45 0.87
PEF +4.47± 20.20 -10.26± 12.89 0.027∗
Raw -7.17± 23.62 +10.43± 14.75 0.09◦
sRaw -9.03± 25.01 +12.84± 14.24 0.036∗
FRC % pred -4.9± 7.06 +3.8± 7.67 0.017∗
TLC % pred -1.6± 3.03 +1.9± 2.77 0.015∗
∗ indicates statistical significance;◦ indicates a trend
Table 8.4: Comparison between the changes in lung function and imaging parameters
induced by the combination product and placebo
Before unblinding, a prediction was made regarding the visit at which the
active product was administered. The hypothesis was that after this visit the values
must improve, where an improvement is defined as an increase in iVaw, FEV1,
FEV1/FVC and PEF and a decline in iRaw, sRaw and Raw. Results showed that the
FEV1 correctly predicted the visit at which budesonide/formoterol was administered
in seven out of 10 cases (Table 8.5). The FEV1/FVC was correct in only five out of
10 patients. Both PEF and Raw predicted eight out of 10 correctly and the sRaw
nine out of 10. The only parameters that in all cases adequately predicted the visit
at which the active compound was administered were iVaw and iRaw (Table 8.6
and 8.7).
8.6 Discussion
In this study we demonstrated that in severe COPD patients, after inhalation of
fixed combinations, changes in image-based three-dimensional airway geometry
can be detected that are not reflected in the spirometric data. The three-dimensional
images clearly provide the possibility to assess the airway tree and the subsequent
changes comprehensively. The traditional two-dimensional approach is typically
limited to a slice-by-slice assessment.
The severity of the disease is predominantly defined by FEV1, which is judged
to be not completely reversible, and in fact barely reversible in stable stage III
COPD patients [2, 14]. Demonstrating an improvement is therefore inherently
almost impossible and a COPD medication is then assessed based on its ability
to slow down the decline in FEV1 [8]. The current study results confirmed this
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Patient ∆FEV1 V2 ∆FEV1 V3 prediction unblind
01 -0.069 0.081 V3 V3
02 -0.02 0 V3 V26=
03 -0.02 0.041 V3 V3
04 0.029 -0.1 V2 V2
05 -0.099 -0.11 V2 V2
06 -0.041 0.19 V3 V3
07 0.02 0.01 V2 V2
08 -0.041 -0.05 V2 V36=
09 -0.021 0.03 V3 V26=
10 0.09 0.02 V2 V2
6= indicates uncorrect prediction
Table 8.5: Predictive value of the change in FEV1 to determine the visit where combination
product was administered
Patient ∆iVaw V2 ∆iVaw V3 prediction unblind
01 -0.25 14.45 V3 V3
02 2.19 -7.32 V2 V2
03 -6.87 -3.11 V3 V3
04 5.16 -7.87 V2 V2
05 -4.59 -6.88 V2 V2
06 -7.27 17.23 V3 V3
07 11.87 -3.34 V2 V2
08 -1.56 6.09 V3 V3
09 2.55 -7.25 V2 V2
10 12.97 5.74 V2 V2
6= indicates uncorrect prediction
Table 8.6: Predictive value of the change in iVaw to determine the visit where combination
product was administered
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Patient ∆iRaw V2 ∆iRaw V3 prediction unblind
01 -0.98 -19.46 V3 V3
02 -0.86 23.10 V2 V2
03 59.41 12.47 V3 V3
04 -18.94 34.23 V2 V2
05 35.18 41.80 V2 V2
06 -43.74 49.05 V3 V3
07 -32.42 29.69 V2 V2
08 9.95 -16.25 V3 V3
09 -14.94 11.34 V2 V2
10 -42.81 -18.93 V2 V2
6= indicates uncorrect prediction
Table 8.7: Predictive value of the change in iRaw to determine the visit where combination
product was administered
hypothesis, as only a minor, insignificant change in FEV1 is observed when patients
are treated with budesonide/formoterol. At least a trend towards decline in FEV1 is
seen in the placebo group. Airway volumes obtained using body plethysmography
appear to be more sensitive and depict a declining trend in FRC in line with recent
studies. The only parameters that describe a small but nonetheless significant
improvement in the treated group and a significant decline in the placebo group are
the iVaw and the iRaw.
The decline in iRaw goes along with a decline (although not statistically
significant) in the Raw measured with body plethysmography. The absolute value
of the Raw is much higher than the iRaw because iRaw does not take into account
the resistance of the upper airway and the equipment and illustrates the relative
importance of upper airway resistance.
Furthermore, from this study it can be seen that when a COPD GOLD stage III
patient doesn’t receive active bronchodilating medication a relatively rapid decline
in airway diameter and function occurs even after some hours, indicating also the
role of the fixed combinations in maintaining airway patency in daily life. Therefore
a highly significant difference is observed when comparing the treated and placebo
groups.
The clinical relevance of these changes is the topic of ongoing research. In the
current study the main question was to assess how different outcome parameters
would describe changes induced by the inhalation product. It would appear valuable
to first have outcome parameters that accurately describe changes in airway structure
and function induced by a product. In a second phase, the clinical relevance of these
changes could be investigated by correlating them to, for example, patient-reported
outcome parameters (PROs). After all, if a parameter is not sensitive enough to
reliably pick up changes in the system following a treatment, what would be the
value of correlating this parameter with PROs? Should a correlation exist, this
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would still not mean that the product caused this change in PRO. Of course it is
important to assess these PROs, as diminishing respiratory symptoms should be
one of the goals of treating COPD. As we can see that some patients have a more
pronounced response to budesonide/formoterol than others, it is interesting to know
whether they also report less dyspnoea.
The double-blind protocol in this study offered an interesting possibility to
assess how well the different parameters could distinguish between the placebo
visit and the visit where the active product was administered. The image-based
parameters appeared to be the only parameters that correctly identified the respective
visits for all patients. The FEV1/FVC ratio performed the worst, followed by the
FEV1.
Even though this trial was performed in a limited number of patients, the
placebo-controlled, crossover design ensured a good power of this pilot study. Based
on these results it could be hypothesised that imaging, or at least a combination of
lung function tests and imaging, is better suited to describe the mode of action of a
product. The sample size calculations that were based on these data and performed
post hoc indicated that imaging parameters could significantly reduce the number
of patients in clinical trials by providing more sensitive information on the mode
of action of a product. This opens the possibility of using this method at an early
clinical stage to compare different compounds to each other or to placebo. Also
dose–response based on imaging parameters in a limited number of patients could
yield a more compelling picture versus the FEV1 response to different doses in very
large clinical trials where results are often ambiguous.
In previous large-scale studies using FEV1 as an end-point, it can be observed
that inhaled therapy with the recommended fixed combinations improves FEV1 in
absolute terms only to a limited extent and that the decline in FEV1 is not altered.
But at the same time other end-points such as quality of life or even, in larger
populations, mortality, show at least a trend to improvement [3, 8, 9, 26]. This
suggests that FEV1 may underscore real changes in airway structure induced by
inhalation of combination therapies.
At present fixed combinations are most frequently and often uniquely used
in severe stage III COPD patients and are considered to be mainly symptomatic
treatments with the aim to improve daily life symptoms and exacerbations, but
not, or to a limited extent, the progression of the disease. We therefore chose
a combination product in this study to see whether the widely used (mainly for
symptomatic improvement) fixed combinations do have an influence on the airway
geometry in severe stage III COPD patients. The aim was not only to understand
and to see the sensitivity of the FEV1 but also to better understand the discrepancies
between some PROs and FEV1 with the fixed combinations. Therefore insight both
into the mode of action and also into the clinical relevance of the fixed combination
inhalation therapy mostly used and recommended could be obtained. For this aim,
a small-scale study seemed to be indicated given that the mentioned discrepancies
between PROs and FEV1 were already demonstrated in previous large-scale and
long-term studies (Tristan, Torch, Euroscope, Uplift).
Treatment is mainly targeted at reducing the work of breathing in COPD
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patients. From physiological and anatomical studies [6, 27] it is known that the
majority of the airway resistance is situated in the first 4 – 6 generations. It is
therefore not unreasonable to assume that airway dilation in this region results in a
clinical improvement in the patient’s condition. It would be worthwhile to assess
the respiratory structure and function in a broader range of disease severity levels in
a larger set of patients. One could for instance take lung function tests and HRCT
images during an episode of exacerbation and after recovery. This would allow
for a correlation between imaging parameters, lung function and patient-reported
outcome parameters.
Even though the functional respiratory imaging appears to provide sensitive
and valuable information, the technique also has its limitations. Segmentation still
involves some manual processing of the images, potentially introducing a level
of variability. Airways smaller than 1 – 2 mm are not visible with the current
state-of-the-art CT scanners and therefore cannot be segmented. The cost and the
use of ionising radiation currently prevents the implementation of the method in
very large phase-III trials and as a standard test in clinical routine for all patients. It
appears that this method is best suited to determine product efficacy in early clinical
phases and to assess treatment of the more severe patients in a clinical routine
setting. As such the method could complement other novel pulmonary function
tests such as multi-breath nitrogen washout and forced oscillation which are targeted
at obtaining more information about the smaller airways. These methods are in
general less expensive and provide information about the tissue and the smaller
airways. However they do not provide regional information and are sometimes
labour intensive. Therefore a proper combination of imaging and lung function
tests could result in an efficient, comprehensive set of tools to treat patients with
respiratory diseases.
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Novel functional respiratory imaging
of changes in small airways of patients
treated with extrafine
beclomethasone/formoterol
Respiration 2013; Online Ahead of Print: doi:10.1159/000347120
Wim Vos, Jan De Backer, Gianluigi Poli, Annick De Volder, Liesbet Ghys, Cedric
Van Holsbeke, Samir Vinchurkar, Lieve De Backer and Wilfried De Backer
9.1 Abstract
Background: Inhaled formulations using extrafine particles of long-acting-β2-
agonists and corticosteroids were developed to optimize asthma treatment. Findings
that these combinations reach and treat smaller airways more effectively are pre-
dominantly based on general, non-specific outcomes with little information on
regional characteristics.
Objectives: This study aims to assess long-term effects of extrafine beclometha-
sone/formoterol on small airways of asthmatic patients using novel functional
respiratory imaging methods.
Methods: 24, stable, asthma patients were subdivided into three groups (steroid-
naive, n = 7; partially-controlled, n = 6; well-controlled, n = 11). Current treat-
ment was switched to a fixed combination of extrafine beclomethasone/formoterol
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(Foster®, Chiesi Pharmaceuticals, Italy). Patients underwent lung function eval-
uation and high resolution thorax computerized tomography scan. Local airway
resistance was obtained from computational fluid dynamics.
Results: After 6 months, the entire population showed improvement in pre-
bronchodilation imaging parameters including, small airway volume (p = 0.0007),
resistance (p = 0.011) and asthma control score (p = 0.016). Changes in small
airway volume correlated with changes in asthma control score (p = 0.004). Forced
expiratory volume in 1 s (p = 0.044) and exhaled nitric oxide (p = 0.040) also im-
proved. Functional respiratory imaging provided more detail and clinical relevance
compared to lung function tests, especially in the well-controlled group where only
functional respiratory imaging parameters showed significant improvement, while
the correlation with asthma control score remained.
Conclusions Extrafine beclomethasone/formoterol results in significant reduction
of small airways obstruction, detectable by functional respiratory imaging. Changes
in imaging parameters correlated significantly with clinically relevant improve-
ments. This indicates that functional respiratory imaging is a useful tool for sensitive
assessment of changes in the respiratory system after asthma treatment.
9.2 Contributions of the author
The contributions of the author to this study are similar to the contributions in
chapter 8. While chapter 8 quantifies the acute effects of medication in chronic ob-
structive lung disease, this study looks at long-term effects in an asthma population.
9.3 Introduction
The prevalence of asthma continues to rise, stimulating an ongoing effort in the
development of new inhaled medications to optimize the treatment of asthmatic
patients. A number of studies have supported the benefit of combining a long-acting
β2-agonist (LABA) with inhaled corticosteroids (ICS) [4, 21]. While the LABA
induces smooth muscle relaxation, and hence reduced airway constriction, the
ICS is predominantly used to control the airway disease and therefore reduces the
number and frequency of exacerbations [5]. Combination products are typically
administered using either dry powder inhalers (DPIs), or metered dose inhalers
(MDIs). The shift from environmentally unfriendly chlorofluorocarbons (CFC)
to hydrofluoroalkane (HFA) propellants allows the development of HFA solution
formulations. These are optimized to either achieve particle deposition patterns
similar to established CFC-based drug formulations (aerosol diameter size for
MDIs being 3 – 4 µm), thus facilitating the transition to new environment-friendly
pMDIs in the clinical setting, or to achieve extrafine drug particles able to penetrate
deeper into the airways (aerosol diameter size 1 – 2 µm) [1]. Initial findings
demonstrated that a combination of extrafine beclomethasone/formoterol (BDP/F)
improved lung function with similar efficacy compared to other non-extrafine fixed
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combinations. This finding is not surprising considering that spirometric tests (i.e.
forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF))
performed in these studies did not provide comprehensive evaluation of the entire
bronchial tree as they lack sufficient resolution to describe subtle changes in the
small airways [22, 23]. This has prompted the need for developing new, image
based [3, 6], techniques capable of detecting functional changes occurring in the
more distal part of the lung following the administration of drugs able to reach and
treat small airways [2, 12, 14].
Novel functional respiratory imaging (FRI) methods using computational fluid
dynamics (CFD) provide new opportunities to gain insights into the mode of action
of newly developed inhalation compounds targeting small airways. By converting
patient specific high resolution computed tomography (HRCT) images to detailed
three-dimensional computer models of the airways, CFD allows description of flow
properties and aerosol behavior in the smaller airways (diameter 1 – 2 mm). By
repeating measurements after an intervention, this approach yields a personalized
assessment of changes in airway volume and CFD-based resistance. The method has
been used in previous studies to assess morphological and flow features of large [9]
and small [8] airways. A recent validation study [10] by our group demonstrated
very good agreement between the HRCT/CFD method and imaging methods such
as single photon emission computed tomography (SPECT). In other studies we
showed that FRI could be used to assess the acute bronchodilating effects of a
LABA in asthma [7] and COPD [11].
However, a trial evaluating the long-term effects of asthma medications on the
imaging parameters described above is still lacking. Therefore, this trial aims to
assess whether FRI can be used to describe changes occurring in the small airways
of asthmatic patients following a 6 month treatment period with BDP/F (which is
able to target the distal airways). Steroid-naive patients, as well as subjects already
treated with non-extrafine fixed combinations, were enrolled in this study. This
allowed the assessment of whether introduction of an extrafine treatment can induce
additional changes in the small airways in steroid-naive and patients previously
treated with non-extrafine combination therapies.
9.4 Material and Methods
9.4.1 Patient Selection
This study involved 24 stable asthmatic patients, as defined by the GINA guidelines
(Global strategy for asthma management and prevention). Patients were subdivided
into three different groups according to their treatment phenotype. The first group
comprised steroid-naive asthmatics (n = 7). The remaining 17 patients were already
under treatment with a daily beclomethasone-equivalent dose of 500 to 1000 µg at
inclusion and were divided in two groups according to their level of asthma control
as measured by the asthma control test (ACT) [19]: 6 were partially controlled and
11 well-controlled (n = 11). All patients gave their informed consent and the study
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has been approved by the Ethics Committee of the Antwerp University Hospital.
9.4.2 Study Medication
Enrolled patients were switched from their current treatment (SABA, LABA,or
ICS/LABA fixed combinations) to a fixed combination of extrafine HFA solution
of beclomethasone/formoterol (BDP/F, Foster®, Chiesi Pharmaceuticals, Italy)
100/6 µg, 2 inhalations twice daily, delivered via a pMDI device. The study
medication has a smaller mean mass aerodynamic diameter (MMAD = 1.3 – 1.4 µm)
compared to medications that patients were receiving before inclusion (MMAD =
2.5 – 4 µm).
9.4.3 Lung function tests and FRI
All patients underwent full lung function evaluation and HRCT scan of the thorax at
inclusion and after 6 months of treatment with the study medication. To assess only
the long term effects of the compound on pre-bronchodilation airway geometry and
not the acute bronchodilator effect, all tests were performed in the morning, before
the patients took their medication and following an appropriate wash-out period for
short and long acting bronchodilators (>12 h and >24 h, respectively).
Lung function tests included spirometry, full body plethysmography, exhaled
nitric oxide (eNO), blood gases, and ACT questionnaire. The following parameters
were considered for this study:
• FEV1
• Tiffeneau ratio (FEV1/forced volume vital capacity (FVC))
• Specific airway resistance (sRaw)
• eNO
• ACT score
HRCT scans were taken on a GE LightSpeed VCT scanner using a dose
reduction protocol (120 kV, 10 – 100 mAs; noise factor 28; collimation 0.625 mm;
rotation time 0.6 s and pitch factor 1.375) resulting in an effective dose of 1 – 2 mSv
per HRCT scan. Scan resolution was 0.5 m2 and slice increment was 0.6 mm. Scans
were taken during a breath hold at two different lung levels, i.e. functional residual
capacity (FRC) and total lung capacity (TLC). The arms of the patients were raised
above their heads. To ensure the correct lung volume, HRCT scans were respiratory
volume-gated during the moment of scanning using a pneumotach flow signal.
Subsequently, HRCT images were imported into Mimics, a commercial,
FDA approved, medical image processing software package (Materialise, Leuven,
Belgium, Food and Drug Administration, K073468; CE certificate, BE 05/1191
CE01). This software package converts HRCT images into patient specific, three-
dimensional computer models of the lung lobes and the airway tree. By segmenting
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lung lobes at FRC and TLC, the internal airflow distribution could be derived from
the relative volume change. The airway tree, i.e. intraluminal air, was evaluated
at TLC level and could be segmented down to bronchi with a diameter of about
1 – 2 mm. Beyond this point the HRCT resolution is insufficient to distinguish
alveolar and intraluminal air. A typical airway model includes 5 – 10 generations,
depending mainly on the disease state of the individual patient. Distal airway
volumes (iVaw) could be assessed at individual airways or in different regions.
Figure 9.1 shows a division of a segmented airway model in central airways (gray)
and distal airways (red, starting at the segmental level). From previous studies it is
known that BDP/F reaches both large and small airways [9], therefore in this study
we focused predominantly on the small airway region.
Figure 9.1: Frontal view of three-dimensional reconstruction of airway structure from HRCT
images showing central (gray) and distal (red) airways. The main focus in this study was on
the distal (red) airways.
9-6 EXTRAFINE BECLOMETHASONE/FORMOTEROL IN PATIENTS WITH ASTHMA
The smoothed airway models were subsequently trimmed perpendicular to the
centerlines at the trachea and the terminal bronchi to obtain a model that is suitable
for flow simulation. Next, these models were exported to a meshing software
package (TGrid 5.0, Ansys Inc, Lebanon, USA) where they were divided into
discrete tetrahedral elements. After proper mesh convergence analysis, mesh size
for this study was set to 4 million elements. Based on the resulting computational
mesh, flow properties were obtained throughout the entire flow domain by means
of Reynolds averaged Navier-Stokes (RANS) computational fluid dynamics (CFD)
(Fluent 6.3.26, Ansys Inc, Lebanon, USA). A steady, normal inspiratory flow
of 25 L/min was simulated for all patients to mimic the flow properties at tidal
breathing. The outflow to each lobe was adjusted iteratively for each patient to
match the internal flow rate distribution obtained from the HRCT scans. Measures
of resistance (iRaw) at TLC in individual airways or different regions, corresponding
to the volume measurements, were obtained from CFD calculations. Resistance was
defined as the total pressure drop over an airway divided by the flow rate through
that airway.
9.4.4 Statistical analysis
Statistical analysis was performed using Statistica 9.1 (StatSoft, Tulsa, USA).
Changes in individual parameters after 6 months of treatment with the study medi-
cation were evaluated using Wilcoxon matched pairs analysis. Correlations between
the changes in different parameters were evaluated using Spearman correlations.
Differences between the three groups of patients were assessed using Mann-Whitney
U test. Sample size calculations were performed using t-test for dependent samples.
All statistical tests were considered significant when p < 0.05.
9.5 Results
9.5.1 Total study population
A total of 24 asthmatic subjects (all Caucasian, 16 females, 52.8± 11.9 years) were
analyzed in this study. Medications used by patients before enrollment are listed
in Table 9.1. The majority of patients were treated with ICS/LABA combinations
delivered as fixed combinations (n = 17), while 2 patients were treated with LABA
only. Reliever therapy consisted of the use of short-acting β2-agonists (n = 5) or
fixed combination of short-acting β2-agonists and muscarinic antagonists (n = 2)
and short-acting muscarinic antagonists (n = 1).
Considering the entire population, a significant difference was found in all
parameters except FVC, FEV1/FVC and sRaw after 6 months of treatment with
the study medication (Table 9.2). A significant improvement was observed in
asthma control with an increase in the ACT score from 19.79 ± 4.46 at base-
line to 21.67 ± 4.55 at the end of treatment, (p = 0.016). FEV1 increased from
96.3 ± 15.72% of predicted normal values to 100.1 ± 16.8%, (p = 0.044). Sig-
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nificant changes were recorded also in imaging parameters with airway volume
(iVaw) increasing from 8.36 ± 4.71 cm3 to 9.64 ± 5.19 cm3, (p = 0.0007) and
CFD-based airway resistance (iRaw), decreasing from 0.082 ± 0.084 kPas/L to
0.050 ± 0.030 kPas/L, (p = 0.01), with a maximal increase in iVaw of 11.7% of the
baseline value.
Figure 9.2 shows that changes in iVaw and iRaw occurred predominantly in the
smaller, more distal airways while changes in larger airways were less pronounced.
In addition, changes in iVaw significantly correlated with changes in ACT score (R
= 0.49, p = 0.015) (Figure 9.3). At the end of treatment a significant decrease was
detected in eNO (p = 0.040), which showed a 38% reduction versus baseline.
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Figure 9.2: Changes in image based airway volume (iVaw, left) and CFD based airway
resistance (iRaw, right) for steroid-naive (top), partially controlled (middle), and
well-controlled (bottom) asthma patients.
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Baseline 6 months
Average SD Average SD p-value
Total n = 24
iVaw [cm3] 8.36 4.71 9.64 5.19 0.0007*
iRaw [kPas/L] 0.082 0.084 0.05 0.03 0.011*
∆ ptot [Pa] 34.1 35 20.8 12.5 0.011*
FEV1 [%] 96.3 15.72 100.08 16.8 0.044*
FVC [L] 3.82 0.99 3.85 1.01 0.584
FEV1/FVC [%] 70.93 6.65 72.89 6.44 0.11
eNO [ppb] 44.07 54.78 27.48 29.47 0.040*
sRaw [kPas/L] 1.52 0.71 1.4 0.84 0.225
ACT score 19.79 4.46 21.67 4.55 0.016*
Steroid-naive n = 7
iVaw [cm3] 7.24 4.23 9.14 6.57 0.043*
iRaw [kPas/L] 0.107 0.112 0.061 0.039 0.237
∆ ptot [Pa] 44.6 46.7 25.4 16.3 0.237
FEV1 [%] 93.34 17.47 99.29 19.65 0.176
FVC [L] 3.78 1.06 3.79 1.18 1
FEV1/FVC [%] 69.54 7.32 73.69 7.04 0.128
eNO [ppb] 61.47 75.81 30.54 26.08 0.31
sRaw [kPas/L] 1.68 0.88 1.55 1.07 0.735
ACT score 15.29 5.02 19.29 6.85 0.018*
Partially controlled n = 6
iVaw [cm3] 8.53 4.37 9.86 4.42 0.116
iRaw [kPas/L] 0.09 0.11 0.047 0.033 0.173
∆ ptot [Pa] 37.5 45.8 19.6 13.8 0.173
FEV1 [%] 88.23 18.45 91.23 18.09 0.116
FVC [L] 3.54 0.71 3.61 0.73 0.5
FEV1/FVC [%] 72.82 8.64 73.51 8.71 0.753
eNO [ppb] 26.4 19.64 22.58 13.67 0.463
sRaw [kPas/L] 1.37 0.5 1.26 0.58 0.402
ACT score 20.33 3.14 21.67 2.8 0.463
Well controlled n = 11
iVaw [cm3] 8.99 5.42 9.84 5.11 0.041*
iRaw [kPas/L] 0.061 0.035 0.044 0.023 0.062
∆ ptot [Pa] 25.4 14.6 18.3 9.6 0.062
FEV1 [%] 102.58 11.25 105.41 13.23 0.374
FVC [L] 4 1.12 4.02 1.08 0.859
FEV1/FVC [%] 70.78 5.35 72.04 5.12 0.657
eNO [ppb] 42.64 53.48 28.2 38.39 0.091
sRaw [kPas/L] 1.49 0.72 1.39 0.86 0.266
ACT score 22.36 2.01 23.18 2.99 0.214
Table 9.2: Changes in imaging and lung function parameters after 6 months of treatment
with extrafine beclomethasone/formoterol. * = p < 0.05
EXTRAFINE BECLOMETHASONE/FORMOTEROL IN PATIENTS WITH ASTHMA 9-11
-4 
-2 
0 
2 
4 
6 
8 
10 
12 
-4000 -2000 0 2000 4000 6000 8000 10000 12000 
D
 A
C
T 
[-
] 
D iVaw [mm3] 
R = 0.56 
p = 0.004 
Figure 9.3: Correlation between changes in image-based airway volume (iVaw) and change
in asthma symptom score (ACT) for all patients.
9.5.2 Steroid-naive patients
For the steroid-naive group, which included seven asthmatic patients (baseline FEV1
= 93.3% of predicted normal value), treatment did not result in significant changes
in lung function parameters as measured by spirometry or body plethysmography
(Table 9.2). However, FRI analysis showed a significant improvement in iVaw from
7.24 ± 4.23 cm3 to 9.14 ± 6.57 cm3 (p = 0.043) and an improvement, although
not significant, in iRaw from 0.107 ± 0.112 kPas/L to 0.061 ± 0.039 kPas/L. A
non-significant trend was observed also for eNO, which decreased by 50% by the
end of the study. Treatment of steroid-naive patients with extrafine BDP/F resulted
in significant improvement of asthma control, as shown by the increase in ACT
score from 15.29 ± 5.02 to 19.29 ± 6.85, (p = 0.018).
9.5.3 Partially controlled patients
In the group of partially controlled patients (n = 6) no parameter changed signifi-
cantly and no correlations were found between any parameters and the ACT score
(Table 9.2).
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9.5.4 Well-controlled patients
The group of well-controlled patients included 11 asthmatics with a baseline ACT
score of 22.4 and FEV1 value of 102%. All patients included in this group were
previously treated with ICS/LABA fixed combinations (Table 9.1) and switching
to the study medication maintained the same high level of asthma control and
good lung function. However, FRI showed significant improvement of iVaw from
8.99 ± 5.42 cm3 to 9.84 ± 5.11 cm3, (p = 0.041) and a clear trend in reduction
of iRaw from 0.061 ± 0.035 kPas/L to 0.044 ± 0.023 kPas/L, (p = 0.062). As
observed in the entire population, changes in iVaw correlated with changes in ACT
score (R = 0.72, p = 0.012, Figure 9.4). No correlation was observed between
changes in FEV1 and ACT score. Furthermore, sample size calculation indicated
that a total of 68 patients would be needed to attain a significant difference with
a power goal of 90% if FEV1 is used as an outcome parameter in a controlled
(baseline versus intervention) study in well controlled mild asthmatics. On the other
hand, when using the average change in iVaw or iRaw as outcome parameter the
required sample size is reduced to 25.
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Figure 9.4: Correlation between changes in image-based airway volume (iVaw) and asthma
symptom score (ACT) for well-controlled patients.
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9.6 Discussion
The aim of this study was to assess whether long-term treatment with extrafine BD-
P/F can induce detectable changes in the distal airways of asthmatic patients, who
are either steroid-naive or already under treatment with non-extrafine ICS/LABA
fixed combinations. When considering the entire study population, the trial shows
that 6 month therapy with extrafine BDP/F results in significant improvements in
pre-bronchodilation imaging parameters such as small airway volume and CFD-
based resistance. Notably, a significant correlation was found between changes in
small airway volume and changes in asthma control score, suggesting that reaching
and treating the small airways with extrafine BDP/F translates into clinical benefits
for patients.
Changes in small airway parameters can be detected by FRI both in steroid-
naive patients and in well-controlled patients previously treated with non-extrafine
combinations. In asthmatic patients well-controlled with non-extrafine combina-
tions, the switch to extrafine BDP/F leads to a significant improvement in pre-
bronchodilator imaged airway volume, which occurred predominantly at the level
of the small airways and was more sensitive than changes in FEV1. The observed
improvement in asthma symptom scores again significantly correlated with the
increase in imaged airway volume indicating that imaged airway volume is of
clinical significance.
Overall these findings indicate that BDP/F extrafine formulation can target
areas of the lungs left untreated by larger particle fixed combinations.
In a previous 6-month, randomized, controlled trial, extrafine BDP/F was
compared to the combination of the same drugs (BDP+F) given as larger, non
extrafine particles. The study showed that, for equivalent steroid dosages, there
was no difference in the morning peak expiratory flow (PEF) between both prepara-
tions, but patients taking the extrafine particle combination did have significantly
better asthma control as a consequence of the improved lung distribution that was
previously demonstrated using Krypton ventilation scan [12, 13, 15]. In other
investigations, the extrafine particle combination was always comparable to either
fluticasone/salmeterol [17] or budesonide/formoterol [18] in terms of FEV1 and
PEF improvements. These findings were not surprising considering that these
spirometric tests did not provide comprehensive evaluation of the entire bronchial
tree as they are unable to properly reflect small airway abnormalities.
There are two main reasons why this study could be considered innovative.
Firstly the study focused on different ‘treatment phenotypes’ as it included steroid-
naive, partially controlled and fully controlled patients. It did not include a typical
run-in period where patients are taken off corticosteroids for a number of weeks.
Secondly, this study employs a novel imaging method, combining HRCT imaging
with flow simulations to investigate whether FRI could describe clinically relevant
changes in well-controlled patients. This would demonstrate the true clinical
significance and potential added value of using extrafine particle formulations.
In the current study, virtually all parameters indicated an improvement when
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considering the complete population. This finding is in line with previous studies
using this combination, which focused mainly on morning PEF [16, 18]. The
current study expanded the knowledge by focusing on additional variables using
multiple approaches such as exhaled breath analyses and in particular imaging.
Also these parameters also suggested an additional beneficial clinical effect.
The imaging parameters showed the best correlation with the changes in
asthma symptoms. The clinical relevance of FRI was further illustrated in the
steroid-naive group where both ACT score and iVaw changed significantly, even
though the sample size was limited. Also in the larger, well-controlled group the
good correlation between changes in iVaw and ACT score supported the hypothesis
that FRI yields clinically significant results.
Additional added value of imaging lies in the enhanced sensitivity to detect
clinically relevant changes. Apparently when patients are well-controlled, FEV1 is
not sensitive enough to describe additional subtle changes and additional improve-
ment in that parameter is difficult to detect. Imaging parameters showed further
consistent improvement in airway caliber and indicated where these changes mainly
occurred. Previously only demonstrated indirectly [20], it is now possible to directly
observe that a dilating effect is present in both the larger and smaller airways.
In a similar manner to FEV1, the ACT score appears to have limited predicting
power to describe additional changes in well-controlled patients, especially consid-
ering the more subjective nature of patient reported outcome (PRO) parameters. A
combination of classical lung function, PRO parameters, and FRI methods has the
potential to enhance the description of the mode of action of new compounds. This
could result in a reduction of the number of patients required in clinical trials as in-
dicated by the power analysis. In addition, by performing studies in well-controlled
patients it could potentially be possible to determine whether switching to a novel
product has a beneficial effect on the number of exacerbations and possible decline
in respiratory function.
Although this study is the largest clinical trial (n = 24) available using FRI,
the power in the subgroups is still limited by the small sample size. In the partially
controlled group (n = 6) especially, this could have had an influence on the final
findings. Future research should consider equal subgroups with a sample size
n ≥ 10 per subgroup. The HRCT based airway models only include airways with
diameters larger than 1 mm due to the limits of the scan resolution. This region,
however, already includes 80 – 90% of the airway resistance [10]. Generations
beyond the reconstructed parts are taken into account through the CFD boundary
conditions that are derived from HRCT-based lobar expansion.
Based on the results from the current study it would be interesting to investigate
the effect of the extrafine BDP/F combination in patients with irreversible airway
disease. The increased sensitivity could also assist in the assessment of anti-
inflammatory compounds where classical outcome parameters alone are likely not
sufficient.
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Part IV
Novel applications

10
Particle deposition in airways of
chronic respiratory patients exposed to
an urban aerosol
Environmental Science & Technology 2012; 46(21): 12162-12169
Benjamin Horemans, Cedric Van Holsbeke, Wim Vos, Larysa Darchuk, Velibor
Novakovic, Angel Conesa Fontan, Jan De Backer, Rene Ernest Vangrieken, Wilfried
De Backer and Karolien De Wael
10.1 Abstract
Urban atmospheres in modern cities carry characteristic mixtures of particulate
pollution which are potentially aggravating for chronic respiratory patients (CRP).
Although air quality surveys can be detailed, the obtained information is not always
useful to evaluate human health effects. This paper presents a novel approach to
estimate particle deposition rates in airways of CRP, based on real air pollution data.
By combining computational fluid dynamics with physical-chemical characteristics
of particulate pollution, deposition rates are estimated for particles of different
toxicological relevance, i.e. minerals, iron oxides, sea salts, ammonium salts
and carbonaceous particles. Also, it enables some qualitative evaluation of the
spatial, temporal and patient specific effects on the particle dose upon exposure
to the urban atmosphere. Results show how heavy traffic conditions increases
the deposition of anthropogenic particles in the trachea and lungs of respiratory
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patients (here, +0.28 and +1.5 µg · h−1, respectively). In addition, local and synoptic
meteorological conditions were found to have a strong effect on the overall dose.
However, the pathology and age of the patient was found to be more crucial, with
highest deposition rates for toxic particles in adults with a mild anomaly, followed
by mild asthmatic children and adults with severe respiratory dysfunctions (7, 5
and 3 µg · h−1, respectively).
10.2 Contributions of the author
Together with dr. Horemans, the author of this thesis was the principal researcher
in this study. The main challenge that was tackled here was the coupling of the
particulate measurements to the simulations. The author converted the data from the
micro-analytical physical-chemical analyses with respect to chemical composition,
particle count and equivalent aerodynamic diameters to boundary conditions for
the particulate simulations in the airways. This novel approach made it possible to
assess deposition rates for selected chemical classes of particles.
10.3 Introduction
It is well known that health effects of air pollution and the associated increase in
morbidity and mortality exert an enormous social and economic pressure on society.
Especially airborne particles received considerable attention due to their chronic
effects on human health. Scientific studies show how the presence of particles in the
lungs causes inflammation of the local tissue, leading to an accelerated progression
or exacerbation of asthma and chronic bronchitis, and can lead to cardiovascular
disease [32]. Also, ultra-fine particles with aerodynamic diameters (AD) below
0.1 µm are known to be translocated from the respiratory epithelium to the blood
circulation and subsequent secondary target organs such as heart, liver, brains and
testis [18, 25, 39]. This causes adverse effects on the cardiovascular and central
nervous system and poses a genetic risk to humans.
Although airway particle deposition affects the entire population, there are
some groups which are more vulnerable than others. Dominici et al. [11] demon-
strated how exposure of elderly (above 65 years of age) to fine particles (AD smaller
than 2.5 µm) increases the risk for hospital admission related to cardiovascular
and respiratory diseases. Children, at the other hand, have a significantly lower
nasal filter efficiency [5] and are more rapidly inflamed by deposited particles in
the tracheobronchial and alveolar regions [24]. Apart from elderly and children,
chronic respiratory patients (CRP) suffering from asthma or a chronic obstructive
pulmonary disorder (COPD) are more sensitive to particulate pollution. High parti-
cle concentrations and black carbon (BC) levels were associated with an increased
fraction of exhaled nitric oxide in asthma patients [23], while chronic exposure to
airborne particles during childhood is hypothesized to initiate the development of a
COPD at later age [17]. Moreover, ultra-fine particles, transition metals and BC are
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known to cause oxidative stress which may enhance pro-inflammatory effects in
the airways of COPD patients that are already inflamed by their disease [28].
Mechanisms of particle induced inflammations are often linked to specific
particle constituents. In their review on the health effects of particulate pollution,
Pope and Dockery [32] underlined the need to study the role of physical-chemical
effects of particles. This uncertainty reflects in the European legislation [14], which
currently does not implement protective measures related to ultra-fine particles and
specific toxic components due to insufficient scientific evidence [13]. The target
values which are currently in use refer to total particle mass (AD < 10 and 2.5 µm)
and do not necessarily restrict the particle dose (total airway deposition) nor the
exposure to toxicological relevant particles.
The particle dose could be estimated theoretically by simulating the size-
dependent deposition processes in human airways. Experimental results support
the accurate predictions of various models, which numerically solve the behavior
of air suspended particles at airway bifurcations or the tracheobronchial area as a
whole [8, 31, 46]. Although powerful, the mathematical approach largely depends
on the definition of the airway model, which may be casts or computer models
obtained from morphometric analysis of the lungs [4, 29]. Recently, combination
of computational fluid dynamics (CFD) with airway models obtained from high
resolution computed tomography (CT) scans proved to be a valuable tool for
simulating particle deposition in the airways of targeted patients [10]. This enables
to evaluate the particle dose for a population which is more sensitive to particulate
air pollution, such as CRP. Moreover, combined with size dependent information
on the chemical composition of an urban aerosol, one can evaluate the toxicological
relevance of air pollution exposure.
Here we demonstrate how the composition of individual particles, obtained
with micro-analytical techniques, can be combined with patient specific simulations
of particle deposition in the airways. This multi-disciplinary – though exploratory
– study gives a quantitative description of particle deposition in airways of CRP
exposed to an urban aerosol. Results are evaluated by considering the toxicological
relevance of the urban pollution and the effects of local traffic conditions.
10.4 Materials and methods
10.4.1 Air quality survey
Three residential areas were selected to study the air quality near various traffic
conditions in the urban environment of Antwerp, Belgium (Figure 10.1). The resi-
dential area at the left river bank is only a few hundred meters from the connection
of the ring way with major highways E17 and E34, which channels all traffic from
and towards the west. The second residential area is located in the southern suburbs
of the city, which accommodates two major highways directing most traffic from
and towards the south. One of them runs underneath the suburban residential area
(E19) and the other at more than 2 km distance in southwestern direction (A12).
10-4 DEPOSITION OF URBAN AEROSOL
Traffic nearby the residential area in the city center is mainly limited by narrow
streets, often with one-way direction. Considering the leading southwesterly winds
(Figure 10.1), the area at the left river bank is supposed to be affected by contin-
uous emissions of the nearby highway, especially as compared to the other areas.
Therefore, this site will be later referenced as a heavy traffic environment while the
others are considered as moderate traffic sites.
Figure 10.1: Schematic map indicating N studied residential areas and • consulted network
stations.
In each of the residential areas, three sampling stations were installed within
600 m distance from each other. Samples were collected concurrently at left bank
and center stations from 12th until 18th of July 2011 and at left bank and suburb
stations from 20th until 27th of July 2011. Fine particles (< 2.5 µm AD) were
collected daily on Teflon membrane filters, using a Harvard-type MS&T sampler
and a vacuum pump operating at 10 L · min−1 (Air Diagnostics and Engineering
Inc., Harrison, ME, USA). Concentrations of BC were monitored every minute
with micro-aethalometers (AE51, Magee Scientific, Berkeley, CA, USA) at one of
the three stations per area. Each week, two sets of aerosol samples were collected
with a berner cascade impactor for gravimetric and micro-analysis. When operated
at 30 L · min−1, the berner impactor collects particles in 8 size fractions with a
50 % collection efficiency for particles of 0.0625, 0.125, 0.25, 0.5, 1, 2, 4 and
8 µm AD (stages 1–8, respectively). Particles above 16 µm AD are retained at the
inlet of the cascade system. Additionally, air quality and meteorological data were
consulted from several stations (a–e) in the measurement network of the Flemish
environmental agency (VMM; see Figure 10.1).
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10.4.2 Chemical analysis
Filter samples were allowed to equilibrate at stable atmospheric conditions (20 ±
1 ◦C and 50 ± 5 % relative humidity) before determining its mass on an electronic
micro balance (MT5, Mettler Toledo, Columbus, OH, USA). The total particle
mass was obtained by simply subtracting the mass of the filter. The bulk elemental
composition of sampled aerosols was analyzed directly on the filters with energy-
dispersive X-ray fluorescence spectrometry (Epsilon-5, PANalytical, Almelo, The
Netherlands), according to an in-house developed method [40]. Finally, filters were
sonicated for 15 min in ultra-pure water and the leachate was analyzed by ion chro-
matography with conductivity detection (DX-120, Dionex, Sunnyvale, CA, USA),
as described elsewhere [19, 20]. The contribution of soil-dust to the collected fine
particles was estimated from the Al, Si, Ca, Fe and Ti concentrations (obtained with
EDXRF), as given by the soil dust equation of the Improve program [22]. Sodium
and ammonium nitrates and sulfates were differentiated by simple assumptions on
the preservation of mass and charge. The basic idea was that ammonium nitrate
is only present if there is a stoichiometric excess of ammonium over sulfate [37],
while any remaining nitrate was attributed to aged sea salt (NaNO3). The amount of
water associated with hygroscopic salts during gravimetric analysis was estimated
with the aerosol inorganic model III [9, 12].
The molecular composition of 300 individual particles was analyzed manually
on each of the stages 3–8 of the berner cascade impactor (cfr. air quality survey) with
an InVia micro-Raman spectrometer, following protocols described elsewhere [33].
The elemental composition was analyzed automatically with electron-probe micro-
analysis with energy-dispersive X-ray detection (200-300 per stage), for which the
procedures were also extensively described in literature [35, 36]. Average particle
diameters were calculated as dp = (d1× d22)1/3, where d1 and d2 are the maximum
and minimum Ferret’s diameter obtained from the electron image. X-ray spectra for
individual particles (1400–1800 per site) were evaluated by non-linear least-squares
fitting with the AXIL code [43], and the elemental composition (m/M %) was
calculated with a home-made quantification method [34]. A recently developed
tool [3] allowed for automatic classification of particles into five chemical classes,
depending on their elemental composition: minerals, iron oxides, sea salts (aged
sea salts included), ammonium salts and carbonaceous particles. About 85–90 %
of the measured particles could be classified into one of these groups. Since the
molecular and elemental composition analysis was only made on stages 3–8 of the
berner impactor (due to instrumental limitations), the obtained size distributions for
each particle type were censored to the left (dp > 0.3 µm).
10.4.3 Airway models
The three-dimensional geometry of the airways of asthma and COPD patients
were obtained from a clinical database. These geometries were retrieved using the
CT scan settings and segmentation algorithms described by De Backer et al. [10].
Institutional review board approval was obtained and a written informed consent
10-6 DEPOSITION OF URBAN AEROSOL
was signed by all patients.
The selection was made to cover the whole range of pathologies at different
stages: one mild asthmatic adult and two mild asthmatic adults that were scaled
to represent children (without airway deformations and with similar inhalation
profiles as for healthy adults and children), one early stage COPD patient (with
some airway deformations and slightly reduced flow), one persistent asthma patient
(with an abnormal extrathoracic region) and a late stage COPD patient (restricted
flow and high airway deformations in the whole lung). The pediatric lung models
were obtained by projecting representative adult asthma models on airway models
of pediatric cystic fibrosis patients such that the tracheobronchial airways were in
good agreement for airway lengths and volumes. This was necessary since we have
no scans of children with asthma and the fact that using cystic fibrosis patients is
not representative for the population. All patients received a low dose CT scan of
the extrathoracic region during slow inspiration (to prevent closure of the epiglottis)
and two low dose CT scans of the tracheobronchial region, one during breath hold
after normal expiration maneuver, i.e. functional residual capacity (FRC), and the
other during breath hold at total lung capacity (TLC). During the scan, breathing
maneuvers were controlled by a pneumotach, providing a real-time breathing signal.
The lobar lung-volumes were reconstructed at both FRC and TLC lung levels of all
patients. The lobar expansion from FRC to TLC (relative to the total increase in
lung volume) was considered as a measure for the internal distribution of inhaled
air. Combined with the inhalation profile (obtained with a pneumotach after the
scans), the internal lobar airflow distribution was determined as a function of time.
10.4.4 Particle deposition rates
CFD calculations were performed for each airway model in order to assess local
particle deposition patterns. A combined extrathoracic and tracheobronchial airway
model was subdivided into 6 million tetrahedral elements for which the partial
differential equations governing turbulent fluid flow were solved. For this evaluation
of particle deposition, the approach of Vinchurkar et al. [45] was used. Kinetic-
Energy Transport was chosen as the large eddy simulation subgrid model. The
pressure-velocity coupling was performed using the SIMPLE scheme and second
order schemes were chosen for the spatial discretization. The transient flow was
calculated with a time step of 0.005 s. The particles were tracked with the fluid time
step using Runge-Kutta scheme and Saffman Lift Force was taken unto account.
The simulated particle sizes were those collected with the berner impactor. The
patient specific inhalation flow profiles at the mouth and the calculated average
internal flow distribution for each lobe at the terminal bronchi were used as boundary
conditions for the flow simulations. This proprietary methodology (EU 09161455.2,
US 61/182,493) was previously reported by De Backer et al. [10].
The contribution of each chemical class to the total mass of particles in a
given AD size range (stage of the cascade impactor) was necessary to discriminate
between the different compounds in the CFD simulations. Total particle mass was
estimated from the AD and abundance of every aerosol type by assuming spherical
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particles of unit density. In the CFD simulation, discrete particles with given AD
were injected from the mouth over the full span of the inhalation cycle. Regional
deposition of each particle type was assessed in the mouth, upper airway (from
nasopharynx to larynx), trachea and lung (all airway generations after the trachea)
segments of airways with a cross section down to 1 mm. Furthermore, exhaled
fractions for all the particle diameters were taken into account by extrapolating the
data from Usmani et al. [41] and the International Commission on Radiological
Protection [1]. The calculated concentrations were converted to deposition rates in
units of mass per hour, by scaling with patient specific inhalation profiles with 1/3
inhalation and 2/3 exhalation per breathing cycle.
10.5 Results
10.5.1 Urban particulate pollution
During the study, the average mass of fine air suspended particles was 9 ± 1 and
8 ± 1 µg · m−3 at the heavy traffic and moderate traffic sites, respectively (Figure
10.2). A paired sample t-test did not assume any significant difference between
the averages of this mass-based metric (p = 0.325). In order to study the size-
distribution of total particle mass, additional sampling was made with a cascade
impactor on the last day of the campaign (Figure 10.3). At both sites, the mass
median diameter (MMD) in the considered size range (0.0625–16 µm AD) was
about 0.7 µm, with 80–90 % of the mass accounted by the fine fraction. However,
the level of particles with an AD below 0.3 µm at the moderate traffic site was
significantly lower as compared to the heavy traffic site, while the accumulation
mode (0.3–2.5 µm AD) at this site was broadened and shifted to smaller particles
(Figure 10.3).
About 60–90 % of the fine particle mass was explained by chemical analysis,
however, it is to be noted that the BC mass at the heavy traffic site could be slightly
overestimated due to repeated instrumental failure (cfr. composition on July 13th;
see Figure 10.2). About 24 % of the mass could be attributed to ammonium salts
(mostly ammonium sulfate), followed by BC (17 %), sea salts (11 %) and minerals
(4 %). The mass fraction which was not accounted by chemical analysis could be
attributed to organic carbon, which is typically twice the amount of BC, depending
on its source [6, 30]. Micro-analysis on individual particles revealed a similar
chemical composition. The most dominant particle types identified with EPMA
were carbonaceous (11–25 % of the investigated particles per site), sodium nitrate
(15–25 %) and mineral particles (18–19 %). Since the abundance of ammonium
salts was relatively low in the studied particle size range (as compared to bulk
composition), they were assumed to be mainly associated with particles with an
AD below 0.25 µm. Raman analysis showed how the mineral fraction was mainly
composed of silicates (24–64 %), among which quartz and Na,K-feldspathoids,
calcite (22–43 %) and gypsum (9–26 %). Additionally, different types of iron
oxides were spotted, such as magnetite, hematite and wüstite, as well as some iron
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Figure 10.2: Average mass and bulk composition of fine air suspended particles at the heavy
(top) and moderate (bottom) traffic sites. * Missing BC data. Lines are drawn with the use of
a b-spline algorithm.
hydroxides, together amounting to about 5 % of the total analyzed particles per
site. No direct differences were observed between the abundance of these particles
among the various sites, however, the size distribution of the main particle classes
did show some slight variations.
10.5.2 Particle deposition rates
The median deposition rate of all particle types in the airways of CRP was found to
be maximally in the upper airway (22 %) and lung (62 %) segments of the model
(Table 10.1). At a heavy traffic environment, deposition rates in the mouth and
upper airways was found to be significantly lower compared to a moderate traffic
environment, while the rate in the lungs was significantly higher (Table 10.1). These
differences result from an increased fraction of sub-micrometer particles at the
environment with heavy traffic (Figure 10.4) and illustrate how particle deposition
is highly dependent on the size distribution of the inhaled aerosol.
Since the presence of a certain aerosol specie can alter the total particle size
distribution, it also significantly affects the received particle dose upon inhalation.
In order to describe particle deposition in clinically relevant terms, particle types
identified with EPMA were grouped according to their toxicity. Carbonaceous
and iron-rich particles are generally acknowledged to induce cytotoxic effects
[16, 27, 42], but also crystalline silicates can cause oxidative stress due to the
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Figure 10.3: Size-distribution of particle mass at the –◦– heavy and ··•··moderate traffic site.
Lines are drawn with the use of a b-spline algorithm.
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Figure 10.4: Size distribution of all (left), toxic (middle) and anthropogenic (right) particles
on 15th of July at the –◦– heavy and ··•·· moderate traffic site. Lines are drawn with the use
of a b-spline algorithm.
Particle typea Airway segment Median (range), µg · h−1 pb
Heavy traffic Moderate traffic
All Mouth 0.20 (0.0 – 0.41) 0.21 (0.0 – 0.69) 0.012
Upper airways 1.9 (0.41 – 6.7) 2.4 (0.40 – 8.4) 0.004
Trachea 1.5 (0.16 – 3.2) 1.5 (0.15 – 3.6) 0.347
Lung 7.8 (2.0 – 13) 7.2 (1.8 - 13) 0.006
Toxic Mouth 0.16 (0.0 – 0.42) 0.20 (0.0 – 0.68) 0.012
Upper airways 1.6 (0.29 – 4.8) 3.0 (0.35 – 7.2) 0.002
Trachea 1.0 (0.11 – 2.3) 1.1 (0.12 – 2.9) 0.015
Lung 4.8 (1.4 – 8.0) 4.9 (1.4 – 9.1) 0.308
Anthropogenic Mouth 0.04 (0.0 – 0.21) 0.01 (0.0 – 0.15) 0.424
Upper airways 0.44 (0.06 – 2.4) 0.15 (0.02 – 1.5) 0.347
Trachea 0.25 (0.02 – 1.1) 0.09 (0.01 – 0.70) 0.136
Lung 1.1 (0.26 – 3.8) 0.46 (0.09 – 2.2) 0.071
aAll: Carbonaceous, iron-rich, minerals, ammonium salts and sea salts; Toxic:
Carbonaceous, iron-rich and minerals; Anthropogenic: Carbonaceous and iron-rich
(refer to text)
bSignificance (bold: p < 0.05) of a Wilcoxon signed rank test; H0: no median
difference (n = 12)
Table 10.1: Particle deposition rates in the airways of chronic respiratory patients by
segment
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presence of ferric ions which are complexed with silanol groups at the surface [15].
Therefore, the carbonaceous, iron-rich and mineral particle fractions (the latter
containing 60–85 % of pure or mixed aluminum silicates) were classified as being
toxic to humans, while the health effects of sea salts and ammonium salts could be
neglected at typical atmospheric concentrations [7].
Size distributions for toxic particles at the moderate and heavy traffic environ-
ment are given in Figure 10.4. Compared to the distribution of all particles, the
maximum of the toxic particle distribution at the moderate traffic site shifted only
slightly from 2.7 to 2.0 µm. However, at the heavy traffic environment one can
see how the fraction of sub-micrometer and coarse (AD > 10 µm) particles gained
importance over intermediate sizes (1–10 µm). Therefore, the increment of toxic
particles deposited in the mouth and upper airways at a moderate traffic environment
(+0.4 and +1.4 µg · h−1 over the heavy traffic environment, respectively) is even
higher as found for total particle deposition, though no significant difference could
be observed for the deposition in the lung segment (Table 10.1). Since particles of
natural origin do not represent the fraction of aerosols due to manmade pollution,
they are not useful in comparing the effects of anthropogenic emissions on particle
deposition rates. Since mineral particles were dominantly present, they significantly
alter the total size distribution and hence deposition rates for the particle group
defined as toxic. Anthropogenic toxic particles (carbonaceous and iron-rich) were
represented by a strong sub-micrometer mode at the heavy traffic site (Figure 10.4).
Therefore, deposition rates for all airway segments at this site were higher than the
moderate traffic site. Although statistical tests proofed these elevated deposition
rates to be non-significant for all airway segments (p < 0.05), the probability value
for the lung segment was found at the borderline of the significance level (Table
10.1).
10.6 Discussion
The daily average mass of fine air suspended particles was significantly correlated
with average wind speeds (Pearson coefficient r = – 0.588; p< 0.05), as well as with
NO2 and SO2 concentrations (r = 0.866 and 0.530, respectively; p < 0.05). This
shows how strong wind speeds from south-westerly directions (Figure 10.1) intro-
duce fresh air and allow for the quick dispersal of local NO2 and SO2 emissions. On
days with low wind speeds, these gases accumulate and produce particulate nitrate
and sulfate in the urban air [38]. This local effect was superimposed on synoptic
meteorology, which determines the particulate pollution load by sending marine or
continental polluted air masses to Antwerp. Backward air mass trajectories indeed
showed how elevated levels of total fine particle mass were associated with air
masses which traveled largely over land in the last 24 hours before arrival (r = 0.645,
p < 0.01).
From the total mass of fine particles and the MMD for particles ranging from
0.0625 to 16 µm AD one would conclude that the particulate pollution load was
hardly affected by local traffic conditions. Also the bulk chemical composition was
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comparable among sites, with fairly equal amounts of each component contributing
to the urban aerosol. Although these estimators did not suggest any difference
between sites, particles smaller than 0.3 µm AD were found to be elevated at the
heavy traffic site (Figure 10.3). This indicates the closeness of an air pollution
source, such as the neighboring highway. At the moderate traffic site (southern
suburbs), these particles were found to be coagulated to bigger sizes, as shown
by the shift in the accumulation mode (Figure 10.3). Micro-analysis of individual
particles also revealed some differences in the size distribution of main aerosol
types. Therefore, inhalation of airborne particles at the heavy and moderate traffic
sites could result in a different total particle dose, since slight shifts in the main
size modes of each aerosol type could definitely affect its deposition efficiency in
human airways.
Simulated median particle deposition rates in the lung segment of CRP are
shown in Table 10.2, as if they were breathing the air at the heavy and moderate
traffic sites during two days of the air quality survey. Differences in the particle
doses received at the moderate and heavy traffic site did not manifest through
deposition rates of all particles, nor for toxic particles. The median deposition rate
of anthropogenic particles at the heavy traffic site was about 0.5–1 µg · h−1 higher
than at the moderate traffic site. Although the results of an air quality study did not
necessarily assumed any significant difference in the mass or bulk composition of
fine particles among sites, deposition rates for anthropogenic particles (silicate-rich
minerals not included) were about 1.5–2.5 times higher at the heavy traffic site.
Nevertheless, from Table 10.2 it can be seen that the differences between the two
days were higher than between sites. This demonstrates how daily variation of air
quality, as determined by local and synoptic meteorological conditions, is more
relevant for the quality of air we breathe compared to the area (i.e. traffic condition)
in which we live. Results clearly show that anthropogenic activity (presumably
traffic) has an incremental effect on top of the background particulate air pollution.
Interpretation of this result in clinical terms may be ambiguous, because differences
in the deposition rates were not significant among sites when minerals were included.
The results also showed significantly different deposition rates between pa-
tients. For example, the total particle deposition rate in the lungs of the six CRP at
the heavy traffic site on the 15th of July ranged from 3.1 to 13.2 µg · h−1. Therefore,
patients were divided in three groups of differing pathological severity and age:
severe/adult, mild/child and mild/adult. Deposition rates were highest for adults
with a mild asthma or early stage COPD, and decreased for mild pediatric asthma
patients and adults with a severe asthma or late stage COPD (Table 10.3). These
differences were statistically significant for deposition of all particles as well as for
toxic and anthropogenic particles (p < 0.012 according to a Wilcoxon signed rank
test). These results show that adults with a mild respiratory dysfunction collect
more particles as compared to mild pediatric asthma patients. This could be the
result of differences in the airway geometry and inhalation profile of each patient.
The airways of children are generally smaller, so they breath less air during each
hour. Moreover, due to the smaller airway dimensions, particles are more easily
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Particle typea Date Median (range), µg · h−1 pb
Heavy traffic Moderate traffic
All 15/7 9.5 (3.1 – 13) 9.0 (3.1 – 13) 0.753
25/7 5.8 (2.0 – 8.4) 5.0 (1.8 – 7.5) 0.917
Toxic 15/7 5.5 (1.8 – 8.0) 5.8 (2.2 – 9.1) 0.753
25/7 4.0 (1.4 – 5.9) 3.5 (1.4 – 5.9) 0.917
Anthropogenic 15/7 2.6 (0.88 – 3.8) 1.5 (0.51 – 2.2) 0.028
25/7 0.79 (0.26 – 1.1) 0.30 (0.09 – 0.42) 0.028
aAll: Carbonaceous, iron-rich, minerals, ammonium salts and sea salts; Toxic:
Carbonaceous, iron-rich and minerals; Anthropogenic: Carbonaceous and iron-rich
(refer to text)
bSignificance (bold: p < 0.05) of a Wilcoxon signed rank test; H0: no median
difference (n = 6)
Table 10.2: Particle deposition rates in the lungs of chronic respiratory patients by date
removed in the upper airways or trachea and do not penetrate as deep as they do in
adult lungs. Similarly, although severe CRP are believed to be a sensitive population
for air pollution, particle deposition was found to be lowest for adults with a severe
respiratory dysfunction. These patients have, in general, airway deformations such
as local narrowing and bends, which leads to enhanced deposition in the upper
airways and trachea. In addition, they have a restricted airflow and thus a smaller air
volume per inhalation cycle. Hence, people which are sensitive to air pollution due
to a respiratory dysfunction protect themselves from particulate pollution by having
a reduced airflow. Nevertheless, for each patient group the dose of anthropogenic
particles at the heavy traffic site was about double of the dose that is received when
inhaling the air at the moderate traffic environment.
In conclusion, the combination of CFD with physical-chemical characteristics
of particulate pollution was found to be useful to calculate particle deposition in
the airways of patients upon exposure to the urban atmosphere. The novelty of
this simulation approach is the use of chemical information on individual airborne
particles, which enables to study deposition rates for selected classes such as
minerals or carbonaceous particles. In this way, one could focus for example on
toxic particles only, for which the deposition rates are not influenced by abundant
and rather coarse particle types without any toxicological relevance. As debates on
particulate matter are mostly held on a local scale, it is important to understand that
location (within the range of an urban environment) is less important in comparison
with pathology and synoptic meteorological conditions. Of course, the only way to
protect people’s health is to keep particulate pollution within limits, especially in
heavy traffic environments.
As this is a proof of concept study describing a novel approach, there are
several limitations which should be underlined. First of all, the aerosol character-
istics used in this study were obtained from airborne particle samples collected
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Particle typea Pathology/age Median (range), µg · h−1 pb
Heavy traffic Moderate traffic
All Severe/adult 3.9 (2.0 – 7.5) 3.6 (1.8 – 7.1) 0.465
Mild/child 7.6 (5.5 – 9.9) 6.9 (4.7 – 9.6) 0.465
Mild/adult 11 (8.2 – 13) 10 (7.4 – 13) 0.465
Toxic Severe/adult 2.6 (1.4 – 4.6) 2.5 (1.4 – 4.6) 1.000
Mild/child 4.7 (3.8 – 6.0) 4.6 (3.0 – 6.4) 1.000
Mild/adult 6.8 (5.7 – 8.0) 7.4 (5.8 – 9.1) 0.465
Anthropogenic Severe/adult 0.78 (0.26 – 2.1) 0.38 (0.09 – 1.2) 0.068
Mild/child 1.6 (0.75 – 2.8) 0.81 (0.28 – 1.6) 0.068
Mild/adult 2.4 (1.1 – 3.8) 1.3 (0.87 – 2.2) 0.068
aAll: Carbonaceous, iron-rich, minerals, ammonium salts and sea salts; Toxic:
Carbonaceous, iron-rich and minerals; Anthropogenic: Carbonaceous and iron-rich
(refer to text)
bSignificance (bold: p < 0.05) of a Wilcoxon signed rank test; H0: no median
difference (n = 4)
Table 10.3: Particle deposition rates in the lungs of chronic respiratory patients by
pathology and age
during only two days. Since it is obvious that the particulate pollution load largely
determines the calculated deposition rates, the quantitative figures on particle doses
could not be considered representative for the studied area. Nevertheless, since the
concentration and composition of particles were rather typical for most medium
sized cities [2, 20, 21, 26, 44], the qualitative evaluation remains valid for most
situations encountered in urban environments. Secondly, the simulations were only
performed in a small amount of patients. Extrapolating these results to a whole
population is therefore dangerous. However, we believe that the concept of using
real geometries obtained from CT scans instead of statistical models make the
results more representative. The models were chosen in a way that they represent
typical airway geometries for a certain group of CRP. Nevertheless, some limitations
remain (1) Most people are nasal breathers, though mouth breathing was modelled
since no nasal geometries were available; (2) The pediatric models were scaled
down adult models, which means that it is possible that they slightly deviate from
airway geometries found for this population; (3) The used CFD methodology was
previously validated with SPECT/CT by De Backer et al. [10], but did not include
the particle diameters that were simulated here; (4) In order to express particle
dose in units of micro gram per hour, particles of well-defined AD were assumed
to be spherical with unit density. Although shape effects could be important for
the behavior of particles in human airways, it is thought that this approach is more
accurate than defining the density for individual particles with a mixed composition.
Considering these limitations, it should be emphasized that this study is only
a preliminary step in the assessment of the deposition rates of toxic particles in
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human airways. Decisive conclusions regarding the potential health risks due to
air pollution exposure require extended research, which combines more elaborated
simulations of airway particle deposition with more extensive chemical analysis of
the urban aerosol. In this regard, the present results must be treated with care when
supporting the general debate on air quality and urban infrastructure.
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Functional respiratory imaging as a
tool to personalize respiratory
treatment in subjects with unilateral
diaphragmatic paralysis
Respiratory care; in press
Cedric Van Holsbeke, Glenn Leemans, Wim Vos, Jan De Backer, Samir Vinchurkar,
Michel Geldof, Pascal Verdonck, Paul Parizel, Paul Van Schil and Wilfried De
Backer
11.1 Abstract
In two subjects with a unilateral diaphragmatic paralysis and complaints of dyspnea,
a completely different treatment approach was chosen despite similar anatomical
and physiological abnormalities. These decisions were supported by the results
generated by Functional Respiratory Imaging (FRI). FRI was able to generate
functional information with respect to lobar ventilation and local drug deposition. In
one subject, it was found that some lobes were poorly ventilated and drug deposition
simulation showed that some regions were undertreated. This subject underwent
a diaphragm plication to restore the ventilation. In the other subject, it was found
that all lobes were still ventilated. A conservative approach with regular follow-up
was chosen to wait for spontaneous recovery of the diaphragmatic function. Both
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subjects improved subjectively and objectively. These cases demonstrate how novel
medical imaging techniques such as FRI can be used to personalize respiratory
treatment in subjects with unilateral diaphragmatic paralysis.
11.2 Contributions of the author
The author of this thesis was the principal technical researcher in this study. The
knowhow that was obtained in the previous chapters was used to bring the technique
to the clinical practice. The main challenge here was to combine the different
techniques from the previous chapters and to use them for clinical decision making.
To make this possible, the author worked in close cooperation with pulmonologists,
thoracic surgeons, radiologists and physiotherapists.
11.3 Introduction
In the last decade, personalised medicine has received special attention for its
potential of individually tailored treatment, based on genetic or other information
on an individual’s health status. Following a statement of the European Society
of Radiology, medical imaging plays a critical role in all aspects of personalised
medicine [6].
New medical imaging techniques are capable of combining medical images
with the quantification of certain biological processes in organs in order to detect
diseases at the earliest possible time, to personalize diagnosis and to individualize
medical or surgical treatment. Functional Respiratory Imaging (FRI) is a clinically
validated computational technique that adds functional data to respiratory anato-
mical images [3]. Starting from low dose high resolution computed tomography
(HRCT) scans, three-dimensional models of airways and lung models are extracted
and computational fluid dynamics calculations are performed. A detailed descrip-
tion of the FRI methodology can be found in De Backer et al [3]. One of the design
features of FRI is that local analyses can be performed while pulmonary function
tests (PFT) are based on a black box approach where the information of the whole
respiratory system is incorporated into single numbers. This results in an increased
sensitivity of FRI as compared to PFT [4, 11].
In this report the clinical value of FRI to personalize and deliver the most
optimal treatment is demonstrated in two subjects with an idiopathic unilateral
paralysis of the diaphragm.
11.4 Case report
11.4.1 Study subject 1
A 57-year-old male subject (102 kg, 175 cm) with a known unilateral diaphrag-
matic paralysis since 1.5 years was referred to the hospital with recent complaints
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of increasing dyspnea and orthopnea. Medical history revealed a condition of
asthma. On clinical examination diminished vesicular breath sounds at the right
lung base were present. The previous practitioner prescribed the subject four doses
of salmeterol 25 µg - fluticason 250 µg (Seritide, GlaxoSmithKline) and fluticason
250 µg (Flixotide, GlaxoSmithKline) per day to control asthma exacerbation. PFT
showed a highly reduced lung function (see Table 11.1) with both restrictive and
obstructive elements. HRCT confirmed unilateral paralysis of the right diaphragm
in combination with hypoventilation-induced atelectasis in the right middle (RML)
and right lower lobe (RLL).
Subject 1 Subject 2
Parameter Initial visit Postoperative Initial visit After 6 months
VC [% predicted] 52 61 75 86
FEV1 [% predicted] 48 57 71 82
Tiffeneau index [%] 70 71 94 94
RV [% predicted] 113 96 69 95
FRC [% predicted] 77 77 67 94
TLC [% predicted] 71 71 71 87
Raw [kPas/L] 0.670 0.419 0.330 0.209
sRaw [kPas] 2.029 1.310 0.969 0.810
Table 11.1: Pulmonary function tests subject 1 & 2. VC: vital capacity; FEV1: forced
expiratory volume in 1 second; Tiffeneau index: FEV1/VC; RV: residual volume; FRC:
functional residual capacity, TLC: total lung capacity; Raw: airway resistance; sRaw:
specific airway resistance
To investigate how much ventilation was still distributed to the RML and RLL,
FRI was performed. The lobar expansion from functional residual capacity (FRC)
to total lung capacity (TLC) was considered as a measure for the lobar ventilation as
this represents the internal airflow lobar distribution (IALD) as defined in Equation
11.1.
IALDlobe[%] = 100
VTLClobe − VFRClobe
VTLClungs − VFRClungs
(11.1)
In this equation, IALDlobe is the internal airflow lobar distribution to a specific
lobe, VTLClobe is the volume of that lobe at TLC, VFRClobe is the volume of that
lobe at FRC, VTLClungs is the total volume of all the lobes at TLC and VFRClungs
is the total volume of all the lobes at FRC. Moreover, computational fluid dynamics
calculations provided measures of local deposition of inhalation medication [3]. In
this way, it was possible to assess to which zones the drug was delivered.
FRI analysis showed a poor ventilation of the RLL and no ventilation of the
RML (Figure 11.1). In addition, very low levels of drug deposition were found in
these lobes (Figure 11.2) when performing particle simulations using the compound
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data of Tarsin and Stein et al [9, 10]. The poor drug deposition results found by
FRI explain why a combination of several inhalation compounds were needed
to treat the asthma, as these zones were probably pharmacological undertreated.
Furthermore, a long-term non-ventilatory status of the RML could set the stage for
repeated episodes of infection accounting for a vicious cycle of recurring bouts of
inflammation that may result in a non-functional lobe [1].
Figure 11.1: The internal airflow lobar distribution of the right upper lobe (red), right
middle lobe (yellow), right lower lobe (orange), left upper lobe (blue) and left lower lobe
(magenta) of subject 1 & 2. FRC: functional residual capacity, TLC: total lung capacity
In recent review Groth and Andrade [7] concluded that diaphragm plication
seems a promising surgical technique to improve ventilation in subjects with di-
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Figure 11.2: A visualisation of drug deposition simulations of subject 1. The green dots are
the locations where the particles deposit. It is shown how much salmeterol and fluticason
deposits in the right upper lobe (red), right middle lobe (yellow), right lower lobe (orange),
left upper lobe (blue) and left lower lobe (magenta) in the pre- and post-operative situation.
aphragm paralysis. Therefore, a diaphragm plication was performed to place the
paralyzed diaphragm in a position of maximum inspiration to relieve compression
on the lung parenchyma and to allow its re-expansion.
Six weeks postoperatively, dyspnea was subjectively better. This was con-
firmed by an improvement in PFT (Table 11.1) and FRI, where the RML and RLL
were much better ventilated than preoperatively (Figure 11.1). FRI also showed an
improved drug deposition in these regions (Figure 11.2). It can be observed that the
amount of active compound reaching RML and RLL increased from 38.2 µg (using
salmeterol - fluticason) to 117.1 µg (using only salmeterol). This was clinically
confirmed as the subject’s asthma was kept stable using only four doses salmeterol
25 µg - fluticason 250 µg per day and as the obstructive components of the PFT
improved despite the reduced medication.
11.4.2 Study subject 2
A 57-year-old male subject (92 kg, 181 cm) with a known unilateral diaphragmatic
paralysis since eleven months presented at follow-up with recent complaints of
increasing dyspnea and orthopnea. Clinical examination showed diminished vesic-
ular breath sounds at the left lung base. The subject did not use any inhalation
medication. PFT showed a significantly reduced lung function (Table 11.1) of
restrictive nature. HRCT confirmed the unilateral paralysis of the left diaphragm
and associated atelectasis of the left lower lobe was observed.
Subject 2 underwent the same FRI analysis as subject 1. This showed that all
lobar regions were ventilated (Figure 11.1). Taken into account these FRI results,
the physician considered a further conservative approach with regular follow-up
since spontaneous recovery of the diaphragmatic function has been reported [5].
After 6 months, the breathlessness was completely resolved and total lung capacity
was significantly improved (Table 11.1). No new FRI analysis was performed as
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the physician found this unnecessary from a clinical point of view.
11.5 Discussion
Unilateral diaphragmatic paralysis is characterized by the loss of muscle contrac-
tility with progressive muscular atrophy that leads to an elevated position of the
affected diaphragm. Treatment depends mainly on the cause of the paralysis, anato-
mical and physiological impairment (e.g. atelectasis) and the severity of symptoms.
A conservative approach, with or without pharmacotherapy, may be considered
since spontaneous recovery of the diaphragm can occur when clinical symptoms are
minimal or tolerable and physiological impairment is absent [5]. In those subjects
with anatomical and physiological impairment with persisting symptoms despite
optimal therapy, surgical correction is indicated. Plication of the diaphragm in a
series of 13 subjects with an unilateral impairment showed improvement in symp-
toms, lung function and quality of life that was maintained during 4–7 years [2].
Despite the promising results on both short-term and long-term outcomes, precise
selection of suitable subjects is necessary [2, 8].
This case report demonstrates the potential of FRI as a new functional imaging
technique in respiratory medicine to choose the right treatment plan in subjects
with an idiopathic unilateral diaphragmatic paralysis. In both subjects, radiological
examination revealed the appearance of atelectasis in the lower lobes. Atelectasis is
commonly seen in combination with compression of the lung parenchyma, which
affects compliance, therefore diminishing the regional ventilation of certain parts
of the lung. Traditional clinical techniques are however not able to quantify these
effects.
Although both subjects had the same anatomical and physiological abnormali-
ties on HRCT, FRI showed a clear difference in regional ventilation. In our first
case there was no lobar expansion of RML and a minor expansion of RLL. However
all lobar regions in study subject two were ventilated. In other words, FRI was able
to identify functional differences in these two subjects with apparently the same
clinical and radiological findings.
Secondly, FRI was able to calculate local deposition of inhalation medication.
In subject one, FRI showed that inhalation therapy was not reaching all zones. As
a result, the proposed pharmacotherapy was probably inefficient in treating the
obstructive symptoms.
Based on the clinical and radiological results, both subjects could be scheduled
for surgery since they presented with anatomical and physiological abnormalities
and still experienced symptoms despite optimal treatment. On the one hand, FRI
analysis in subject two revealed that there was still regional ventilation in the left
lower lobe even though atelectasis was present. Therefore a conservative approach
with regular follow-up was chosen and spontaneous recovery of the diaphragm
occurred after 6 months. On the other hand, taking into account the FRI results of
subject one, we could conclude that surgery in subject one was the correct decision.
Finally, this report demonstrates also that FRI was able to quantify the regional
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functional redistribution of airflow to the right lung after the diaphragm plication,
and this even without major clinical changes in classical lung function tests.
In conclusion, this case report demonstrates the clinical value of FRI as a
tool to personalize medical treatment. In the future, this new functional imaging
technique may result in a more precise diagnosis and treatment in a rapidly growing
number of respiratory patients.
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Challenges in engineering
12.1 Introduction
While most work in biomedical engineering handles about the design of algorithms
that are then tested in a few patient models, this works strives to create a technology
that can be applied to large datasets. In this thesis, FRI is applied on 486 unique
patient geometries and the results in the chapters are obtained by processing more
than 75 TB of data. This is equivalent to 4500 piles of typed paper stacked as tall
as the Eiffel Tower. The processing of this huge amount of patient specific data
poses many challenges in engineering. Scalability in a clinical setting is mostly
determined by repeatability and time-efficiency. In order get a technology that is of
a high quality, consistent and fast, the amount of manual work has to be minimized
by designing robust automation algorithms. In biomedical engineering, automation
is very challenging as the anatomical variation within and in between subjects is
very large, especially when dealing with diseased subjects. Besides automation,
steps have to be taken to reduce the calculation time without losing precision by
reducing the problem and only simulating the things that are needed to obtain the
relevant results. In this chapter, some examples of challenges that were tackled to
improve the scalability are described. In addition, some advanced algorithms that
can be used in future studies but are not yet scalable enough are discussed.
12.2 Pre-processing and simulation
In the pre-processing and simulation phase, most work is put in the detection of
user errors and optimization of the queuing and run time. Anatomical zones are
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very difficult to map using computer algorithms due to the large inter and intra
subject variation. That is why, in this thesis, anatomical zones are defined manually
(although they are post-processed automatically). Every form of user interaction
is however prone to errors and both automatic and manual control mechanisms
are needed to ensure the quality. Several checks are built into the workflow that
warn the user about unphysiological structures, unusual anatomical zones, missing
data and mesh quality issues. Also, every step in the workflow is adapted for every
different case. For example, when creating a volume mesh in SnappyHexMesh
(OpenCFD Ltd., Bracknell, UK) like in chapters 4 and 6, one has to define a point
inside the closed region that needs to be meshed. When the point is defined outside
of the surface mesh of the airway, the bounding box surrounding the airway will be
meshed which is not the desired behaviour when one wants to simulate the flow
inside the airways. It is however not straightforward to automatically define a point
inside the mesh as every airway object has different dimensions defined in different
coordinate systems. An algorithm is designed to solve this problem.
In a first step, a point ~P is defined with the same coordinates as a point on the
surface mesh and it is moved in a certain direction. To check if the chosen point
~P is inside the surface mesh, the solid angle of every planar face as seen from this
origin point is calculated. The solid angle Ω subtended by a surface mesh S is
defined as the surface area of a unit sphere covered by the surface’s projection from
a point ~P onto the sphere and is measured in steradians (sr). It can be calculated
with equation 12.1.
Ω =
∫∫
S
~r · ~NdS dS
‖~r‖3 (12.1)
In equation 12.1, ~r is the vector position of a face with respect to point ~P
with an (idealised) infinitesimal surface area dS and with ~NdS representing the
unit vector normal to dS. If the surface integral of all solid angles dΩ from all
faces (Figure 12.1) to the point is equal to 4pi sr, then the point is inside the closed
surface S as the projections in all directions will cover the complete sphere. If it is
equal to 0, then ~P is outside the mesh because the opposite normal vectors of the
faces will cancel out the projections on the sphere. Depending on the result, the
point can be moved in another direction and the algorithm can be repeated until a
point is found inside the closed volume that needs to be meshed.
Several steps are taken to reduce the turnaround time of the simulations. A
queuing mechanism is implemented to distribute the computational resources and
software licenses in an optimal way. This system makes it possible to perform
calculations while other tasks are waiting for input from a previous process. The
insights gained from sensitivity analyses with respect to mesh, turbulence, time
step, parallelization and particle convergence ensure fast and precise simulations.
CHALLENGES IN ENGINEERING 12-3
P
→
dS
dΩ
Figure 12.1: Solid angle
12.3 Post-processing
Quite some challenges in this thesis are in the phase of post-processing. The
large amounts of data that are generated need to be converted in a form that
allows human interpretation. It is important that the post-processing is completely
automated and does not depend on graphical user interfaces, making it very cluster
friendly. In sections 12.3.1 and 12.3.2, some morphometric measurement methods
are described.
12.3.1 Surface area and volume
In most chapters, airway volumes are important outcome parameters. In chapter
7, the surface areas of the branches are needed to calculate the concentrations of
inhaled antibiotics. To calculate the surface area and volume of a triangulated
surface S, one has to assess these properties of every individual triangulated face.
The area of an individual triangle is simply calculated by multiplying the base
by the height divided by two. This is done by extracting the points of that triangle
and calculating the vectors from point 1 ( ~P1) to point 2 ( ~P2) and from point 1 to
point 3 ( ~P3) as ~P1,2 and ~P1,3. If these vectors would define a parallelogram, the
area of that parallelogram would be defined by multiplying the base by the height
which can also be written as equation 12.2.
12-4 CHALLENGES IN ENGINEERING
∥∥∥ ~P1,2∥∥∥∥∥∥ ~P1,3∥∥∥ sin (θ) = ∥∥∥ ~P1,2 × ~P1,3∥∥∥ (12.2)
In equation 12.2, θ is defined as the angle between ~P1,2 and ~P1,3 (see Figure
12.2). The half of that area is then the area of the triangle dS.
P1
→
P3
→
P2
→
θ
P1,3
→
P1,2
→
P1,2
→
×P1,3
→
Figure 12.2: Area of a triangle
The volume under every triangle has to be defined for a certain direction. First,
one has to construct the normal vector ~NdS for the triangle from equation 12.3.
~NdS = ~P1,2 × ~P1,3 (12.3)
If the direction is chosen to be the direction of the z axis, the z component
of ~NdS , ~P1, ~P2 and ~P3 have to be extracted as NdSz , P1z , P2z and P3z . The z
component of the triangle centroid is now calculated using equation 12.4.
Cz =
P1z + P2z + P3z
3
(12.4)
With this information, the projection of dS in the direction of the z axis on
the x− y plane can be calculated with equation 12.5.
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dSz = dS
NdSz∥∥∥ ~NdS∥∥∥ (12.5)
Multiplying dSz with Cz is then the contribution dV of that triangle to the
total volume as seen in Figure 12.3.
z
y
x
dS
dSz
Cz
Figure 12.3: Volume under a triangle
Finally, the total surface area Ssurf and volume Vtot are respectively given by
the equations 12.6 and 12.7.
Ssurf =
∫∫
S
dS (12.6)
Vtot =
∫∫
S
dV (12.7)
(12.8)
12.3.2 Cross-sectional area
In chapters 3, 4 and 6 mean and minimal cross-sectional area’s are used as outcome
parameters. To get these values, cross-sectional areas have to be calculated at every
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level in the airway. First, a centerline is generated using a proprietary algorithm. In
a desired point ~P on that centerline, a plane with normal vector ~N is constructed
perpendicular to this line. The plane is now given by equation 12.9.
Nx(x− Px) +Ny(y − Py) +Nz(z − Pz) = 0 (12.9)
The triangulated mesh S consists out of points and the connections between
them. For every point ~P1 in the triangulated mesh with a connection to a point ~P2, a
vector ~P1,2 can be constructed. This vector can be parametrized by equation 12.10.
(x, y, z) = (P1x + P2xλ , P1y + P2yλ , P1z + P2zλ) (12.10)
When substituting equation 12.10 into equation 12.9, and solving for the
parameter λ, the coordinates of the intersection point can be constructed. These
coplanar intersection points form a closed polyline (Figure 12.4). Assuming a
Delaunay triangulated mesh, this closed polyline can be constructed by connecting
the intersection points on the connections that have a mutual point in the mesh as
visualised in Figure 12.5.
Figure 12.4: Closed polylines on an upper airway surface
If we now create a coordinate system (x′, y′) parallel to the plane, the cross-
sectional area inside the polyline is defined by equation 12.11.
Scross =
1
2
n−1∑
i=0
(Pix′P(i+1)y′ − P(i+1)x′Piy′) (12.11)
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Figure 12.5: Connecting the intersection points: The coplanar intersection points are
visualised by the black dots. The red dots represent the mutual points in the mesh
12.4 Advanced algorithms
Scalability is an important factor when creating a clinically relevant technology.
However, this does not mean that additional research in more advanced algorithms
is useless. As Moore’s law is still valid nowadays, it is possible that technologies
that require too much computer power to be incorporated in the FRI workflow
are common practice in a few years. In section 12.4.1, a method to perform one-
way coupled fluid structure interaction (FSI) simulations in airways is proposed.
FSI adds some extra functional information by incorporating the movement of
the airways during flow simulations. In section 12.4.2, it is described how the
incorporation of realistic device boundary conditions can improve the simulations
of nasal sprays.
12.4.1 One-way coupled fluid structure interaction
Modeling human breathing using FSI is a challenging topic due to the complex
interactions between flow and structure. Flow is simulated in an airway model, the
forces on the geometry are calculated and depending on the material properties a
movement is induced. This movement has an effect on the flow, creating the need of
a coupling between the flow and structure equations. Performing this in a subject-
specific way is almost impossible as tissue properties and muscle interactions vary
a lot inter- and intra-subject. However, one-way coupled FSI is possible when only
the airway movement is known.
Imaging modalities such as high resolution computed tomography (HRCT)
scans make it possible to make a detailed anatomical model of the subject’s airways.
A HRCT at functional residual capacity (FRC) and at total lung capacity (TLC)
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gives the initial and the final geometry of a breathing cycle. Mapping the nodes of
the TLC mesh to the nodes of the FRC mesh using a point set registration algorithm
gives the transformation matrix of every node, resulting in a moving mesh that
steers the flow. This mapping is performed using the nonrigid Coherent Point Drift
Algorithm (CPD) [1]. In CPD, the alignment of two node sets is considered as a
probability density estimation problem and the Gaussian mixture model centroids
(representing the TLC node set) is fitted to the FRC node set by maximizing the
likelihood.
In this example, lower airway models of a healthy subject are reconstructed
until the first generation of segmental airways at both TLC and FRC. The FRC
model is then mapped to the TLC model using CPD. The resulting transformation
matrix is used to create models of 50 intermediate airway states. Correct meshes
are generated for these models and computational fluid dynamics simulations are
performed. Using a piecewise constant interpolation algorithm, the results of the
previous mesh are transformed to the next mesh after which the calculations can
continue. Examples are given in Figure 12.6.
The generation of these models is however not feasible with the original code.
The main problem with the original CPD algorithm is that huge amounts of memory
are required to perform the morphing. The largest memory hog is the construction
of the affinity matrix, determining the similarity between points. For two points ~P1
and ~P2, the affinity is given by equation 12.12.
G1,2 = exp
(
− 1
2β2
∥∥∥ ~P1 − ~P2∥∥∥2) (12.12)
In equation 12.12, β defines the width (smoothness) of the Gaussian kernel.
The memory usage of original algorithm that is used to construct the affinity matrix
is heavily influenced by the dimension of the Euclidian space. When constructing
this matrix with 64 bit double precision, the memory usage is defined by equation
12.13.
Memory =
(
2× dimension× n2p + 2× dimension× np
)× 64 bits (12.13)
In equation 12.13, np is the amount of points in the mesh. The amount of
memory needed to perform morphing on a coarse three-dimensional mesh consisting
of 50000 points is 112 GB, making it very difficult to handle. A new algorithm
is constructed for which the memory usage is less influenced by the Euclidian
dimension and that is able to reduce the memory usage for the purposes in this
thesis. When constructing the affinity matrix with 64 bit double precision using this
algorithm, the memory usage is defined by equation 12.14.
Memory =
(
n2p + 3× dimension× np
)× 64 bits (12.14)
The amount of memory needed to perform morphing on a coarse three-
dimensional mesh consisting of 50000 points is 19 GB, which is already more
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(a) FRC model (b) 20% between FRC and TLC
(c) 40% between FRC and TLC (d) 60% between FRC and TLC
(e) 80% between FRC and TLC (f) TLC model
Figure 12.6: One-way coupled FSI simulation
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in the range of a typical computer cluster node. The memory usage in function of
the number of points in the mesh of both algorithms is given in figure 12.7. When
one a has a cluster node with 23 GB of free memory, it is now possible to deal with
55556 instead of 22682 points.
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Figure 12.7: Memory usage when constructing the affinity matrix
At this moment, 24 hours of computer time and a few hours of manual work are
needed to get the models. It is also not known if these simulations yield in clinically
relevant results. One of the possible applications is in the field of phenotyping.
When assessing the lobar resistances as a function of airway volume, the possibility
exists that this can be related to a physiological phenomenon. When looking at
Figure 12.8, it can be observed that the resistance towards the left lower lobe follows
a different trend than the other lobes when inhaling. This heterogenous pattern can
possibly be an indication for an underlying condition.
12.4.2 Realistic device boundary conditions
Metered-dose inhalers deliver a specific amount of medication to the patient by
injecting a suspension of liquefied gas propellant and active compound into the oral
or nasal cavity. When assessing aerosol deposition in the lungs after administration
of a product in the oral cavity, the effect of the liquid propellant can be neglected
since the aerosol cloud almost instantly takes the much higher momentum of the
inhalation flow due to its small response time. However, when simulating breath
hold conditions or nasal sprays with negligible inhalation flow, the momentum that
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Figure 12.8: Lobar resistance as a function of volume
is transferred from the propellant to the particles will have a large influence on the
deposition.
This situation is quite complex as different materials and the interactions
between them need to be simulated. The results of a test case be seen in figures
12.9(a) and 12.9(b). In this case, a suspension of a liquid ethanol dilution and inert
particles with a diameter of 4 µm are injected from a small orifice. The boundary
condition at the left boundary is a zero total pressure, the boundary condition at
the right boundary is a transient under pressure profile. Figure 12.9(a) shows the
situation during the injection and figure 12.9(b) shows what happens 5 ms after the
injection. The black dots represent the positions of the particles, the colour scale
represents the concentration of ethanol where red is a high concentration and blue
is a low concentration. It can be seen that during the injection, the particles are
driven by the cloud of diluted alcohol and that dispersion occurs afterwards.
In order to use this approach in real cases, the properties of both propellant
and compound exiting the device need to be assessed accurately. In the future,
this system will be used in a study after it is investigated what level of complexity
(evaporation, diffusion sources, ...) is needed to obtain accurate results.
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(a) During injection
(b) 5 ms after injection
Figure 12.9: Particles in an ethanol dilution
CHALLENGES IN ENGINEERING 12-13
References
[1] A. Myronenko and Xubo Song. Point set registration: Coherent point drift.
IEEE Transactions on Pattern Analysis and Machine Intelligence, 32(12):2262–
2275, 2010.

13
Conclusion
This conclusion starts with an overview of the results that are obtained in this thesis.
It is shown that FRI is able to quantify the effects on upper airway morphology
and functionality of mandibular repositioning in adult OSA patients. Furthermore,
the treatment effects can be predicted from baseline measurements, making it
possible to split the population in risk groups. This enables the physician to provide
more effective patient treatment, which is especially useful in techniques with a low
success rate. The results are in line with clinical literature but the biomechanical
observations cannot be mapped directly to clinical outcome due to the lack of sleep
data for this population. This issue is addressed in pediatric OSA patients where
it is found that baseline measured FRI parameters are better correlates for OSA
severity than clinical scores of upper airway patency. Preliminary data also show
that there are differences in upper airway morphology in subjects who do not benefit
from a treatment.
When looking at the behavior of inhalation medication, FRI is able to capture
the importance of patient specific features, such as upper airway morphology, in
having a significant impact on the effective lung dose and therefore the treatment
efficacy. Furthermore, FRI analyses show that there is a large inter- and intra-subject
variation in upper airway morphology and functionality. This states the importance
of using as much subject specific information as possible when simulating particle
deposition. FRI is also shown to be useful in optimizing treatment on a patient
specific base. A high heterogeneity in concentration levels of inhaled antibiotics is
observed in cystic fibrosis patients and this heterogeneity is connected to the disease
severity. While some patients receive high concentrations of inhaled antibiotics in
the whole lung, other patients receive low concentration in some, mostly the more
diseased, lobes.
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When looking at the effects of inhalation medication in small airway diseases,
FRI is very sensitive in picking up changes in local airway morphology and func-
tionality. In both asthma and COPD patients, FRI parameters are three to six-fold
more sensitive in picking up drug-induced changes as compared to PFT. Even when
compared to other state-of-the-art imaging techniques, FRI seems to be a more
sensitive marker. In a very recent trial that is very similar to the study in chapter 8,
oxygen-enhanced MRI is used to assess the acute effects of formoterol in COPD
patients. There it is found that the effect size measured with the imaging technique
is only around 30% higher than PFT [1]. This increased sensitivity can lead to
smaller numbers of patients in clinical trials without losing power. Besides the
increased sensitivity of FRI, an increased specificity is observed compared to the
traditional techniques. Correlations were found between changes in FRI parameters
and changes in patient feeling. This gives an indication that FRI has the possibility
to measure changes in quality of life after treatment.
This increased sensitivity also opens the possibility for FRI in pilot studies
and clinical practice. It is shown that FRI can help to understand the behaviour
of airborne particles in the lungs. This study is the first study combining detailed
physical-chemical analyses of particulate pollution with patient specific particle
simulations. The main finding is that location within the range of an urban environ-
ment is less important in comparison with pathology and synoptic meteorological
conditions when measuring lung doses of airborne particles. FRI can also help
physicians in selecting the right treatment for the right person. In two patients with
an idiopathic unilateral diaphragmatic paralysis, a different treatment approach was
chosen despite both having similar anatomical and physiological abnormalities on
radiological examination. FRI showed impairments in ventilation and drug delivery
in one patient, while this was not the case in the other patient, resulting in a surgical
and conservative approach respectively. These cases demonstrate the potential of
FRI in personalizing respiratory treatment.
The question that most people will have is: Is FRI a better alternative to
traditional techniques like PFT and AHI? The short answer is “no”. The long
answer is “we don’t know yet”. While traditional techniques have their flaws, they
have been validated in numerous long-term clinical trails and have been linked to
comorbidities and mortality. Their inherent black box approach does not have to be
a disadvantage as a lot of the subject’s physiology is taken into account, reducing
the risk of defining a wrong region of interest. FRI is still in its early development
phase and is at this moment no competitor for PFT and sleep scores. However, this
thesis shows that FRI can have an added value in several domains.
The strengths of FRI are the regional information, quantified outcome, minimal
invasiveness and multi-facet approach, resulting in a high sensitivity and specificity.
These properties make it possible to use FRI in early clinical trials as a design
tool rather than a mere analysis tool. A myriad of information about the efficiency
of the intervention becomes available through FRI, allowing tailoring of the drug
formulation or medical device to optimize the treatment. As a lot of clinical trials
lead to inconclusive results on the general study population, FRI can be used to
distinguish responders from non-responders. As fewer patients in fewer centres are
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needed, the overall costs of clinical trials can be reduced. FRI is very well suited
to reach go/no go decisions early in the development process of a device or drug.
Using FRI in small-scale clinical phase IIa trials can significantly de-risk the very
expensive phase III trials. Validated traditional tests can here be combined with
FRI, where the latter is used as a tool to assess the mode of action. This means
that the quantitative results will be reported, but no clinical conclusions will be
connected to these results. In Figure 13.1, an example of such a workflow is given
when dealing with inhalation medication.
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Figure 13.1: Workflow example for a phase IIa study in pharmacological development
Suppose that a study is performed to assess the efficacy of an inhalation
medication in 15 – 30 subjects. There are now different possibilities:
• Both FRI and PFT give positive signals: This means that the compound
is probably effective and that further phase IIb and phase III trials can be
performed.
• Both FRI and PFT give negative signals: This means that the compound is
probably not effective and that further phase IIb and phase III trials are not
useful.
• FRI gives a signal (either positive or negative) and PFT is inconclusive:
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– Sensitivity: If FRI gives a signal (preferably positive) and no specials
reasons are found for the inconclusiveness of PFT, then probably the
number of included patients was to low. Phase IIb and phase III trails
with more patients can be started.
– Phenotyping: FRI gives a signal in general, but some opposite signals
are seen for some patients. FRI can now be used to distinguish respon-
ders from non-responders. If the general FRI signal is positive, this
probably means that the chosen population is valid and further phase
IIb and phase III studies can be performed to investigate the details. If
the general FRI signal is negative, this probably means that the cho-
sen population is not the correct one for this medication. The in- and
exclusion criteria can be changed and the trial can be performed again.
– Deposition: It is found that the drug does not deposit in the targeted
regions. If it is related to the phenotype of the patient, the in- and
exclusion criteria can be changed and the trial can be performed again.
If it is related to the device, the formulation or the device can be changed
and the trial can be performed again.
– Dosage: The drug deposits in the targeted regions but the required
dosage or concentration is not reached. The formulation or the device
can be changed and the trial can be performed again.
FRI is also an interesting technology for niche markets with high unmet needs.
People who undergo major surgery, such as lung transplantation, can profit from
FRI as this technology allows very local follow-up analyses, possibly detecting
signs of rejection in an early stage. Also people suffering from orphan diseases
such as radiation pneumonitis, pulmonary alveolar proteinosis, cystic fibrosis,
idiopathic pulmonary fibrosis and alpha-1 antitrypsin deficiency can benefit from the
patient specific nature of FRI, as most of these diseases are difficult to standardize.
Another problem with these rare diseases is that some of them are so rare that it is
almost impossible to perform large-scale studies. Chances are real that traditional
techniques are not sensitive enough to detect possible effects in these studies. This
opens the possibility for FRI to become a surrogate endpoint for orphan diseases.
This means that clinical conclusions can be connected to the FRI results. Another
challenge that can be tackled using FRI is the question of bioequivalence. When
a manufacturer wants to introduce a generic drug to the market, the behavior of
that drug needs to be similar to the behavior of the original product. FRI can be
used to assess the effective lung deposition of both compounds. Furthermore, the
in vivo effect can be assessed in relatively small and short clinical trials using a
crossover design. In this way, the characteristics of the device and formulation can
be linked to therapeutic effect and it can be determined whether the two products
induce similar effects. Personalized medicine is another domain where FRI can
have an added value. As novel therapies are becoming more and more expensive
while the budgets in healthcare are decreasing, regulatory authorities will demand
superiority over the standard of care to justify the additional expenditure. Apart
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from very novel breakthroughs, superiority can mostly only be demonstrated by
selecting the appropriate patients. FRI allows these patient specific insights, making
it possible to deliver the right treatment to the right patient.
FRI can also help to understand the health effects of air pollution in a multidis-
ciplinary approach. Real air pollution measurements can be performed at different
locations and under different conditions. The physical-chemical characterization of
these data can be used as input data for FRI, which on his turn can generate input
data for health-effect modelling algorithms. Combining this approach with clinical
trials can result in a better understanding of the mechanics and clinical effects of air
pollution.
FRI is still in its early development phase and further research is needed in
order to expand its possibilities. A first research line that comes to mind is to search
for correlations between drug deposition and effect size, making a link between the
second and the third part of this thesis. A lot of attention will have to be given to
correct characterization of the compound, the device and inhalation manoeuvre in
order to perform correct patient specific simulations. In a later stage, these insights
can be used to construct dose-response curves for a specific medication.
It would also be interesting to search for threshold values for changes in FRI
parameters that indicate clinical significance. Is a 1% decrease in airway resistance
clinically significant? Or is 80% needed? Or does it depend on the patient? An
approach that could be taken is to perform FRI analyses on the same patients in
two extreme states of their disease. For example, patients with extreme airway
deformation during exacerbation and with more normalized airways after recovery
could be analyzed. Or severe sleep apnea patients before and after successful
treatment could be compared. The broad spectrum of both FRI parameters and
patient reported outcomes could make it possible to determine cut-off values for
clinical relevance.
A last line of research for the near future is the power of FRI in phenotyping
patients. Traditional clinical tests are used to classify patients by disease severity.
Due to the insensitive nature of these techniques, the possibility exists that patients
are wrongly categorized, perhaps resulting in patients not receiving the optimal
treatment. Ideally, a phenotyping study would start with a set of healthy volunteers
for whom FRI parameters such as airway shape, resistance, compliance, vasculature,
emphysema and inflation are locally measured at different lung levels. In this way
standard values and their variations over a breathing cycle are known. Afterward,
sets of patients that are classified with the traditional method can be analyzed in
a similar manner and can be compared to the healthy population. This makes it
possible to detect overlaps, gaps and shifts in the normal classification methods.
These insights will undoubtedly lead to new research questions, making FRI a
very exciting technique with endless possibilities.
Despite the fact that quite some challenges in engineering are tackled (Chapter
12), the readers of this thesis will notice that the research approach is more from a
clinical than from an engineering point of view. While a lot of research in biomedi-
cal engineering is targeted towards the creation of very complicated mathematical
models in idealised geometries or small cross-sectional patient datasets, the author
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of this thesis strives to design simple, clinically relevant and scalable models that
are easy to understand and that can be used in a normal clinical setting in large
longitudinal studies. Although both top-down and bottom-up approaches have their
advantages and disadvantages, one should not forget that biomedical engineering
is not only about the algorithm but about the patient. If a model is able to help a
patient, then it is a useful model. If adding some complexity to the model leads
to a better quality of life for the patient, then it is a better model. This thesis
shows that engineering and medicine do not have to clash. The author believes that
multidisciplinary teams consisting of doctors, engineers and (life) scientists are the
future of medicine and hopes that this thesis is a good step forward in that direction.
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Appendices

A
Computational fluid dynamics
A.1 The Generic Scalar Transport Equation
The most fundamental law of physics is the law of conservation. A differential
equation expresses such a conservation principle where each term in this equation
represents a physical mechanism through which the conserved quantity evolves.
There are three mechanisms that the terms in a differential equation usually describe
[11, 16]:
• The accumulation or transient process accounts for the temporal rate of
change of a given quantity within an infinitesimal volume.
• The convection process accounts for the transport of the quantity due to any
existing velocity field. Convection occurs at the macro level and it is the
source of nonlinearity in the Navier-Stokes equations.
• The diffusion process describes the transport of the quantity due to the
presence of any gradients of that quantity. This happens at the molecular
level. By itself, diffusion is a linear process provided the diffusion coefficient
is a constant.
In certain cases, there are terms that cannot be cast into the transient, convec-
tive, and diffusive terms. These are then lumped into what is a called a source term.
For example, the gravitational effects, the pressure gradient and any other body
forces are part of the source term in the Navier-Stokes equations.
The universality of the three mechanisms discussed above makes it possible to
construct a general differential equation that describes the conservation principle
A-2 APPENDIX A
of a quantity. Note that the placement of the terms comes from the fundamental
principles of deriving the conservation equations, i.e. transient and convective terms
should balance diffusive and source terms. For generality, we shall pick a dummy
physical quantity and call it φ. The generic scalar transport equation is now given
as equation A.1 [11, 16].
∂ρφ
∂t︸︷︷︸
Transient term
+ ∇ · (ρUφ)︸ ︷︷ ︸
Convection term
= ∇ · (Γ∇φ)︸ ︷︷ ︸
Diffusion term
+ Sφ︸︷︷︸
Source term
(A.1)
In this equation, ρ is the density, t the time, U the velocity vector and Γ the
diffusion coefficient. The del operator is given by∇. The recognition that all the
relevant differential equations for heat and mass transfer, fluid flow, turbulence,
and related phenomena can be thought of as particular cases of the generic scalar
transport equation is an important time-saving step. As a consequence, we need to
concern ourselves with the numerical solution of only equation A.1. Even in the
construction of a computer program, it is sufficient to write a general sequence of
instructions for solving equation A.1, which can be repeatedly used for different
meanings of φ along with appropriate expressions for Γ, S and with appropriate
initial and boundary conditions [11].
A.2 The Navier-Stokes Equations
The Navier-Stokes equations are the basic governing equations for a viscous, heat
conducting fluid and are based on the three fundamental conservation laws [13]:
• The mass of a fluid is conserved (continuity): section A.2.1
• The linear momentum is conserved: the rate of change of momentum equals
the sum of the forces on a fluid particle (Newton’s second law): section A.2.2
• The energy is conserved: the rate of change of energy is equal to the sum of
the rate of heat addition to and the rate of work done on a fluid particle (first
law of thermodynamics): section A.2.3
The resulting continuity equation, momentum equation and energy equation
are mostly referred as the Navier-Stokes equations. These equations are specialized
forms of equation A.1.
A.2.1 Continuity equation
The procedure for casting any particular differential equation into the generic scalar
transport equation is to manipulate it until, for the chosen dependent variable, the
unsteady term and the convection and diffusion terms conform to the standard
form [11]. To obtain the continuity equation (for compressible flows) set φ = 1.
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Since diffusion is not present and in the absence of sources set the diffusion
coefficient and the source term to zero to obtain equation A.2 [1, 5, 13]. This
equation mathematically expresses that the sum of the time rate of change of mass
inside the control volume and the net mass flow over the boundaries of the control
volume equals zero [2].
∂ρ
∂t
+∇. (ρU) = 0 (A.2)
The right hand side can be replaced by a term source SC . This is any mass
added to the continuous phase and any user-defined sources [7].
A.2.2 Momentum equation
The momentum equation is completely based on Newton’s second law, given by
equation A.3.
n∑
i=0
F = m.a (A.3)
The momentum equation can be written as equation A.4. The mass times the
acceleration is expressed on the left-hand side of the equation while the right-hand
side describes all the possible surface and body forces that can act on an object [2].
∂ (ρU)
∂t
+∇. (ρUU) = −∇p+∇. (τ) + SM (A.4)
As the most common body force is the gravitational force, the source term
(SM ) can be replaced by the sum of the gravitational body force (ρg) and external
body forces (F ). F also contains other model-dependent source terms such as
porous-media and user-defined sources [7].
To define the viscous stress tensor τ in a more understandable way, we will
transform equation A.4 in its Cartesian form, given as equation A.5 [1, 13].
∂ (ρux)
∂t
+∇. (ρuxU) = ∂(−p+τxx)∂x + ∂τyx∂y + ∂τzx∂z + SMx (A.5)
∂ (ρuy)
∂t
+∇. (ρuyU) = ∂τxy∂x + ∂(−p+τyy)∂y + ∂τzy∂z + SMy
∂ (ρuz)
∂t
+∇. (ρuzU) = ∂τxz∂x + ∂τyz∂y + ∂(−p+τzz)∂z + SMz
For a Newtonian fluid, assuming Stokes Law for mono-atomic gases, the
components of the viscous stress tensors τij are now given by equation A.6 [12]. In
these equations, µ is the dynamic viscosity.
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τxx =
2
3µ
(
2∂ux∂x − ∂uy∂y − ∂uz∂z
)
(A.6)
τyy =
2
3µ
(
2
∂uy
∂y − ∂ux∂x − ∂uz∂z
)
τzz =
2
3µ
(
2∂uz∂z − ∂ux∂x − ∂uy∂y
)
τxy = τyx = µ
(
∂ux
∂y +
∂uy
∂x
)
τxz = τzx = µ
(
∂uz
∂x +
∂ux
∂z
)
τyz = τzy = µ
(
∂uy
∂z +
∂uz
∂y
)
A.2.3 Energy equation
The energy equation is the mathematical expression that energy cannot be created
nor destroyed but it can change form. The left-hand side of this equation expresses
the rate of change of energy inside a fluid element while the right-hand side is
the sum of the net flux of heat into the element and the rate of work done on
the element due to surface and body forces [2]. The energy equation is given as
equation A.7 [13].
∂ (ρE)
∂t
+∇. (ρEU) = −∇. (pU) +
[
∂(uxτxx)
∂x +
∂(uxτxy)
∂y (A.7)
+∂(uxτxz)∂z +
∂(uyτxy)
∂x +
∂(uyτyy)
∂y
+
∂(uyτzy)
∂z +
∂(uzτxz)
∂x +
∂(uzτyz)
∂y
+∂(uzτzz)∂z
]
+∇. (kH∇T ) + SE
In this equation, E is the total energy, T the temperature and kH the heat
conduction coefficient. The source term SE includes the heat of chemical reaction
and any other volumetric heat sources that have been defined [7].
A.3 Discrete phase
When one wants to assess the behaviour of a discrete element in a flow (for example
the modelling of particle transport), not only the flow equations from section A.2,
but also the additional governing transport equation A.8 describing the discrete
phase trajectory need to be solved [7].
dvi
dt
= FD︸︷︷︸
Drag force
(ui − vi) + gi (1− α)︸ ︷︷ ︸
Gravity force
+ Fx︸︷︷︸
Additional acceleration forces
(A.8)
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In this equation, vi and ui are the components of the particle and local fluid
velocity, respectively, gi denotes gravity and α is the density ratio ρ/ρp where
ρp is the density of the discrete phase. The drag force FD is a function of the
relative velocity between the continuous and discrete phase and is given by f/τp
where f is the drag factor and τp is the response time for the particles. The
additional acceleration forces Fx can include forces generated by pressure gradients,
thermophoretics, rotating reference frames, brownian motions, lift and user defined
sources.
Additional equations with respect to heat and mass transfer can be solved in
addition to equation A.8 to model heating, evaporation and coagulation, but these
are out of the scope of this thesis.
Equation A.8 can be used to calculate the discrete phase patterns based on the
results of the equations in section A.2. One can decide that the solution is then
complete (1-way coupling), or that feedback to the continuous phase is needed
(2-way coupling). In the latter approach, the continuous phase is impacted by
the discrete phase (and vice versa), yielding in additional source terms in the
Navier-Stokes equations. Calculations of both phases need to be alternated until a
converged coupled solution is achieved.
A.4 Computational fluid dynamics
Computational fluid dynamics is a computer simulation technique that allows to
determine the behavior of a flow [6]. In this method, flow is described by the
Navier-Stokes equations and is numerically solved on a computational grid (the
mesh). This method makes it possible for the system of mathematical equations to
be solved iteratively. The result is that flow features such as speed, pressure and
density are known everywhere in the model.
The numerical technique that is mostly used in CFD nowadays, is the finite
volume method (FVM), but several other methods exist. The difference between the
methods are associated with the way in which the flow variables are approximated
and with the discretization processes. In outline, the numerical methods that form
the basis of the solver perform the following steps [13]:
• An approximation of the unknown flow variables by means of simple func-
tions
• A discretization by substitution of the approximations into the governing
flow equations and subsequent mathematical manipulations
• A solution of the algebraic equations
The key step of the finite volume method is the integration of the transport
equations over a three-dimensional control volume. To perform a CFD calculation
in a computational domain, the domain is divided into a number of smaller, non-
overlapping sub-domains: a grid (or mesh) of control volumes (or cells). After
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setting the appropriate boundary conditions and fluid properties, a FVM calculation
can be run. In this numerical technique, the steps given above are implemented in
the following manner [13]:
• A formal integration of the governing equations of fluid flow, described in
section A.2, over all the finite control volumes of the computational domain.
The resulting statements express the exact conservation of relevant properties
for each finite size cell. This clear relationship between the numerical algo-
rithm and the underlying physical conservation principle forms one of the
main attractions of the finite volume method
• A discretization process involving the substitution of a variety of approxi-
mations for the terms in the integrated equation that are representing flow
processes such as convection, diffusion and sources. This converts the integral
equations into a system of algebraic equations
• A solution of the algebraic equations by an iterative method
When analyzing the FVM technique, it can be noticed that the accuracy of a
CFD solution is governed by the number of cells in the grid. In general, the larger
the number of cells, the better the solution accuracy.
CFD programs contain discretization techniques suitable for the treatment of
the key transport phenomena, convection and diffusion as well as for the source
terms and the rate of change with respect to time. The underlying physical phenom-
ena are complex and non-linear so an iterative solution approach is required [13].
A.4.1 Laminar flow
Flows in the laminar regime are completely described by the equations that are
developed in section A.2. In simple cases, these equations can be solved analytically.
More complex flows can be calculated numerically with CFD techniques such as
the finite volume method without additional approximations [13]. To see whether a
flow is laminar or not, the Reynolds number, which is given by equation A.9, has to
be calculated [14].
Re =
ρUdh
µ
(A.9)
In this equation, dh is the hydraulic diameter, defined as 4 times the cross-
sectional area, divided by the wetted perimeter. The Reynolds number of a flow
gives a measure of the relative importance of inertial forces and viscous forces.
In experiments on fluid systems it is observed that at values below the so-called
critical Reynolds number Recrit, the flow is smooth and adjacent layers of fluid
slide past each other in an orderly fashion. If the applied boundary conditions do
not change with time, the flow is steady. This regime is called laminar flow [13].
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At higher Reynolds numbers, flows are observed to become turbulent. Even
with constant boundary conditions applied, a chaotic and random state of motion
develops in which the velocity and pressure change continuously with time within
substantial regions of flow [13]. In this case, the inertial forces are dominant with
respect to the viscous forces [2].
The transition from laminar to turbulent flow occurs at Recrit. In all systems,
this Recrit value is different and depends on the irregularity and the compliance
of the wall. Irregular geometry can trigger early transition to turbulent flow [2].
Typically, for pipe flows, laminar flow occurs in regions where Re < 2000 and
turbulent flow is present in circumstances under which Re > 4000. The range of
2000 < Re < 4000 is known as the transition range [14].
A.4.2 Turbulent flow
Turbulent flows are characterized by three-dimensional, time-dependent, random
fluctuations of velocity. These fluctuations cause a mixing of transported quantities
such as momentum and energy [2]. Turbulence is characterized by the presence of
a large range of excited length and time scales. The irregular nature of turbulence
stands in contrast to laminar motion [15].
Turbulence can be solved without any modelling. However, despite the per-
formance of modern supercomputers, a direct simulation of turbulence by the
time-dependent Navier-Stokes equations, called direct numerical simulation (DNS),
is only possible for rather simple flow cases at low Reynolds numbers. The restric-
tions of DNS become quite obvious when recalling that the number of grid points
needed for sufficient spatial resolution scales as Re9/4 and the computational time
as Re3 [4]. For complex cases, turbulence has to be approximated by a model.
Due to the complexity of turbulent flow and difficulties in its understanding
and physical interpretation, it is difficult to introduce a unique conceptual model.
However, there are certain characteristics and properties associated with turbulence,
which have been shown experimentally and numerically, that are used commonly
in describing turbulent flows [9].
Turbulence modelling is, together with grid generation and algorithm devel-
opment, one of three key elements in computational fluid dynamics. However, far
less precision has been achieved in turbulence modelling compared to the other
key elements. This is not really surprising since this is an approximation of an
extremely complicated phenomenon [15]. Several turbulence models are discussed
in sections A.4.2.1 and A.4.2.2.
A.4.2.1 Reynolds Averaged Navier-Stokes equations
To make the explanation of the Reynolds Averaged Navier-Stokes (RANS) equa-
tions easier, the Navier-Stokes equations described in section A.2 are simplified
to represent an adiabatic, incompressible flow with constant dynamic viscos-
ity [1, 12, 13]. The Navier-Stokes equations are now given by the continuity
(equation A.10) and momentum (equation A.11) equations:
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∇.U = 0 (A.10)
ρ
(
∂U
∂t
+ U.∇U
)
= −∇p+ µ∇2U + SM (A.11)
To derive the RANS equations for this case, equations A.10 and A.11 are
rewritten in another form as equations A.12 and A.13 [10, 15].
∂ui
∂xi
= 0 (A.12)
ρ
∂ui
∂t
+ ρ
∂ (uiuj)
∂xj
= − ∂p
∂xi
+
∂
∂xj
[
µ
(
∂ui
∂xj
+
∂uj
∂xi
)]
(A.13)
+SM
The RANS equations govern the transport of the averaged flow quantities, with
the whole range of the scales of turbulence being modelled. A turbulent flow may
be defined as a flow which contains self-sustaining fluctuations of flow properties
imposed on the main flow [9]. The flow quantities can thus be expressed as the sum
of an average quantity and a fluctuation as given by the Reynolds decomposition in
equations A.14 and A.15 [2].
ui = ui + u
′
i (A.14)
p = p+ p′ (A.15)
Time averaging equations A.12 and A.13 by using equations A.14 and A.15
yields to equations A.16 and A.17.
∂ui
∂xi
= 0 (A.16)
ρ
∂ui
∂t
+ ρ
∂ (uiuj)
∂xj
= − ∂p
∂xi
+
∂
∂xj
(A.17)[
µ
(
∂ui
∂xj
+
∂uj
∂xi
)
− ρu′ju′i
]
+ SM
Equations A.16 and A.17 are usually referred to as the Reynolds Averaged
Navier-Stokes equations. The quantity −ρu′ju′i is known as the Reynolds-stress
tensor [15]. This tensor has to be modelled in order to close the system of equations.
Some additional equations are introduced to solve for the turbulent viscosity [2].
By far the most popular turbulence models utilized today for flow and heat
transfer calculations are the low-Reynolds number two-equation eddy viscosity
models. The k −  and k − ω models are the most utilized as these models often
offer a good balance between complexity and accuracy [8]. They belong to the
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so-called first-order closures and are mostly based on the eddy-viscosity hypothesis
of Boussinesq [4]. The turbulence viscosity is solved trough the introduction of a
scalar for the turbulent kinetic energy (k) and the turbulent dissipation rate () or
the specific dissipation rate (ω) [2].
The standard k −  model is a semi-empirical model that assumes a fully
turbulent flow and negligible molecular viscosity. It is semi-empirical because
only the value of k is derived from the exact equation,  is obtained using physical
reasoning. Improved models exist in the form of the realizable k −  model and the
RNG k −  model [2].
The standard k − ω model is a fully empirical model that does not assume a
fully turbulent flow. The low Reynolds number k − ω can even obtain an accurate
laminar solution when the turbulent viscosity approaches zero [3, 15]. An improved
model exist in the form of the SST k − ω model. New features make this model
more accurate for a wider class of flows [2].
Since all scales of turbulence must be modelled in the RANS equations, a
model which is capable of predicting turbulence over a wide range of flow conditions
and geometries does not exist [9].
A.4.2.2 Filtered Navier-Stokes equations
The filtered Navier-Stokes are obtained by filtering the time-dependent Navier-
Stokes equations in a way that certain eddies, whose scales are smaller than the
filter width or grid spacing used in the computational grid, are filtered out. In this
way, only the dynamics of the large eddies are governed. This is called the large
eddy simulation (LES) approach [2].
LES provides a compromise between DNS, where all scales of turbulence
are computed directly from the Navier-Stokes equations, and RANS equations,
where all scales of turbulence are modelled. In this approach, the filtered Navier-
Stokes equation is solved for the large-scale motion, while the small scales are
computed from a turbulence model, known as the subgridscale model [9]. This is
a good approach because the larger eddies can not be modelled well as they are
highly dependent on the geometry of the computational domain and the boundary
conditions, they are mostly anisotropic. Small eddies are better suited for modelling
as they are mostly isotropic [2].
After the application of the filtering process, the incompressible Navier-Stokes
equations are given by equation A.18 and A.19 [9].
∂ui
∂xi
= 0 (A.18)
ρ
∂ui
∂t
+ ρ
∂ (uiuj)
∂xj
= − ∂p
∂xi
+
∂
∂xj
[
µ
(
∂ui
∂xj
+
∂uj
∂xi
)]
(A.19)
−∂τij
∂xj
+ SM
Where τij is the subgrid scale stress tensor which represents the effect of small
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scales. The subgrid scale stress tensor is given by equation A.20 [9].
τij = ρuiuj − ρuiuj (A.20)
Since the small-scale eddies are more or less universal and homogeneous, it
is postulated that the subgrid scale model would be applicable to a wide range of
flow regimes and conditions [9]. The use of the subgrid scale model allows to use a
coarser grid and a smaller time-step compared DNS. However, the requirements
are still much higher than needed for RANS simulations [2]. Typically, LES takes
5 to 10 % of the computing time compared to DNS [9]. Subgridscale models
that are frequently used are the Smagorinsky-Lilly subgrid scale model and the
Wall-adapting local eddy-viscosity model [2].
A.5 Conclusion
In this chapter, the numerical technique used in most CFD software packets is
described. It is explained what a laminar and a turbulent flow is and when there
is a transition between these types of flow. In the end, a summary of different
turbulence models is given.
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